Nicole Gray

2603 ARTICLES BY Nicole Gray

• Aug. 19, 2016 PhRMA: US remains vaccine R&D leader
• Aug. 19, 2016 Roche, Eleven Bio eye the ocular market
• Aug. 19, 2016 Nutrinia raises $30M for pediatric oral insulin
• Aug. 18, 2016 Chinese/Indian manufacturing facilities facing repercussions
• Aug. 18, 2016 Another Indian API facility added to EU's 'do not import' list
• Aug. 18, 2016 FDA expedites Aspen's prostate drug ahead of merger
• Aug. 18, 2016 Trek Therapeutics in-licenses Medivir hep C drug
• Aug. 18, 2016 Rasna Therapeutics taps public market with merger
• Aug. 17, 2016 GSK enters pay-for-performance deal for gene therapy
• Aug. 17, 2016 Ipsen hopes to be David to Allergan's Goliath
• Aug. 17, 2016 JAMA: PCSK9s should cost $4536, but don't
• Aug. 16, 2016 Chiasma slashes staff as problems persist
• Aug. 16, 2016 Boehringer seeks real-world data to support reversal agent
• Aug. 16, 2016 Cynapsus proceeds after safety OK
• Aug. 16, 2016 Aurinia succeeds, but safety concerns loom
• Aug. 12, 2016 Allergan to consolidate operations in NJ
• Aug. 12, 2016 Mallinckrodt plans regen med acquisition
• Aug. 12, 2016 Gilead licenses bi-specific tech from Danish biotech Genmab
• Aug. 11, 2016 Spark Therapeutics on track to file gene therapy in 2017
• Aug. 11, 2016 Medivation bullish on Xtandi as PDUFA approaches
• Aug. 11, 2016 AstraZeneca bolsters stake in Moderna by $140 million
• Aug. 10, 2016 Shire launches new treatment for hereditary bleeding disorder
• Aug. 10, 2016 AstraZeneca's lung cancer hopeful fails in Phase 3
• Aug. 10, 2016 Novartis execs indicted in bribery scandal—this time in Korea
• Aug. 9, 2016 BIO president defends Orphan Drug Act after op-ed criticism
• Aug. 9, 2016 Swiss Helsinn picks up late-stage cancer drug from MEI Pharma
• Aug. 9, 2016 Does MannKind have a shot at a successful Afrezza re-launch?
• Aug. 8, 2016 Biosimilar battle heats up as AbbVie sues Amgen over Humira copy
• Aug. 8, 2016 Experimental asthma pill from Novartis posts encouraging results
• Aug. 8, 2016 Merck locks up another cancer approval for Keytruda
• Aug. 4, 2016 Chinese drug manufacturer lies to FDA, promptly gets banned
• Aug. 4, 2016 Keryx says Auryxia shortage 'imminent'
• Aug. 4, 2016 FDA hits Adaptimmune with partial hold on T-cell therapy
• Aug. 4, 2016 New poll suggests Big Pharma losing battle over CA pricing ballot
• Aug. 3, 2016 UK court orders coverage of Gilead's HIV drug in England
• Aug. 3, 2016 With new exclusions, payers draw line on pricing
• Aug. 2, 2016 Big Pharma benefits more from breakthrough therapy designations: report
• Aug. 2, 2016 Celgene facing charity-related kickback allegations
• Aug. 2, 2016 Lymphoma drug from Takeda, Seattle Genetics beats out existing meds in late-stage trial
• Aug. 1, 2016 Private equity firm Advent buys 50% stake in InVentiv
• Aug. 1, 2016 Tokai cuts workforce by 60% after phase 3 failure with prostate cancer drug
• July 31, 2016 Bayer leans on partnering for new growth
• July 29, 2016 Editas teams up with Italian gene therapy institute
• July 29, 2016 US, UK pledge to combat antibiotic resistance through new alliance
• July 28, 2016 Shnaghai Fosun to buy large stake in Gland Pharma for $1.4 billion
• July 28, 2016 Pfizer may sell its stake in Latin America's largest manufacturer
• July 28, 2016 Phase 1 trial reveals high efficacy for hemophilia A gene therapy
• July 28, 2016 GSK enters $230 million licensing deal with Janssen
• July 27, 2016 Janssen: Bristol-Myers' newest Opdivo combo research partner
• July 27, 2016 J&J, Genmab line up second-line use for multiple myeloma med
• July 27, 2016 Tokai Pharma tumbles after Phase 3 failure
• July 26, 2016 FDA strengthens warnings on class of antibiotics
• July 26, 2016 Celgene abandons plans for new Revlimid indication after trial disappointment
• July 26, 2016 Regulators to expedite review of Merck's Ebola vaccine
• July 26, 2016 Kite eyes off-the-shelf T-cell therapies with UCLA research deal
• July 25, 2016 FDA delays decision on Merck's C. diff drug
• July 25, 2016 Japanese government to set new controls on specialty drugs: report
• July 25, 2016 After scandal, China begins vaccine inspections nationwide
• July 22, 2016 Amgen, Allergan get biosimilar lift with positive data on Herceptin copy
• July 22, 2016 Theranos expands compliance team with new execs, committee
• July 21, 2016 Pfizer presses on with expansion of Irish manufacturing site
• July 21, 2016 Merck KGaA building $115 million life science facility in MA
• July 21, 2016 Novartis CEO sees more restrictive drug pricing to come in US
• July 21, 2016 Mylan gets 'all clear' from EU regulators for $7.2 billion Meda deal
• July 20, 2016 What's so scary about biosimilars?
• July 20, 2016 Zafgen shuts down development of obesity drug, cuts staff
• July 19, 2016 US, EU regulators to review Opdivo for new cancer indication
• July 19, 2016 Teva raises $15 billion through bond sale
• July 19, 2016 After phase 2 success, Brainstorm sees promise for ALS drug
• July 19, 2016 FDA: Flood of orphan drug applications slowing review process
• July 18, 2016 PDUFA 6 procedures will include patients, biomarkers for 2018-2022
• July 18, 2016 Celgene picks up broader EU approval for key cancer drug
• July 17, 2016 Samsung Bioepis continues biosimilar push with EU submission of Humira copy
• July 15, 2016 Santhera hopes for accelerated approval of Duchenne drug dashed
• July 15, 2016 Shkreli's securities fraud case set for June 2017
• July 14, 2016 FDA bans imports from four Indian and Chinese drugmakers
• July 14, 2016 Cipla invests $90 million in South African biosim plant
• July 14, 2016 High-profile VC firm hires former Merck exec as chief medical officer
• July 14, 2016 Two for two: FDA panel gives green light to Novartis' Enbrel biosim
• July 14, 2016 Lilly, Boehringer enter R&D pact to test breast cancer combo
• July 13, 2016 Amgen touts new dosing option for underperforming cholesterol drug
• July 13, 2016 FDA approves broader use of Pfizer's pneumonia vaccine
• July 13, 2016 FDA panel unanimously recommends approval of Amgen's Humira biosimilar
• July 12, 2016 Increase in US cancer center ad spending fueled by single company
• July 12, 2016 Nichi-Iko expands into US with $736 million Sagent buy
• July 11, 2016 EMA says benefits of Gilead's Zydelig outweigh risks
• July 11, 2016 Drug manufacturer Patheon plans major IPO to pay down debt
• July 11, 2016 Canadian court overrules Alexion's efforts to avoid price caps
• July 11, 2016 Gilead secures European approval for new hepatitis C drug
• July 11, 2016 Medicines Patent Pool expands access to HIV, hepatitis C drugs with new deals
• July 8, 2016 Pfizer's leukemia drug approved by UK cost watchdog after previous rejection
• July 8, 2016 Democrats exhort FDA to approve generic versions of Crestor
• July 7, 2016 Pfizer planning expansion of Irish manufacturing facility
• July 7, 2016 3-D drug firm Aprecia wins another $30 million in venture-funded debt
• July 7, 2016 Moderna and Vertex partner to target cystic fibrosis with RNA therapies
• July 7, 2016 Bial's Parkinson's drug wins approval in Europe
• July 7, 2016 Pfizer, German Merck to test new combo against ovarian cancer
• July 6, 2016 Valeant mulling sale of dermatology assets to Spanish Almirall: report
• July 6, 2016 Japanese regulators approve PCSK9 drug from Sanofi, Regeneron
• July 6, 2016 Another loss for J&J: Court sides with teenager in Risperdal case
• July 6, 2016 Despite sluggish IPO market, biotechs continue to lead the way
• July 5, 2016 Chinese biotech CStone raises $150 million in new financing
• July 5, 2016 With insulin market set for shake-up, Novo Nordisk expands production plant
• July 5, 2016 Pfizer makes bid for Bind after repayment woes
• July 1, 2016 Patent Office accelerates patent review for cancer drugs in pilot program
• July 1, 2016 J&J, AbbVie eye new indication for cancer drug Imbruvica
• July 1, 2016 Boehringer continues to restructure, cuts 725 jobs in US
• June 30, 2016 InVentiv Health comes on board as Pfizer's fourth CRO
• June 30, 2016 Icagen to buy Sanofi lab, widening R&D reach
• June 30, 2016 Two more Chinese drugmakers run afoul of FDA inspections
• June 30, 2016 Pfizer's PCSK9 drug notches two Phase 3 wins
• June 30, 2016 Shire's adult ADHD drug shows promise in late-stage study
• June 30, 2016 Cancer Moonshot summit adds new partnerships to lofty goals
• June 29, 2016 Roche eyes faster approval for multiple sclerosis drug
• June 29, 2016 More generic drugs from India clearing FDA approval: report
• June 29, 2016 Teva, Allergan sell off more drugs in quest for approval of generics deal
• June 29, 2016 What does it take to succeed as a New York biotech startup?
• June 28, 2016 Dr. Reddy's breaks off marketing partnership with Glaxo
• June 28, 2016 Bristol-Myers eyes new indication as Opdivo nabs breakthrough tag in bladder cancer
• June 27, 2016 Takeda hands back two developmental drugs to Amgen
• June 26, 2016 FDA should be independent agency, former commissioners say
• June 26, 2016 Industry group pushes back against proposed bill to reduce drug exclusivity
• June 24, 2016 Study says Novartis heart med could prevent 28,000 US deaths per year
• June 23, 2016 Eleven Bio slashes workforce after drug test failures
• June 23, 2016 India targets drugmakers with wave of inspections
• June 23, 2016 Opko wins approval for kidney drug after manufacturing snag
• June 23, 2016 Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug
• June 23, 2016 Russian biosims company accuses Roche of undercutting its business
• June 23, 2016 Celgene puts up $50 million to partner with four NCI cancer centers
• June 22, 2016 Doctors who ate on pharma's dime prescribed drugs more often, study finds
• June 22, 2016 Supreme Court asks for DOJ input on biosimilar case, delaying decision
• June 22, 2016 Could label update for diabetes med Jardiance boost drug class?
• June 22, 2016 Austin biotech Savara adds two lung drugs in deal for Serendex
• June 21, 2016 Philips ad for lung device wins top honors at Cannes
• June 21, 2016 Kite Pharma opens cell therapy plant as lead CAR-T candidate gathers steam
• June 21, 2016 Incidence of Parkinson's may be increasing: Mayo Clinic study
• June 20, 2016 Clinton racks up donations from pharma industry
• June 20, 2016 NICE greenlights Bristol-Myers' combo drug for melanoma
• June 20, 2016 Epizyme stock falls after mixed Phase 2 results for blood cancer drug
• June 20, 2016 Hologic's Zika test can be used on emergency basis, FDA says
• June 17, 2016 Why Novartis' new heart med could reverse slow start
• June 17, 2016 Payer interest grows in outcomes-based drug deals: report
• June 17, 2016 Roche's combo melanoma treatment turned down by UK cost watchdog
• June 17, 2016 Venture funding for UK biotechs hits new high
• June 16, 2016 EMA cites US-based Pii for manufacturing violations
• June 16, 2016 Roche selling Spanish facility to CMO Famar
• June 16, 2016 Lawmakers introduce bill to end REMS abuse, boost generic competition
• June 16, 2016 Shkreli's stake in KaloBios cut after judge OK's bankruptcy plan
• June 15, 2016 NYC-based Rgenix raises $33 million to advance cancer immunotherapy
• June 15, 2016 Lilly and Boehringer's Jardiance sets new bar, shows kidney benefit
• June 15, 2016 Teva hands back global rights for heart drug to Australian Mesoblast
• June 15, 2016 Success rate for clinical trials climbed in recent years: study
• June 14, 2016 Infinity Pharma to lay off one-fifth of staff in wake of phase 2 setback
• June 14, 2016 Merck eyes US approval with positive data on Lantus copy
• June 14, 2016 Novo's diabetes drug shown to decrease heart risks, boosting competitive edge
• June 14, 2016 Dr. Reddy's snaps up eight generics from Teva for $350 million
• June 13, 2016 Merck, Pfizer expand trial studying CV benefit of experimental diabetes drug
• June 13, 2016 Valeant weighs sale of Egyptian drug company
• June 12, 2016 FDA approves world's first single-dose cholera vaccine
• June 12, 2016 Lilly presents solid long-term data for baricitinib in RA patients
• June 10, 2016 GSK wants to replace drugs with tiny implants
• June 10, 2016 Amgen's chronic migraine-prevention drug shows promise in midstage trials
• June 10, 2016 FDA wants to suspend more than 4,000 illegal Rx sites
• June 9, 2016 Alexandria Center for Life Sciences offers $25M in seed funding for small biotechs
• June 9, 2016 Will the approval of Inflectra be a biosimilar adoption tipping point?
• June 9, 2016 Sun Pharma selling off two more US facilities
• June 9, 2016 Researchers discover 11 acute myeloid leukemia subtypes
• June 9, 2016 Gene therapy CMO Brammer Bio moves HQ to Massachusetts
• June 8, 2016 Study: Blood-based 'liquid biopsy' cancer testing works
• June 8, 2016 Vermont becomes first state with drug pricing justification law
• June 8, 2016 Kite, Juno anticipating 2017 approvals for T-cell therapy
• June 8, 2016 Genentech/OSI fined $67 million for skewing cancer-drug survival data
• June 8, 2016 FDA approves Allergan's fixed-dose combo for hyertension
• June 8, 2016 Senators request pricing info from opioid-overdose drugmakers
• June 7, 2016 ASCO update: Biden announces launch of cancer data-sharing system
• June 7, 2016 Alexion's Soliris fails in late-stage myasthenia gravis trial
• June 6, 2016 Study: Cancer drugs most expensive in US, least accessible in China, India
• June 6, 2016 Regeneron/Sanofi's dupilumab shines in phase 3 eczema trial
• June 6, 2016 Study: Bristol-Myers' immunotherapy combo boosts response in lung cancer
• June 6, 2016 Roche positioning Tecentriq as first-line therapy in bladder cancer
• June 6, 2016 Mylan's Herceptin biosim shows comparable efficacy/safety
• June 3, 2016 AstraZeneca continues to shed rights to gout drug
• June 2, 2016 Novartis cancer drug wins expanded indication in Europe
• June 2, 2016 FDA approves liquid biopsy test from Roche
• June 2, 2016 Sanofi Pasteur starts up vaccine production at new facility in India
• June 2, 2016 Sun Pharma continues to feel effect of Halol plant problems
• June 2, 2016 Swiss biotech AC Immune readies US IPO
• June 2, 2016 Two San Diego biotechs merge to create new oncology-focused company
• June 2, 2016 Report: Investors concerned Teva overpaid for Allergan generics unit
• June 2, 2016 Kite Pharma rides CAR-T momentum into ASCO
• June 1, 2016 AstraZeneca discontinues 'Take it From a Fish' ad campaign
• June 1, 2016 Federal judge orders Washington state to cover hep C medications
• June 1, 2016 Daiichi Sankyo halts late-stage study of lung cancer drug
• May 31, 2016 Next-generation eczema drugs on pace for 2017 launch
• May 31, 2016 FDA knocks back Teva drug for Huntingon's, requests more information
• May 31, 2016 EMA recommends approval for hepatitis C meds from Gilead, Merck
• May 31, 2016 Wellcome Trust scores with startup investment in diagnostic company
• May 31, 2016 Multiple sclerosis drug from Biogen, AbbVie clears FDA review
• May 31, 2016 Second biosimilar of J&J's blockbuster Remicade approved in Europe
• May 27, 2016 Contract researcher BioClinica reportedly weighing sale
• May 27, 2016 FDA approves first implanted buprenorphine for opioid dependence
• May 27, 2016 Fate of Ionis drug in doubt after GSK decides against Phase 3 study
• May 26, 2016 FDA reprimands German API supplier for manufacturing violations
• May 26, 2016 MIT lab shrinks drug manufacturing process into a small prototype machine
• May 26, 2016 Aiming to make living tissue, Israeli companies test 3-D stem cell printing
• May 26, 2016 Novartis moves toward sale of $14 billion stake in Roche
• May 26, 2016 Two states sue Johnson & Johnson over vaginal mesh device problems
• May 26, 2016 Kevin Young to return to Gilead as COO
• May 25, 2016 In unanimous vote, FDA panel recommends Novo diabetes drug
• May 25, 2016 Sandoz's biosimilar rituximab gets regulatory review in EU
• May 25, 2016 While advancing cancer pipeline, Halozyme builds up through pharma collaborations
• May 25, 2016 EMA reportedly reviewing clinical guidelines in wake of fatal drug trial
• May 24, 2016 New ad for Bristol's Opdivo highlights testing advantage over Keytruda
• May 24, 2016 Arbor Pharma buys XenoPort for $467 million
• May 24, 2016 Sanofi diabetes chief to leave company as US business struggles
• May 24, 2016 Lilly hopes to catch rivals with abemaciclib data
• May 24, 2016 Novartis faces new challenges as top executives leave
• May 23, 2016 China slashes prices of top-selling cancer, hep B drugs
• May 23, 2016 Novartis' Entresto gets boost from leading US cardiology groups
• May 23, 2016 Oramed's oral insulin shines in mid-stage trials
• May 20, 2016 Merck KGaA/Pfizer's PD-L1 skin cancer drug shows encouraging interim results
• May 19, 2016 Novartis launches ambitious clinical program for Entresto
• May 19, 2016 AbbVie takes on AD at new Cambridge research facility
• May 19, 2016 In reversal, Braeburn Pharma will stay in NC despite controversial law
• May 19, 2016 Capsugel subsidiary flagged by Swedish regulator for GMP failures
• May 19, 2016 BMS completes $280 million biologics plant expansion in MA
• May 19, 2016 Novartis breast cancer drug proves efficacy, trial stopped early
• May 19, 2016 AstraZeneca's gastric cancer drug falls short in phase 3
• May 19, 2016 Janssen ponies up $740 million for another MacroGenics cancer drug
• May 18, 2016 As big pharma moves in, biotech Galectin looks to stake claim to NASH market
• May 18, 2016 Everyday low price? Walmart teams with McKesson to source generics
• May 18, 2016 Orexigen struggles to stay afloat as obesity market stagnates
• May 18, 2016 Celgene expands partnership with Agios into immuno-oncology
• May 17, 2016 FDA looks to ease burden for compassionate drug use
• May 17, 2016 Roche continues generics battle with latest lawsuit over Avastin copies
• May 17, 2016 Novartis debates how to crack sales code for CAR-T therapy
• May 17, 2016 Editas forges $5 million CRISPR research deal with Cystic Fibrosis Foundation
• May 16, 2016 Aduro's pancreatic immunotherapy fails phase 2, sending stock tumbling
• May 16, 2016 Eisai's kidney drug wins expanded indication in the U.S.
• May 16, 2016 AstraZeneca looks to DNA damage-response drugs for edge in oncology
• May 15, 2016 New phase 3 data boosts Pfizer's meningitis vaccine
• May 13, 2016 Valeant pressured on promise to provide heart drug discount
• May 13, 2016 Regneron CEO counters criticism from ICER on pricing
• May 12, 2016 Oracle founder Larry Ellison donates $200 million for USC cancer center
• May 12, 2016 J&J expands JLABS into Canada with new Toronto site
• May 12, 2016 NIH-funded malaria vaccine shows safety, efficacy in early trial
• May 12, 2016 Cigna signs value-based pricing deals with Amgen, Sanofi for PCSK9 drugs
• May 12, 2016 Sanofi R&D chief, ex-FDA head cite need to improve international regulatory coordination
• May 12, 2016 Opko Health's quest to redefine treatment for secondary HPT
• May 11, 2016 Updated survival data added to Imbruvica's label
• May 11, 2016 GSK's lupus drug finally wins NICE backing, but only after discounts
• May 11, 2016 Daiichi snaps up Japanese rights to CVD stem-cell therapy
• May 11, 2016 Americans may have overspent billions on brand-name drugs, study finds
• May 11, 2016 Pfizer planning first triple-drug immuno-oncology study
• May 10, 2016 NewLink Genetics writes off pancreatic cancer immunotherapy after phase 3 failure
• May 10, 2016 Pharma opposition to Brexit cites concern for UK patients, life sciences
• May 10, 2016 Wave Life Sciences touts more effective Duchenne drug
• May 9, 2016 Cellectis' T-cell therapy clears leukemia in second baby
• May 9, 2016 U.K. cost agency recommends new PCSK9 drugs, but only after further discounts
• May 9, 2016 ICER questions high prices of multiple myeloma meds
• May 6, 2016 Clovis shuts down cancer drug, will reduce staff by 35%
• May 6, 2016 Regeneron reports strong Q1, but key drug faces pressure
• May 6, 2016 Pfizer bets on Wave with drug development deal
• May 5, 2016 New Zealand pushes back on coverage for Merck's Keytruda
• May 5, 2016 Bayer's Stivarga shows efficacy in liver cancer
• May 5, 2016 India may require more clinical trials for Sanofi's dengue vaccine
• May 4, 2016 J&J loses another talcum powder case, ordered to pay victim $55 million
• May 4, 2016 FDA warns antipsychotic can cause uncontrollable urges to gamble, have sex
• May 4, 2016 Bayer's Xarelto projected to become top-selling drug in Europe by 2022
• May 4, 2016 Former Turing CEO Martin Shkreli could face new federal charges
• May 4, 2016 Generic drug backlog persists as FDA slowly clears applications
• May 3, 2016 How Aprecia Pharma hopes to tackle patient noncompliance with 3-D printed drug
• May 3, 2016 Caught by repayment demand, cancer biotech Bind Therapeutics files for bankruptcy
• May 3, 2016 Colombia reportedly set to override Novartis patent on a key cancer drug
• May 3, 2016 Takeda renames antidepressant after name confusion leads to errors
• May 1, 2016 Multiple sclerosis drug from Biogen, AbbVie clears regulatory hurdle in EU
• May 1, 2016 Crestor tumbles off patent cliff as first generic copy approved in US
• May 1, 2016 Acadia wins FDA approval for first drug to treat Parkinson's disease psychosis
• April 29, 2016 Amid pharma lobbying, US trade rep keeps India on priority watch list
• April 29, 2016 Canadian drugmaker tells CMS it can make cheaper version of cancer drug Xtandi
• April 29, 2016 New Express Scripts program aims to react faster to spikes in drug prices
• April 28, 2016 Alexion eyes new manufacturing investment in Ireland
• April 28, 2016 Sanford Weill and wife donate $185 million to UCSF for neuroscience research
• April 28, 2016 Novartis aims for $1 billion in savings from centralization plans
• April 28, 2016 NantKwest's billionaire CEO pocketed $148 million in total compensation last year
• April 28, 2016 UBS venture fund raises $471 million for early-stage cancer investments
• April 28, 2016 Pfizer settles Wyeth Medicaid rebate case for $784.6 million
• April 27, 2016 AstraZeneca debuts new tech along with approval of COPD inhaler
• April 27, 2016 Biogen's 'active woman' Tecfidera ad will go off air soon
• April 27, 2016 Keeping pace with rival Keytruda, Bristol-Myers' Opdivo wins new breakthrough designation
• April 27, 2016 Why Inflectra may face greater challenges than Zarxio in winning over US docs
• April 27, 2016 Non-profit urges big pharma to take responsibility for drug take back programs
• April 26, 2016 AstraZeneca hands off Zurampic marketing rights to Ironwood for $100 million
• April 26, 2016 Viiv Healthcare expands access to HIV drug through patent pooling
• April 26, 2016 Novartis may divest $14B stake in Roche, could generate M&A funding
• April 26, 2016 With CEO Papa headed to Valeant, Perrigo faces new challenges
• April 25, 2016 Major study shows no increased suicide risk from smoking cessation drugs
• April 25, 2016 Proton pump inhibitors linked to serious kidney diseases in study
• April 25, 2016 Germany mulling changes to limit prices drugmakers can charge
• April 25, 2016 Chinese FDA to expedite review of new hepatitis C meds
• April 22, 2016 Actelion denies reports of takeover
• April 22, 2016 FDA issues critical response to Sarepta's latest DMD drug data
• April 22, 2016 Boosting pipeline, AbbVie inks two deals for preclinical cancer drugs
• April 21, 2016 In $205 million deal, Recipharm buys Kemwell's US, India CDMO businesses
• April 21, 2016 Sanofi to invest €300 million in Belgian biologics site
• April 21, 2016 CRISPR-Cas9 editing technology gets a precision upgrade
• April 21, 2016 Combo of J&J Ebola vaccine, Nordic Bavarian booster yields 100% success in small-scale tests
• April 21, 2016 New survey finds consumers unlikely to act on drug ads
• April 20, 2016 Biosimilar update: Zarxio one year later
• April 20, 2016 New analysis boosts cost-effectiveness argument for Merck's Zepatier
• April 20, 2016 Indian pharma companies ramp up R&D to expand reach in US
• April 20, 2016 PhaseRX, Gemphire move forward with IPOs despite challenging market
• April 20, 2016 Armed with genetic data, UK biotech revisits abandoned Roche cholesterol drug
• April 19, 2016 Merck vs. Merck: Trademark suit over brand name heats up
• April 19, 2016 Chiasma shares nosedive after FDA rejects acromegaly drug, asks for more data
• April 19, 2016 Study finds long-term health gains, cost-effectiveness benefits to new HPV vaccine
• April 19, 2016 Eli Lilly cuts ties with Transition, ends diabetes drug collaboration
• April 18, 2016 EMA broadens scope of safety review for Hep C antivirals
• April 18, 2016 Starboard presses on with proxy efforts against Depomed
• April 18, 2016 AbbVie's experimental hep c combo proves highly effective across genotypes
• April 18, 2016 EASL 2016: Merck's 'no patient left behind' approach to hepatitis C
• April 15, 2016 Roche rules out quality problems with Avastin in India
• April 15, 2016 Glaxo investigating alleged bribes to government officials in Yemen: report
• April 15, 2016 Most cancer drug labels don't include patient experiences: study
• April 14, 2016 Fallout from China vaccine scandal continues with arrests of officials
• April 14, 2016 Two Indian generic companies bow to pressure, end appeal for compulsory licenses
• April 14, 2016 In first, FDA approves Janssen's switch to continuous manufacturing for HIV drug
• April 14, 2016 Horizon expects most sales to come later in the year, precipitating share's slide
• April 14, 2016 UK antitrust regulators fine Pfizer over epilepsy drug price increase
• April 14, 2016 Billionaire Sean Parker stakes $250 million on cancer immunotherapy research
• April 13, 2016 ICER questions cost effectiveness of multiple myeloma therapies
• April 13, 2016 Federal court reverses dismissal of class-action suit against Pfizer over pain drugs
• April 13, 2016 PledPharma takes on chemo-induced neuropathy with an eye to US market
• April 12, 2016 With Sanofi gone, Mannkind tries to reinvigorate Afrezza marketing
• April 12, 2016 Alkermes' Vivitrol gets second chance as opioid crisis deepens
• April 12, 2016 California lawmakers debate bill requiring pharma companies to report 10% price increases
• April 12, 2016 Celgene snaps up $50 million option for select Juno CAR-T programs
• April 11, 2016 With polio near eradication, global switch to a new vaccine set to begin
• April 11, 2016 Juno aims to bring CAR-T therapy to China with new joint venture
• April 11, 2016 Activist hedge fund targets Depomed board
• April 11, 2016 Ahead of key meeting, FDA reviewers question efficacy of Clovis' lung cancer drug
• April 8, 2016 Major NGO drops India's IPCA Labs as a source of anti-malarials
• April 8, 2016 FDA advisory board unanimously supports approval of Intercept's liver drug
• April 8, 2016 Relypsa reportedly reviewing buyout offers on renewed interest in hyperkalemia drug
• April 7, 2016 FDA approves Medtronic's Micra, first wireless pacemaker in the U.S.
• April 7, 2016 Inventiv Health sets up IPO to pay down debt
• April 7, 2016 Lilly invests $40 million in Irish continuous manufacturing facility
• April 7, 2016 In potential $450 million licensing deal, J&J to develop prostate cancer drug
• April 7, 2016 Broad Institute offering cloud-based access to trove of genomic data
• April 7, 2016 Federal judge dismisses hundreds of Zoloft birth defect lawsuits
• April 6, 2016 Philippines launches world's first public immunization program against dengue
• April 6, 2016 New data: Pharma magazine ad spending surpasses $1.5 billion in 2015
• April 6, 2016 Key panel nears vote on OCA, Intercept's potential blockbuster liver therapy
• April 6, 2016 FDA chastises Shionogi for misleading copay voucher
• April 6, 2016 BIO Spring 2016: Immunovia's quest to make early-stage pancreatic diagnosis a clinical reality
• April 6, 2016 FDA warns on heart failure risk associated with Onglyza, Nesina
• April 5, 2016 Analysis shows pharma companies aggressively increased prices on widely used drugs
• April 5, 2016 Federal government appoints blue-ribbon advisory panel for cancer moonshot
• April 5, 2016 Nimbus liver drug bought by Gilead for $400M cash plus incentives
• April 4, 2016 With a biosim in the wings, Samsung Bioepis sues AbbVie over patent defense of Humira
• April 4, 2016 ACC 2016: Boehringer's Pradaxa 'antidote' passes real-world test
• April 3, 2016 ACC 2016: Novartis' Entresto reduces risk of hospitalization in HF patients
• April 1, 2016 Price of success: Medivation reportedly hires JP Morgan to help fend off deal-hungry buyers
• April 1, 2016 Lilly's arthritis drug baricitinib notches another success
• April 1, 2016 Federal inspection report reveals major problems at Theranos lab
• March 31, 2016 Urging more robust FDA response, lawmakers warn of contaminated heparin
• March 31, 2016 FDA allows use of Roche's experimental test for Zika virus in endemic areas
• March 31, 2016 Shire boosts CEO Ornskov's pay in light of "exceptional performance"
• March 31, 2016 In cancer moonshot push, Biden and Bloomberg highlight potential of immunotherapy
• March 31, 2016 FDA approves Jazz's rare liver disorder drug
• March 30, 2016 Could long-term "mortgages" help patients fund short-term curative treatments?
• March 30, 2016 Xenoport sells US rights to psoriasis drug to Dr. Reddy's
• March 30, 2016 Denmark-based Lundbeck emerges as top-ranked company in survey of US patient groups
• March 30, 2016 In reversal, FDA denies cognitive dysfunction label expansion for Brintellix
• March 30, 2016 Novartis allegedly paid bribes in Turkey to secure advantages for its drugs
• March 29, 2016 Eagle Pharma's Bendeka denied orphan exclusivity
• March 29, 2016 Emulate raises $28 million for organ-on-chip technology
• March 29, 2016 As vaccine scandal continues, WHO urges China to more strictly police regulations
• March 29, 2016 Shire prevails in Lialda patent case against Allergan
• March 29, 2016 Theranos blood testing inconsistent with other labs, study shows
• March 28, 2016 New poll finds widespread support for cancer research funding
• March 28, 2016 US gov demands more information from Novartis on purported kickbacks
• March 28, 2016 Amid safety concerns, FDA adcomm set to review Acadia's Parkinson's drug
• March 24, 2016 Trial begins in federal court over $60 million heist of Lilly drugs
• March 24, 2016 South Korean, US researchers develop diabetes skin patch
• March 24, 2016 Growing anger in China as vaccine scandal comes to light
• March 24, 2016 Valeant doubled price of physician-assisted suicide drug
• March 24, 2016 Biotech IPOs continue as Corvus prices public listing
• March 24, 2016 Philanthropist Paul Allen launches new $100 million bioscience research initiative
• March 23, 2016 NICE reverses course, endorses expanded use of J&J's Zytiga
• March 23, 2016 Brexit could complicate marketing status of drugs, new licenses
• March 23, 2016 J&J and Genentech partnering in two cancer studies combining Darzalex with atezo
• March 23, 2016 Denying recent reports, India government say it hasn't promised to restrict compulsory licensing
• March 22, 2016 Why ViiV Healthcare leads the pharma industry in corporate reputation
• March 22, 2016 23andMe enabling iPhone users to share DNA data with medical researchers
• March 22, 2016 BioMarin's PKU drug meets primary goal in phase 3, but falls short on secondary endpoints
• March 22, 2016 Indian court temporarily blocks government ban on sales of FDCs
• March 22, 2016 As FDA review approaches, Duchenne experts push for approval of Sarepta's eteplirsen
• March 21, 2016 WHO suspends all TB products from India's Svizera Labs
• March 21, 2016 Biden names corporate exec Greg Simon to lead Cancer Moonshot
• March 21, 2016 EMA issues safety guidance for Gilead's Zydelig in wake of patient infections
• March 18, 2016 OptumRx signs on with Walgreens Boots Alliance
• March 18, 2016 Top Gilead cancer researcher has left company
• March 18, 2016 Former Turing exec to Senate panel: We warned Shkreli about Daraprim price hike
• March 17, 2016 Bayer planning new life sciences hub in Cambridge, MA
• March 17, 2016 Cellectis and MabQuest team up to develop new class of anti-PD1 antibodies
• March 17, 2016 Valeant's stock collapse triggers closer scrutiny
• March 17, 2016 In limited study, NIH-developed dengue vaccine proves 100% effective
• March 17, 2016 Despite promising clinical results, uptake challenges continue for Novartis' Entresto
• March 16, 2016 Valeant acquires Orexigen's obesity drug, stock continues its slide
• March 16, 2016 CDC issues new guidelines for prescribing opioids
• March 16, 2016 Survey: Pharma advertising works—especially with millennials
• March 16, 2016 EMA finalizes clinical trial redaction guidelines
• March 16, 2016 Lilly changes endpoint for phase 3 Alzheimer's trial
• March 15, 2016 Indian authorities withdraw alert on off-label use of Roche's Avastin
• March 15, 2016 As U.S. biosim market grows, FDA's regulatory work has cost nearly $82 million
• March 15, 2016 GW Pharma stock doubles after positive phase 3 cannabis drug results
• March 15, 2016 Sanders proposes cash prize for development of lower-priced AIDS drugs
• March 15, 2016 Allergan would pay $86M in 'golden parachute' taxes if senior execs dismissed
• March 14, 2016 KaloBios sets up funding to clear bankruptcy, acquire Chagas drug
• March 14, 2016 EU regulators investigating Gilead's Zydelig after infection deaths
• March 14, 2016 Indian Health Ministry bans nearly 350 combo drugs
• March 14, 2016 Boehringer turns to 'red fish' for Pradaxa boost
• March 11, 2016 Sarepta's Duchenne drug gets a new date for FDA review
• March 11, 2016 Bispecifics emerging as alternative cancer immunotherapy to CAR-T
• March 11, 2016 Major opioid abuse bill passes 94 to 1 in Senate
• March 10, 2016 Whistleblower sues Indian drug regulators for poor oversight
• March 10, 2016 Merck names new manufacturing head, replacing 12-year veteran
• March 10, 2016 French regulator halts manufacturing at HIV-focused biotech
• March 10, 2016 Senate HELP Committee advances seven bills as counterpart to 21st Century Cures
• March 10, 2016 Gilead and Merck lock horns in court over sofosbuvir patent
• March 10, 2016 CRISPR patent battle begins, setting 'first to file' against 'first to invent'
• March 9, 2016 Black box warning order clouds future for Bayer's Essure
• March 9, 2016 Colombia health ministry recommends compulsory license for Novartis' Gleevec
• March 9, 2016 FDA accepts new Keytruda data, opening door for wider indication
• March 9, 2016 Kentucky Senate overwhelmingly passes biosimilar prescription bill
• March 8, 2016 Senate HELP Committee to mark up 21st Century Cures legislation
• March 8, 2016 Counterfeit Harvoni from India found in Israel
• March 8, 2016 Industry groups, doctors ask CMS to withdraw proposed Part B experiment
• March 7, 2016 Novartis' Cosentyx proves superior to Janssen's Stelara in head-to-head comparison
• March 7, 2016 New study strengthens link between Zika and serious birth defects
• March 7, 2016 GSK's asthma drug Nucala boosted by long-term safety study
• March 4, 2016 Alaska Permanent Fund betting big on biotech startups
• March 4, 2016 Endo to pay $200K penalty, overhaul marketing of opioid painkiller
• March 3, 2016 FDA approves first Zika diagnostic for emergency use
• March 3, 2016 In major expansion, Lupin subsidiary setting up plant in Japan
• March 3, 2016 BMJ study: Single dose vials cost nearly $2B a year in wasted cancer drugs
• March 3, 2016 Merck forges ahead with phase 3 trial of Humira biosimilar
• March 3, 2016 Sanofi's generics divestment in the E.U. likely to be delayed
• March 3, 2016 Amgen going after Novartis for Enbrel patent infringement
• March 2, 2016 Bayer's Essure permanent birth control gets black-box warning
• March 2, 2016 San Diego-based Conatus takes aim at unmet medical need in cirrhosis
• March 2, 2016 AstraZeneca's mesothelioma drug fails monotherapy testing
• March 2, 2016 Teva planning global rebrand as it works to close Allergan generics deal
• March 2, 2016 Clinton ad lambastes Valeant for 'predatory' pricing
• March 2, 2016 Federal investigation probing Horizon Pharma's patient assistance program
• March 1, 2016 AstraZeneca sells off more 'non-core' assets, raising nearly $600M
• March 1, 2016 AARP report: Average prescription drug cost rose by 10% in 2013
• March 1, 2016 Roche's asthma drug stumbles on mixed phase 3 results
• March 1, 2016 Boehringer/AbbVie reportedly in cancer-collaboration talks
• Feb. 29, 2016 Report: Pfizer attempting to dodge $35 billion in taxes through merger with Allergan
• Feb. 29, 2016 Chinese Food and Drug Administration vows to expedite drug approvals
• Feb. 29, 2016 CDC reports new cases of sexual transmission of Zika virus
• Feb. 28, 2016 How the ambitious Cancer Moonshot hinges on the potential of immunotherapies
• Feb. 26, 2016 Doctors Without Borders blasts $1700 price tag of Otsuka TB drug
• Feb. 25, 2016 AZ's deal for Acerta already showing promise as cancer drug wins orphan nod
• Feb. 25, 2016 Valeant's Pearson recovering, but timetable for return remains uncertain
• Feb. 25, 2016 Sandoz issues major recall for hypertension drug made in India
• Feb. 25, 2016 Banned Chinese supplier given exemption to ship chemotherapy drug to U.S.
• Feb. 25, 2016 Merck's Zepatier holds its own in safety comparison to Gilead meds
• Feb. 25, 2016 Lilly's lung cancer drug Portrazza wins EU approval as first-line biologic
• Feb. 25, 2016 Novo Nordisk notches another phase 3 success for GLP-1 drug
• Feb. 24, 2016 Merck CEO Frazier acknowledges pricing 'challenges,' need for new models
• Feb. 24, 2016 Amgen's bone-building osteo drug dazzles in phase 3, but could face hefty competition
• Feb. 24, 2016 IBM buys Truven for $2.6 billion, continues to build its big data focus in healthcare
• Feb. 24, 2016 Alibaba under siege as Chinese regulators & pharmacies fight its e-drug tracking system
• Feb. 24, 2016 Why uptake of new PCSK9 cholesterol meds has been so slow
• Feb. 24, 2016 Do big name journals have a 'marketing trial' problem?
• Feb. 23, 2016 Startup turns to 'video game' medical tech to address brain-based disorders
• Feb. 23, 2016 Alzheimer's startup Chase plots $70M in 2016 funding
• Feb. 23, 2016 AstraZeneca nabs two big European nods for gout & heart meds
• Feb. 23, 2016 UK firm may have just revolutionized NSAID delivery with ibuprofen patch
• Feb. 23, 2016 Allergan's Q4 earnings best expectations on back of US sales
• Feb. 22, 2016 FDA approves new UCB drug to treat epilepsy-related seizures
• Feb. 22, 2016 Startup AvroBio touts gene therapy candidates for blood cancer, Fabry disease
• Feb. 21, 2016 The flip side of the T-cell hype: Experts urge caution on huge costs, safety concerns
• Feb. 19, 2016 UPDATE: Teva to hawk $1 billion in assets to clear massive Allergan generics deal
• Feb. 19, 2016 The next overdose crisis? Benzo-related deaths on the rise in US
• Feb. 19, 2016 Celgene hitches wagon to Bluebird, doles out $10M as biotech launches 1st CAR-T trial
• Feb. 19, 2016 New Zafgen data shows obesity med's promise in diabetics—but will FDA lift its clinical hold?
• Feb. 18, 2016 Eight pharma suppliers band together to improve packaging testing, compatability
• Feb. 18, 2016 Pfizer issues major recall of children's Advil in Canada
• Feb. 18, 2016 Armed with strong new data, Regulus aims to defy skeptics of its hep C injectable
• Feb. 18, 2016 AstraZeneca scores a clutch 'breakthrough' for major bladder cancer med
• Feb. 17, 2016 AMD Awareness Month: For drugmakers, value is the name of the game
• Feb. 17, 2016 Pfizer downgrades Q4 outlook after $785M DOJ settlement spurred by 'serial whistleblower'
• Feb. 17, 2016 FDA expands Gilead's Harvoni label for advanced cirrhosis patients
• Feb. 17, 2016 Express Scripts putting all Valeant scripts under the microscope amid pricing furor
• Feb. 16, 2016 Amgen launches Kyprolis in the UK for multiple myeloma
• Feb. 16, 2016 HHS chief mulling controversial 'march-in' to smack down patents & tackle drug prices
• Feb. 16, 2016 New PCSK9s & heart meds face slow uptake, brush up against payer review requirements
• Feb. 16, 2016 Global API market ballooning, will hit $186 billion by 2020: report
• Feb. 16, 2016 UK regulator smacks Glaxo with $54.4 million fine over pay-for-delay deals
• Feb. 16, 2016 UK High Court delivers heavy blow to Lilly in patent spat over blockbuster Alimta
• Feb. 16, 2016 Struggling Clovis to once again chase FDA favor for would-be Tagrisso competitor
• Feb. 16, 2016 China's next big move to bolster domestic drug industry: Market consolidation
• Feb. 11, 2016 Dr. Reddy's Q3 earnings flat despite FDA woes
• Feb. 11, 2016 Taiwan earthquake leaves drug API plants unscathed
• Feb. 11, 2016 In search for specialists, Teva laying off factory workers at UK plant
• Feb. 11, 2016 Biopharma giants Biogen & Sanofi buy into round A for Tony Coles' Yumanity
• Feb. 11, 2016 Egypt facing major drug supply crisis fueled by weak currency & political turmoil
• Feb. 11, 2016 Gene editing: The latest national security threat?
• Feb. 10, 2016 Competition from Lilly's Trulicity weighs on Novo's otherwise solid Q4
• Feb. 10, 2016 Breaking down Super Bowl 50's pharma ads: A bold moment for gut drugs
• Feb. 10, 2016 Shire gets new PDUFA date for eye drug hopeful once spurned by FDA
• Feb. 10, 2016 J&J, Viacyte team up on a potential stem cell therapy 'cure' for type 1 diabetes
• Feb. 10, 2016 You've got InMail: Pharma ratcheting up use of LinkedIn for marketing
• Feb. 10, 2016 Sanofi CEO wants to leverage Dengue vax success to expedite Zika vaccine development
• Feb. 10, 2016 BIO CEO 2016: What it will take to achieve Cancer MoonShot 2020
• Feb. 9, 2016 Clinics peddling unauthorized stem cell treatments face FDA heat
• Feb. 9, 2016 A besieged drug industry launches major new ad campaign to woo lawmakers
• Feb. 9, 2016 BIO CEO 2016: Purdue pursues deals, boosting the NIH, Schumer slams Shkreli, & more
• Feb. 7, 2016 FDA staff sounds encouraging note on Celltrion's biosim of J&J blockbuster Remicade
• Feb. 7, 2016 Supernus wins court victory over Allergan in epilepsy drug patent spat
• Feb. 7, 2016 OncoGenex slashes workforce after phase 3 cancer med setbacks
• Feb. 5, 2016 UPDATE: LifeSci Advisors apologizes for JPM party that stoked sexism critiques
• Feb. 5, 2016 A bankrupt KaloBios may still buy Chagas drug that Shkreli wanted to acquire-and-hike
• Feb. 5, 2016 Lundbeck wins key FDA backing for expanding depression drug Brintellix's label
• Feb. 5, 2016 Agilent accuses Twist Bioscience CEO of stealing trade secrets
• Feb. 4, 2016 Glaxo, Adaptimmune ratchet up cancer collab in $500 million deal
• Feb. 4, 2016 Statisticians question methods used in deadly Bial study
• Feb. 4, 2016 Allergan's Texas plant primed for expansion, possible job growth
• Feb. 4, 2016 Pfizer, Merck, & other pharmas reviewing vaccine portfolios to address Zika emergency
• Feb. 4, 2016 Martin Shkreli goes to Washington—and refuses to say anything to Congress
• Feb. 3, 2016 From blunt force to electrical currents: Cancer treatment in the 21st century
• Feb. 3, 2016 New study: Pfizer's Chantix no more effective than nicotine patches
• Feb. 3, 2016 Old Novartis cancer flagship Gleevec heads to pharmacies as lower-cost generic
• Feb. 3, 2016 J&J heads to court over alleged talcum powder, ovarian cancer link
• Feb. 2, 2016 Insulin wars heat up as Novo's Tresiba bests Lantus in major safety outcomes trial
• Feb. 2, 2016 21st Century Cures progress may be hitting a partisan buzzsaw
• Feb. 2, 2016 Appeals court upholds drug companies' right to manufacture generic OxyContin
• Feb. 2, 2016 Obama seeks $755M for Cancer MoonShot, boosts to NIH & FDA
• Feb. 1, 2016 Express Scripts ditches Valeant diabetes med as part of 2016 formulary shakeup
• Feb. 1, 2016 A promising sign for 'Pfallergan' pipeline as Allergan depression med nabs 'breakthrough'
• Feb. 1, 2016 Hep C market poised for pricing rumble as Merck's cheaper med approved
• Jan. 29, 2016 How the brain disease model of addiction drives innovation in drug development
• Jan. 29, 2016 Q4 update: Bristol-Myers outperforms and Celgene misses EPS estimates
• Jan. 28, 2016 FDA alleges deleted files, hidden data at India's Wockhardt
• Jan. 28, 2016 Eisai grabs an FDA approval for life-extending soft tissue cancer drug
• Jan. 28, 2016 Catalent still in strategic acquisition mode after a slew of big deals
• Jan. 28, 2016 Editas Medicine prepping for IPO even as biotech market struggles
• Jan. 28, 2016 New study: Schizophrenia may be caused by gene-driven 'overpruning'
• Jan. 28, 2016 Novartis blames slower-than-expected Entresto growth in US on insurer tardiness
• Jan. 28, 2016 Top NCI scientist: 'Autologous' cell approach of firms like Kite, Juno will be main CAR-T focus
• Jan. 27, 2016 Focus on Brazil: In pursuit of the Zika vaccine
• Jan. 26, 2016 NEJM editor Drazen hit with big backlash over 'research parasites' comments
• Jan. 26, 2016 DTC TV ad spending fell in December, but Pfizer topped peers
• Jan. 26, 2016 Oxford Pharmascience hunting for a big pharma partner for painkiller marketing
• Jan. 26, 2016 US temporarily halts enrollment in Cigna Medicare Advantage & drug plans
• Jan. 26, 2016 Valeant CEO Pearson on the mend, but timing of return uncertain
• Jan. 26, 2016 Judge amends Shkreli's bail to let him travel to DC for drug pricing hearing
• Jan. 26, 2016 Roche investigating off-label Avastin use after 15 Indian patients hospitalized
• Jan. 26, 2016 Zika vaccine quest begins as WHO warns of spread to most countries in the Americas
• Jan. 25, 2016 Why 2 senators, including Sanders, just blocked a vote on Obama's FDA chief nominee
• Jan. 25, 2016 OPDP warns Hospira about misleading YouTube video
• Jan. 25, 2016 The biggest implications of ICJME's new clinical trial data sharing proposal
• Jan. 25, 2016 Researchers probing links between Down syndrome and Alzheimer's
• Jan. 25, 2016 Amgen wins big with Kyprolis expansion in US and Repatha approval in Japan
• Jan. 25, 2016 Sanofi expected to slash jobs as diabetes franchise feels the squeeze
• Jan. 22, 2016 Glaxo chief: Consumer unit can stand on its own—but don't expect a spinoff soon
• Jan. 22, 2016 Novo Nordisk eyes the future, expands presence in Iran as sanctions lift
• Jan. 21, 2016 Alkermes' depression drug flunks phase 3, shares nearly sliced in half
• Jan. 21, 2016 Study: FDA scrutiny, other competition likely to eat into Indian pharma growth
• Jan. 21, 2016 Drug firms like J&J cautious on FAAH inhibitors in wake of trial death in France
• Jan. 21, 2016 Glaxo, Qualcomm reportedly mulling med tech joint venture
• Jan. 21, 2016 Biden pushes Cancer MoonShot to corporate leaders in Davos, pitches faster approvals
• Jan. 20, 2016 Express Scripts shares rocked by antitrust suit, Anthem breakup threat
• Jan. 20, 2016 Nivalis grabs a key orphan designation for its cystic fibrosis drug
• Jan. 20, 2016 Big data: The key to healthier patients, better margins, & making Cancer MoonShot 2020 a reality
• Jan. 19, 2016 Off-label use of Avastin in India hospitalizes 15, sales halted in two states
• Jan. 19, 2016 Taiwan election results buoy biotech sector, president-elect seen as major ally
• Jan. 19, 2016 Eleven Bio shares fall off a cliff as ophthalmic drug fails second phase 3 trial
• Jan. 19, 2016 Samsung Bioepis scores first-ever Enbrel biosim approval in EU
• Jan. 15, 2016 FDA harshly criticizes Sarepta's Duchenne drug just one day after rejecting BioMarin's
• Jan. 15, 2016 Cipla's pipeline bursting with more than 200 drugs
• Jan. 15, 2016 Glaxo heading to court over generic Paxil claims in suicide case
• Jan. 15, 2016 Behind the scenes at the FDA: Why they ultimately approved Addyi
• Jan. 14, 2016 Analysts skeptical about Shire's Baxalta 'growth play' strategy
• Jan. 14, 2016 ASCO: Reform the 'clinical pathways' approach to cancer
• Jan. 14, 2016 Pay-for-delay deals continue to fall following FTC court victory
• Jan. 13, 2016 Cancer MoonShot 2020: Independence Blue Cross to cover genome sequencing costs
• Jan. 13, 2016 Pharma execs dismiss protests over drug pricing, focus on deal-making at JPM16
• Jan. 13, 2016 Cervical Health Awareness Month: How far we've come since Nixon declared war on cancer
• Jan. 13, 2016 Glaxo to stop paying physicians to promote its drugs
• Jan. 13, 2016 Roche and AbbVie move promising CLL drug towards finish line
• Jan. 12, 2016 Baxter again forced to recall IV solutions due to insect presence
• Jan. 12, 2016 Allergan acquires Anterios to enhance neurotoxin delivery, bolsters Botox portfolio
• Jan. 12, 2016 Study: PPIs for heartburn linked to increased risk of kidney disease
• Jan. 12, 2016 Supreme Court rejects Janssen appeal over $124 million Risperdal fine
• Jan. 12, 2016 Seres signs on with Nestlé Health Science in gut drug partnership
• Jan. 12, 2016 Novartis CEO to unveil growth program for Alcon unit amidst falling sales
• Jan. 12, 2016 Lawmakers urge NIH to combat high drug prices with patent overrides
• Jan. 11, 2016 Walgreens' leadership defends unconventional Valeant deal
• Jan. 11, 2016 Biotech Moderna partners with CRO to advance promising RNA therapies into trials
• Jan. 11, 2016 FDA accepts Sanofi/Regeneron application for RA drug
• Jan. 11, 2016 New year brings higher prices for 100 Pfizer drugs
• Jan. 8, 2016 Positive hemophilia B gene-therapy results boost UniQure stock
• Jan. 8, 2016 Medical marijuana clinics open in New York with strict restrictions
• Jan. 8, 2016 Deal-hungry J&J partners with Chinese firm to focus on hep B breakthrough
• Jan. 7, 2016 Zydus Cadila slapped with FDA GMP violation letter
• Jan. 7, 2016 Large cancer database upgraded to provide 3D insights
• Jan. 7, 2016 In efficiency bid, Novartis selling Alcon unit to Recipharm in $20M deal
• Jan. 7, 2016 Brazil trims vaccine doses as recession deepens
• Jan. 7, 2016 Biogen partners with Rodin on Alzheimer's research, possible buy-out opp
• Jan. 7, 2016 Number of violation letters issued by FDA hits all-time low
• Jan. 6, 2016 Global breast cancer treatment market forecast to hit $17.2 billion by 2021
• Jan. 6, 2016 How one pharma marketing exec hit back at the AMA's call to ban DTC drug ads
• Jan. 6, 2016 Actelion lines up a $160,000 price tag for PAH orphan med Uptravi
• Jan. 6, 2016 ACCME vs. PharmedOut: How credible is CME in the age of Addyi?
• Jan. 6, 2016 A lesson in DTC: What happened when a Vogue contributor took Addyi for a test run
• Jan. 5, 2016 Major Chinese pharma firm plots a $3 billion IPO in Hong Kong
• Jan. 5, 2016 Rat study finds link between neural tube defects and low PCSK9 levels
• Jan. 5, 2016 Baxalta strikes a $1.6B immuno-oncology deal ahead of potential Shire deal
• Jan. 4, 2016 Teva's MS hopeful takes another big hit in phase 3
• Jan. 4, 2016 New UK program gave 500 melanoma patients early access to Merck's Keytruda
• Jan. 4, 2016 Take two: Dr. Reddy's relaunches generic Nexium in new blue color
• Jan. 4, 2016 FDA oncology chief Pazdur scrutinized over cancer drug approvals after wife's death
• Jan. 4, 2016 Bill Ackman sells 14% of Valeant shares, citing tax purposes
• Jan. 4, 2016 WellCare ditches UnitedHealth in PBM scuffle, opts for CVS
• Jan. 4, 2016 The year ahead: 11 execs & experts predict what's in store for biopharma in 2016
• Dec. 23, 2015 Bionor Pharma's 'kick and kill' HIV therapy shows promise
• Dec. 23, 2015 In unique Valeant-Walgreens distribution deal, drugmaker to retain titles to its therapies
• Dec. 23, 2015 New CMS drug spending database reveals 7 drugs at least doubled in cost
• Dec. 23, 2015 Actelion lines up 2016 launch for newly approved PAH orphan drug Uptravi
• Dec. 23, 2015 Baxalta fielding buyout offers, but may land with Shire after all
• Dec. 23, 2015 FDA approves 2015's 45th new drug, AstraZeneca's gout med
• Dec. 22, 2015 11 biopharma execs & experts look back on 2015: A record year for record-breaking
• Dec. 22, 2015 Health regulators step in to investigate employee complaints against Theranos
• Dec. 22, 2015 Bayer pumping 335 million euros into CRISPR Therapeutics gene-editing partnership
• Dec. 22, 2015 ICER: Glaxo's new asthma drug massively overpriced, should cost 70% less
• Dec. 22, 2015 For pharma reps, typical in-service fare includes burgers & fries—but not pizza
• Dec. 22, 2015 UC Davis & Moffitt Cancer Center suspend KaloBios cancer trial after Shkreli debacle
• Dec. 21, 2015 Employers turn to new tactics to rein in drug costs
• Dec. 21, 2015 Sun Pharma's Halol plant gets FDA warning, shares slump 7%
• Dec. 21, 2015 Isis Pharma ditches its terrorism-tainted name, will now be Ionis Pharmaceuticals
• Dec. 21, 2015 Novartis CEO: Pharma needs to share both pain and gain with payers, providers
• Dec. 21, 2015 AstraZeneca's hopes for major cancer hopeful durvalumab dim
• Dec. 18, 2015 Fortune reporter offers apology for previous glowing coverage of Theranos
• Dec. 18, 2015 Shire-Baxalta takeover drama barreling towards its final act
• Dec. 18, 2015 University of California invests $250 million in biotech venture fund
• Dec. 18, 2015 Chinese FDA's crackdown on poor-quality drugs shows no signs of easing up
• Dec. 18, 2015 Gilead snags 15% stake in Galapagos 3 months after AbbVie backs out
• Dec. 18, 2015 Narcan is just the beginning: Unleashing the power of opioid antagonism
• Dec. 17, 2015 Why genetic testing could be coming to a workplace near you
• Dec. 17, 2015 Novartis poaches a Harvard oncologist to head up immuno-oncology program
• Dec. 17, 2015 With eye on the future, AstraZeneca to beef up manufacturing, R&D presence in China
• Dec. 17, 2015 Glaxo's IL-6 antibody shows promise in rheumatoid arthritis
• Dec. 17, 2015 Advaxis soars as FDA releases patient death-related clinical hold on its drugs
• Dec. 16, 2015 Ted Cruz proposes controversial plan to expedite drug approvals through 'reciprocity'
• Dec. 16, 2015 Mylan to Strides: Help us cover the tab for your noncompliant plants
• Dec. 16, 2015 Amgen to snatch 3 drugs back from Glaxo in key int'l markets
• Dec. 16, 2015 Pharma's 1st Amendment battle rages on as Pacira, FDA reach Exparel settlement
• Dec. 15, 2015 Boehringer, Sanofi prepping complex asset swap of consumer, animal health units
• Dec. 15, 2015 Reckitt Benckiser taking heat from Australian, British watchdogs for pain med ads
• Dec. 15, 2015 Major research institutions fail transparency requirements, and pharma's not much better
• Dec. 15, 2015 Akebia strikes $350 million deal with Mitsubishi Tanabe for next-gen anemia pill
• Dec. 15, 2015 In surprising setback for Merck, FDA panel refuses to back broader Zetia indication
• Dec. 14, 2015 New study: Antidepressants in pregnancy may be linked to autism
• Dec. 14, 2015 FTC wants even more info from Walgreens & Rite Aid on proposed merger
• Dec. 14, 2015 Lilly prices cancer med Portrazza at nearly 10 times docs' recommendation
• Dec. 14, 2015 Valeant, in the hot seat, beefs up its legal and crisis management muscle
• Dec. 14, 2015 UPDATE: AstraZeneca buys 55% stake in Acerta for $4 billion
• Dec. 14, 2015 It's official: FDA shoots past 2014's new drugs record with Roche lung cancer med nod
• Dec. 14, 2015 FDA approves first-of-its-kind chemo overdose antidote, Vistogard
• Dec. 11, 2015 The new PCSK9 scorecard: Praluent favored by UnitedHealth, Repatha by CVS, both by Express Scripts
• Dec. 11, 2015 New study: Too many factories, too few inspectors for India's pharma industry
• Dec. 11, 2015 FDA AdComm recommends Teva asthma drug for adults—but not teens
• Dec. 11, 2015 The 'Soliris-killer' cometh? Alnylam plans final 2017 trials to take on world's priciest drug
• Dec. 11, 2015 A lead researcher and a Boehringer SVP on the drumbeat of innovation in oral anticoagulants
• Dec. 10, 2015 WSJ details the painstaking process behind pricing a major Pfizer cancer med
• Dec. 10, 2015 Sanofi scores landmark approval for world's 1st Dengue vaccine in Mexico
• Dec. 10, 2015 21st Century Cures orphan drug exclusivity measures could divide consumer and patients advocates
• Dec. 10, 2015 EMA chief: Faster drug approvals can quell Rx sticker shock
• Dec. 10, 2015 New analysis boosts Harvoni as 'safest' next-gen hep C option
• Dec. 9, 2015 New study: Chemical castration doubles risk of Alzheimer's disease
• Dec. 9, 2015 Flush with cash, Gilead chasing a mid-range deal like the one that gave it Sovaldi
• Dec. 9, 2015 Alexion scores FDA nod for orphan drug derived from genetically engineered chickens
• Dec. 9, 2015 FDA approves Baxalta's Vonvendi for von Willebrand bleeding disorder
• Dec. 8, 2015 Obama FDA nominee under the microscope as regulators review pivotal Xarelto trial he ran
• Dec. 8, 2015 Hillary Clinton to unveil 'exit tax' plan to combat inversion mergers like Pfizer/Allergan
• Dec. 8, 2015 Laguna Pharma calls it quits after phase 3 CVD drug flop
• Dec. 8, 2015 ASH15: Early-stage Keytruda trial shows unprecedented response in advanced multiple myeloma
• Dec. 8, 2015 Merck & Samsung Bioepis nab 2nd major biosim approval in Korea
• Dec. 7, 2015 Lilly's next-gen insulin hopes hit a buzzsaw as firm ditches late-stage diabetes candidate
• Dec. 7, 2015 Merck's Keytruda gets presidential lift as Jimmy Carter announces he's cancer-free
• Dec. 7, 2015 Mylan slapped with Justice Department subpoena over doxycycline pricing
• Dec. 7, 2015 ASH15: J&J/AbbVie's Imbruvica cuts CLL death risk; Bluebird/Celgene buoyed by NIH myeloma data
• Dec. 7, 2015 ASH15: Bluebird tanks 35% on gene therapy data; Novartis preps 2017 filing for blood cancer CAR-T
• Dec. 4, 2015 Medtronic's inversion deal has already saved it more than $9 billion
• Dec. 4, 2015 Inside the bold new fight for an HIV cure: An exclusive interview with amfAR CEO Kevin Robert Frost
• Dec. 4, 2015 Experts at gene-editing summit warn against using CRISPR-Cas9 to cure embryos
• Dec. 4, 2015 High specialty drug prices help drive renewed spike in 2014 healthcare spending
• Dec. 4, 2015 Pfizer shutting down another UK R&D site, nixing more than 100 jobs
• Dec. 4, 2015 Martin Shkreli's big regret: Not pricing Daraprim even higher
• Dec. 3, 2015 Can Rich Heyman score a buyout hat-trick with prostate cancer drug startup ORIC?
• Dec. 2, 2015 Pharma's PR problem: 53% of Americans blame pursuit of profits for high drug prices
• Dec. 2, 2015 Game on: Amgen files biosimilar Humira, pulls ahead of the pack
• Dec. 2, 2015 Pentagon official's emails demonstrate that Theranos concerns date back to 2012
• Dec. 2, 2015 US Senate report slams Gilead over Sovaldi price, insinuates culture of profits over patients
• Dec. 2, 2015 Adaptimmune heats up the immuno-oncology race & stares down Cellectis with Universal Cells deal
• Dec. 2, 2015 Influential GOP lawmaker calls for tax overhaul in wake of Pfizer-Allergan inversion deal
• Dec. 2, 2015 As Theranos deal fizzles, Safeway brings in Sonora Quest Labs for diagnostic tests
• Dec. 2, 2015 Express Scripts banishes Turing from formulary, turns to compounder for generic Daraprim
• Dec. 1, 2015 World AIDS Day: PrEP uptake main hurdle to 2030 eradication goal as Obama unleashes action plan
• Dec. 1, 2015 FDA approves 3rd multiple myeloma med in a month, this time from Bristol-Myers & AbbVie
• Dec. 1, 2015 World class panel of experts to tackle CRISPR, genome editing ethics during DC summit
• Dec. 1, 2015 How China is getting serious about developing quality drugs right at home
• Dec. 1, 2015 SCOTUS rejects Medtronic's patent-infringement restoration request against J&J
• Dec. 1, 2015 New York Stem Cell Foundation doubling its footprint in Manhattan
• Nov. 30, 2015 What's driving the rapid rise in dermatology drug prices?
• Nov. 30, 2015 Roche severs 'superbug' antibiotic R&D pact with Polyphor
• Nov. 30, 2015 Allergan beefs up its CNS portfolio ahead of Pfizer merger
• Nov. 30, 2015 In rare setback, Bristol-Myers' Opdivo denied expanded melanoma label
• Nov. 30, 2015 Could CRO revenues become a victim of the Pfizer-Allergan merger?
• Nov. 25, 2015 UPDATE: BioMarin Duchenne drug appears destined for failure after brutal FDA meeting
• Nov. 25, 2015 Defiant Ackman doubles down on stake in embattled Valeant
• Nov. 24, 2015 Robots, sound waves, and software: How AZ is beefing up tech at its UK R&D hub
• Nov. 24, 2015 After Pfizer-Allergan, few large inversion deal options for cash-rich companies
• Nov. 24, 2015 America's favorite pharma stock is Israel's Teva
• Nov. 24, 2015 Pricey hep C drugs found to be cost-effective in early disease and beyond
• Nov. 24, 2015 Int'l experts reprimand WHO over Ebola crisis response
• Nov. 24, 2015 In blow to Sanofi/Regeneron, CVS favors Amgen's competing PCSK9 med for its formulary
• Nov. 24, 2015 Bristol-Myers' unstoppable Opdivo now approved for advanced kidney cancer
• Nov. 24, 2015 Bristol-Myers, U.N. strike generic hep C drug production pact for poor nations
• Nov. 24, 2015 Roche's immuno-oncology blockbuster hopeful shines in early melanoma trial
• Nov. 24, 2015 How biopharma companies can thrive in the era of megamergers and shrinking budgets
• Nov. 23, 2015 Horizon Pharma ditches $1 billion hostile bid for Depomed
• Nov. 23, 2015 Samsung Bioepis close to major EU approval for Enbrel biosimilar
• Nov. 23, 2015 FDA approves 3rd multiple myeloma med of 2015, Takeda's Ninlaro
• Nov. 23, 2015 New data: Celldex brain cancer vaccine boosts long-term survival in advanced disease
• Nov. 23, 2015 AstraZeneca, Sanofi strike massive compound-sharing open research pact
• Nov. 20, 2015 KaloBios has been 'rescued' by Martin Shkreli—who is now its CEO
• Nov. 20, 2015 Multidrug resistant bacteria now stronger than super-strength antibiotics
• Nov. 20, 2015 Big pharma trying to quash CA drug price cap effort with massive campaign war chest
• Nov. 20, 2015 FDA approves first-ever nasal spray to fight opioid overdose
• Nov. 19, 2015 CAR-T companies scale up production with eye towards lowering costs
• Nov. 19, 2015 IMS 2020 forecast: Drug spending will hit a whopping $1.4 trillion
• Nov. 19, 2015 Sandoz chases 2-for-2 record as US biosim pioneer as FDA agrees to review copycat Neulasta
• Nov. 19, 2015 Early scripts for female libido pill Addyi fall flat, Valeant left holding the bag
• Nov. 19, 2015 In unexpected setback, UK cost regulators reject Amgen's PCSK9 drug
• Nov. 19, 2015 Innovation update: Advancing the standard of care in rheumatoid arthritis
• Nov. 18, 2015 Clovis Oncology's stock plummets on bad news about lung cancer drug
• Nov. 18, 2015 Genmab's multiple myeloma drug gets FDA approval, boosts EU biotech sector
• Nov. 18, 2015 Ex-Biogen exec presses ahead with new biotech
• Nov. 18, 2015 Paris attack forces Isis Pharma to again consider name change
• Nov. 18, 2015 AMA backs ban on direct-to-consumer pharma ads
• Nov. 17, 2015 J&J nabs early approval for first-of-its-kind multiple myeloma med Darzalex
• Nov. 17, 2015 Beyond trials: Real-world studies strengthen case for PrEP in HIV prevention
• Nov. 17, 2015 Lucentis more effective than lasers for reversing diabetes-induced blindness in new study
• Nov. 17, 2015 Senators to grill Obama's FDA commish nominee on pharma ties
• Nov. 17, 2015 India's Sun Pharma reportedly plotting to snatch Japanese drug portfolio from Novartis
• Nov. 16, 2015 Specialty pharma Irmat fights back, files suit against UnitedHealth Group in NY
• Nov. 16, 2015 NEJM joins the fray in drug pricing debate as 2 thought leaders share divergent perspectives
• Nov. 16, 2015 Billionaire Soon-Shiong's NantKwest forgoes R&D in favor of stock buyback
• Nov. 15, 2015 Merck stands by its CETP inhibitor for heart disease even as others flop
• Nov. 15, 2015 FDA approves Baxalta's longer-lasting hemophilia A drug
• Nov. 15, 2015 In major victory, AstraZeneca wins FDA approval for potential $3B lung cancer med
• Nov. 13, 2015 Roche to slash up to 1,200 jobs, shutter 4 plants in US and EU in major restructuring
• Nov. 13, 2015 Bioethics group: Gilead, Sanofi flunk the clinical trial transparency test
• Nov. 13, 2015 Merck's Cubicin protection efforts fail as appeals court invalidates 4 patents
• Nov. 13, 2015 China FDA cracks down on pharmas in quality control effort
• Nov. 13, 2015 Class-action suit alleges Endo birth control packaging errors led to unplanned pregnancies
• Nov. 12, 2015 With an eye towards more collabs, Boehringer takes an axe to its R&D budget
• Nov. 12, 2015 Google Life Sci, American Heart Association to pour $50M into heart research
• Nov. 12, 2015 In potential mega-merger with Pfizer, Allergan chief Saunders could become CEO
• Nov. 12, 2015 Horizon swipes back at Express Scripts as PBM cuts off drugmaker's specialty pharma
• Nov. 12, 2015 WSJ: $350M Theranos-Safeway deal dissolving, adding to startup's recent woes
• Nov. 11, 2015 Amgen flexes biologics muscle as Humira biosim nails an equivalence test for RA
• Nov. 11, 2015 FDA approves Genentech's Cotellic as part of melanoma combo
• Nov. 11, 2015 AstraZeneca may have a lupus blockbuster-in-waiting
• Nov. 11, 2015 Sanofi intentionally slowed a drug approval to avoid a $708M payout, Genzyme shareholder suit alleges
• Nov. 11, 2015 AHF: Gilead's new HIV med an attempt to evergreen, avoid patent expiration
• Nov. 10, 2015 Researchers just discovered how to make blood stem cell genome editing a lot better
• Nov. 10, 2015 Is Pfizer spinning its tax rate to justify a domicile-shifting merger with Allergan?
• Nov. 10, 2015 Another heart failure hopeful: Cytokinetics/Amgen med shows phase 2 promise
• Nov. 10, 2015 Allergan asks SCOTUS to take a hard look at pharma's controversial 'hard switch' tactic
• Nov. 10, 2015 Advantage grows for Lilly's Jardiance with more stellar heart failure data
• Nov. 9, 2015 AstraZeneca leapfrogs Actelion with $2.7B deal for ZS Pharma
• Nov. 9, 2015 Payers: Forget specialty drug costs—generic prices are crushing our budgets, too
• Nov. 9, 2015 23andMe redux? Startup DNA4Life gets FDA warning letter on DTC genetic testing kit
• Nov. 9, 2015 Novo's Victoza fails the 'Jardiance test,' doesn't improve heart outcomes in trial
• Nov. 9, 2015 Armed with FDA panel nod, Merck hopes long-languishing sugammadex will finally win approval
• Nov. 6, 2015 Insys Therapeutics under investigation for pushing powerful pain drug
• Nov. 6, 2015 Celgene takes M&A-related hit and posts Q3 loss, but optimistic about full year
• Nov. 6, 2015 Sanofi tries to reclaim diabetes momentum with $4.2B deal with Korean drug maker
• Nov. 6, 2015 Hello, Genvoya: Gilead does it again with approval of single-dose, once-daily HIV pill
• Nov. 6, 2015 A huge untapped opportunity for pharma marketing: Social media engagement with doctors
• Nov. 6, 2015 Why biotech darling Bluebird crashed on Thursday despite solid gene therapy data
• Nov. 5, 2015 Harvard study: Americans' prescription med use may be ballooning along with their waistlines
• Nov. 5, 2015 Pfizer late to immunotherapy game, teaming up with Merck for lung cancer treatment
• Nov. 5, 2015 The Jardiance effect: Novo hopes Victoza will show heart benefit, but wary of CV study design
• Nov. 5, 2015 How Roche is applying immunotherapy techniques to fight bacterial infections
• Nov. 5, 2015 AstraZeneca & Teva's Cephalon to pay feds, states $54M for alleged rebate fraud
• Nov. 5, 2015 As generic drug savings reach all-time high, experts ponder biosims' long-term impact
• Nov. 4, 2015 Walgreens, Mylan act to avoid antitrust violations as they pursue mega-deals
• Nov. 4, 2015 Doctors' 'do-not-see' policies for pharma reps may be declining—here's why
• Nov. 4, 2015 Bristol-Myers to snatch Cardioxyl for $2B, aiming for a novel heart failure med
• Nov. 4, 2015 With Philidor out, Valeant lays out new derm program for patients
• Nov. 4, 2015 Glaxo lays out ambitious plans for 20 new drugs by 2020, market shrugs
• Nov. 3, 2015 Shire snatches rare disease firm Dyax for $5.9B, won't take eyes off Baxalta prize
• Nov. 3, 2015 Why Mylan is taking its Perrigo pursuit to Tel Aviv's stock exchange
• Nov. 3, 2015 Why has uptake of Novartis' expected sales superstar Entresto been so slow?
• Nov. 3, 2015 AstraZeneca to generics makers: Back off our 'purple pill'
• Nov. 3, 2015 Express Scripts to put specialty pharmas under the microscope, focusing on Teva & AbbVie
• Nov. 2, 2015 FDA alleges major violations, use of old ingredients at Chinese Pfizer plant
• Nov. 2, 2015 Activist investor Ackman holds marathon call defending embattled Valeant
• Nov. 2, 2015 Merck chief Frazier's R&D-based drug price defense a tough sell for pharma
• Nov. 2, 2015 Can Novartis take on Boehringer and Glaxo with its new COPD combo?
• Nov. 2, 2015 The next challenge for CAR-T: Large-scale production
• Oct. 30, 2015 Valeant severs ties with controversial specialty pharma after mass PBM exodus
• Oct. 30, 2015 Sanofi, Novo forecasts dim prospects for insulin's unchallenged dominance
• Oct. 30, 2015 CA residents to vote on major drug price cap referendum in 2016
• Oct. 30, 2015 Vertex inches closer to profitability as CF drug sales smash estimates
• Oct. 30, 2015 Meet Baxter's new CEO: Covidien vet José Almeida
• Oct. 30, 2015 Hep C and long-term costs: Why safety is suddenly part of the value equation
• Oct. 29, 2015 Merck lowers cost of Remicade in UK as biosimilars enter market
• Oct. 29, 2015 Senate efforts to advance 21st Century Cures aims appear stymied
• Oct. 29, 2015 FDA approves Amgen's first-in-class oncolytic viral therapy
• Oct. 29, 2015 Despite concerns, Express Scripts sticks with AbbVie's hep C therapy
• Oct. 29, 2015 Theranos filed $200M stock offer days before critical news report
• Oct. 28, 2015 Gilead beats Q3 estimates substantially, shares slide anyways
• Oct. 28, 2015 A 1st gen Pfizer Alzheimer's drug may help keep patients out of the nursing home
• Oct. 28, 2015 How 2 biotechs are chasing a pioneering peanut allergy med
• Oct. 28, 2015 Glaxo faces another cardio R&D failure for a lead candidate
• Oct. 27, 2015 FDA inspection calls Theranos 'nanotainers' uncleared devices, cites quality assurance problems
• Oct. 27, 2015 A mixed bag for Merck despite data showing Keytruda extends lung cancer survival
• Oct. 27, 2015 Drug shortages & patent expiration: Authorized generics as more than a lifecycle strategy
• Oct. 27, 2015 Vertex, CRISPR Therapeutics strike gene editing pact worth up to $2.6B
• Oct. 27, 2015 Amgen reviewing privacy policy for Repatha patient assistance program
• Oct. 26, 2015 Alexion shocks with lower-than-expected price for just-approved orphan drug
• Oct. 26, 2015 Decade-old Novartis Parkinson's drug redeemed as FDA sees no CVD risk
• Oct. 26, 2015 Walgreens puts expansion of Theranos presence on hold
• Oct. 25, 2015 WHO: Introduction of first malaria vaccine should be delayed
• Oct. 25, 2015 FDA cautiously recommends approval of AZ's gout drug
• Oct. 25, 2015 ICER: US drug prices should align with value
• Oct. 25, 2015 Bristol-Myers' new HIV drug shines in mid-stage trials
• Oct. 23, 2015 GNC stock plunges as Oregon sues company, alleging drug-spiked supplements
• Oct. 22, 2015 Ouch: PhRMA SVP says Valeant isn't 'innovative,' acts more like a hedge fund
• Oct. 22, 2015 San Diego-based compounder to offer $1 alternative to Turing's Daraprim
• Oct. 22, 2015 Moderna launches yet another startup, Caperna, to develop cancer vaccines
• Oct. 22, 2015 FDA approves a new pancreatic cancer drug, Merrimack's Onivyde
• Oct. 22, 2015 Michigan governor urges Perrigo shareholders to reject Mylan deal
• Oct. 22, 2015 FDA questions AstraZeneca about safety of phase 3 gout drug
• Oct. 22, 2015 Novartis expands its immuno-oncology portfolio via M&A, partnerships
• Oct. 22, 2015 Biogen cutting 11% of workforce, betting big on Alzheimer's R&D
• Oct. 22, 2015 Theranos CEO goes to the lion's den, refutes accusations at WSJ Live conference
• Oct. 21, 2015 REPORT: American man in India illegally exported execution drugs to Nebraska, other states
• Oct. 21, 2015 The Amarin effect? FDA removes warning letter aimed at Pacira from web site
• Oct. 21, 2015 Merck plans to enter hep C market, take on Gilead & AbbVie with faster-acting combo drug
• Oct. 21, 2015 Valeant trading at 52-week low on report alleging 'phantom pharmacies' & fake sales
• Oct. 21, 2015 Actelion: We're interested in ZS Pharma, but not dependent on M&A
• Oct. 21, 2015 US, Saudia Arabia may collaborate on MERS vaccine
• Oct. 20, 2015 A Boehringer SVP and BioSig's CEO dish on the 'heart' of innovation
• Oct. 20, 2015 Daiichi Sankyo laying off more than 1,000 US workers
• Oct. 20, 2015 Bluebird stock plunges after patient treated with company's gene therapy relapses
• Oct. 20, 2015 Lilly's unconventional launch for Trulicity's consumer campaign
• Oct. 20, 2015 J&J's psoriasis star Stelara found effective for Crohn's patients in phase 3
• Oct. 19, 2015 Novartis cancer med Tasigna may hold promise for Parkinson's patients
• Oct. 19, 2015 FDA tells Theranos to stop using its tech except for approved herpes test
• Oct. 19, 2015 Shire's case for a Baxalta takeover dims as FDA spurns lead eye drug
• Oct. 19, 2015 FDA approves first-ever Pradaxa 'antidote,' BI's Praxbind
• Oct. 19, 2015 Bristol-Myers, Novartis score big in major blood cancer drug cost-benefit analysis
• Oct. 16, 2015 Pfizer chief Read: Lackluster insurance driving pharma's pricing woes
• Oct. 16, 2015 Breast Cancer Awareness Month: A look at recent innovations in breast cancer
• Oct. 16, 2015 Judge sides with PhRMA, rules orphan drugs not covered by 340B discount program
• Oct. 15, 2015 FDA schedules separate meetings to review BioMarin, Sarepta Duchenne drugs
• Oct. 15, 2015 Bristol-Myers, Five Prime forge $1.75B immuno-oncology development deal
• Oct. 15, 2015 Bombshell report puts Theranos in the hot seat, alleges blood test inaccuracies & false claims
• Oct. 15, 2015 J&J bullish that its own SGLT2 diabetes med will show Jardiance-like CV benefit
• Oct. 15, 2015 September DTC TV ad spending for pharma hits $231 million
• Oct. 15, 2015 Chinese firm plans large-scale production of Ebola vaccine
• Oct. 15, 2015 23andMe nabs $115M in new financing and a $1.1B valuation
• Oct. 15, 2015 The curious case of Zafgen's stock and a phase 3 patient death
• Oct. 14, 2015 Diabetes therapeutics: A hotbed of innovation and reservoir of pharma progress
• Oct. 14, 2015 NY Attorney General probing Turing, Shkreli over antitrust concerns
• Oct. 14, 2015 Why Bernie Sanders' opposition to Califf's FDA nomination is misguided
• Oct. 14, 2015 Lilly to collaborate with ImaginAB on T-cell therapies for cancer
• Oct. 13, 2015 Researchers: Bowel cancer can be categorized into four diseases
• Oct. 13, 2015 FDA delays decision on Collegium's painkiller
• Oct. 13, 2015 What Lilly's CVD drug failure means for other pharmas
• Oct. 13, 2015 J&J bests Q3 estimates, announces $10B buyback; Earnings dogged by strong dollar
• Oct. 13, 2015 Big pharmas to meet police chief who published CEOs' numbers over opioid crisis
• Oct. 13, 2015 Good news on the horizon for Indian pharma as FDA ramps up approvals
• Oct. 13, 2015 Reuters: Prices for top drugs in US 3 times higher than in UK
• Oct. 13, 2015 Controversy erupts over pediatric OxyContin guidance
• Oct. 12, 2015 AstraZeneca hits the brakes on 2 lung cancer trials after safety concerns
• Oct. 12, 2015 Cigna eliminates mail-order requirement for HIV drugs
• Oct. 12, 2015 Novartis pours another $15M into Israeli stem cell company
• Oct. 12, 2015 Bristol-Myers' Opdivo nabs expanded lung cancer indication
• Oct. 9, 2015 Senators propose adding nurses, physician assistants to Open Payments database
• Oct. 9, 2015 Neurocrine's movement disorder drug shows promise, has blockbuster potential
• Oct. 9, 2015 Could 'pay-for-performance' be coming to a prescription drug near you?
• Oct. 9, 2015 Allergan, Valeant rethink 'acquire-and-hike' pricing strategy amid Shkreli-driven anger
• Oct. 9, 2015 Roche MS drug shows big promise in harder-to-treat form of disease
• Oct. 9, 2015 An inside look at Lilly's NYC expansion & focus on cancer immunotherapy
• Oct. 8, 2015 Ireland-based Horizon plans big expansion, hiring spree in Chicago suburbs
• Oct. 8, 2015 Pharma loves priority review vouchers—The FDA? Not so much
• Oct. 8, 2015 FDA halts Advaxis immuno-oncology trials after patient death
• Oct. 8, 2015 An innovation challenge: Using pharma R&D as a tool for social change
• Oct. 8, 2015 FDA commish-in-waiting removes name from papers criticizing agency
• Oct. 7, 2015 Study: Merck hep C combo effective in kidney disease patients
• Oct. 7, 2015 Roche looks to Cotellic melanoma combo to boost Zelboraf sales
• Oct. 6, 2015 Feds lose dietary supplement case against Bayer
• Oct. 6, 2015 Valeant fights back against drug pricing criticism as stock tumbles
• Oct. 6, 2015 The bubble burst cometh? Biotech stocks down 21% since July
• Oct. 6, 2015 Alkermes generic for blockbuster schizophrenia med Abilify bags FDA nod
• Oct. 6, 2015 Bristol-Myers settles SEC charges over China bribery scandal for $14.2M
• Oct. 6, 2015 Spark inches closer to a pioneering US gene therapy approval
• Oct. 6, 2015 Indian foreign secretary: EU ban on generic drugs 'unwarranted'
• Oct. 6, 2015 CA governor signs controversial medication-assisted suicide bill
• Oct. 5, 2015 Almost half of UK doctors have negative view of pharma industry
• Oct. 5, 2015 TPP trade deal reached, BIO & PhRMA unhappy with drug patent compromise
• Oct. 5, 2015 Amicus delays regulatory submission for Fabry drug
• Oct. 5, 2015 Where are the women in HIV drug trials?
• Oct. 5, 2015 Merck's Keytruda wins lung cancer indication—but it's not as broad as Opdivo's
• Oct. 2, 2015 Sarepta's new strategy for winning a landmark Duchenne drug approval
• Oct. 2, 2015 FTC asks Court of Appeals to reexamine Doryx 'product-hopping' case
• Oct. 2, 2015 EMA nominates Guido Rasi as executive director—again
• Oct. 2, 2015 TPP trade talks stuck in the mud over US drug exclusivity demands
• Oct. 2, 2015 Bristol-Myers' Opdivo/Yervoy combo wins FDA approval, will cost $256,000
• Oct. 2, 2015 Chasing a ghost: Why is FDA guidance on biosim interchangeability taking so long?
• Oct. 1, 2015 Private artificial intelligence firm to help data mine for UK genomics project
• Oct. 1, 2015 Teva exec: Pharma needs to face its pricing demons head-on
• Oct. 1, 2015 WHO pushes for far more aggressive worldwide use of HIV meds
• Oct. 1, 2015 Clovis set for showdown with AZ as it wins fast-track for lung cancer drug
• Oct. 1, 2015 Global standoff looms between US, developing nations over WTO waiver extension
• Sept. 30, 2015 Sanofi hopes to broaden diabetes portfolio as FDA accepts lixisenatide submission
• Sept. 30, 2015 Can Lilly & Incyte elbow their way into a crowded market with promising RA drug?
• Sept. 30, 2015 Pioneering Novavax RSV vaccine passes protection to newborns, wins $89M from Gates Foundation
• Sept. 30, 2015 Aiming to cure blindness, UK team implants embryonic retinal cells in AMD patient
• Sept. 29, 2015 Allergan riding high with 10% increase in branded product revenues
• Sept. 29, 2015 Novartis backs graphic novel featuring a teen with a rare disease—and his dog
• Sept. 29, 2015 Kyle Bass escapes USPTO sanctions on drug patent challenges, BIO balks
• Sept. 29, 2015 Lilly settles Sanofi dispute, plans 2016 launch for biosim Lantus
• Sept. 29, 2015 House Dems demand Valeant CEO testify on price hikes with Shkreli, stock plunges
• Sept. 28, 2015 FDA approves Bayer's autoinjector for MS drug
• Sept. 28, 2015 Glaxo shutting down French research lab, laying off 70 employees
• Sept. 28, 2015 FDA revokes Sun Pharma's approval for epilepsy drug after compliance concerns
• Sept. 28, 2015 Bristol-Myers' Opdivo boosts kidney cancer survival, Roche PD-L1 hopeful shrinks tumors
• Sept. 28, 2015 The diabetes king? Novo finally gets its Tresiba long-acting insulin approval
• Sept. 25, 2015 FDA warns Pathway Genomics cancer blood test 'may harm the public health'
• Sept. 25, 2015 After bad news on Breo, Glaxo's monthly asthma drug wins an EU rec
• Sept. 25, 2015 Arrowhead hep B treatment shows early promise, sends shares flying
• Sept. 25, 2015 Novartis to tackle chronic diseases in poor countries with new program
• Sept. 24, 2015 Top US cardiologists push to limit PCSK9 drug patient pool
• Sept. 24, 2015 Nestlé partners with AC Immune to expand into Alzheimer's diagnostics
• Sept. 24, 2015 Amgen-Allergan's Avastin biosimilar shows promise in lung cancer trials
• Sept. 24, 2015 Are the EU's steep biosim discounts the ghost of US biosimilars' future?
• Sept. 24, 2015 FDA approves Taiho Oncology's pill for metastatic colorectal cancer
• Sept. 24, 2015 How the FDA is trying to demystify clinical trial data
• Sept. 23, 2015 Has the era of the super successful pharma sales rep really come to an end?
• Sept. 23, 2015 A 'reverse Turing?' Nonprofit reacquires TB drug, rolls back massive price hike
• Sept. 23, 2015 Report: J&J had plan to block more FDA restrictions on Tylenol
• Sept. 23, 2015 AZ using crowdsourcing to find effective cancer drug combos
• Sept. 23, 2015 India's Serum Institute chases fast-track approval for dengue treatment as cases spike
• Sept. 23, 2015 Study: Cancer drugs in US cost up to 6,000% of production cost
• Sept. 22, 2015 UPDATE: Shkreli backtracks on 5,000% price hike after outrage, doesn't specify new cost
• Sept. 22, 2015 Clinton calls out Turing & Shkreli on wild price hike, releases pharma cost cap plan
• Sept. 22, 2015 Bristol-Myers' immuno-oncology star Opdivo nabs kidney cancer priority review
• Sept. 22, 2015 Shire's once-daily extended-release ADHD drug now approved in Europe
• Sept. 22, 2015 Mass. police chief lists big pharma CEO phone numbers as part of opioid addiction fight
• Sept. 22, 2015 After Harvoni: A pangenotype hep C combo could be Gilead's next breakthrough
• Sept. 21, 2015 Merck's antibody-in-development reduces risk of C. difficile re-infection
• Sept. 21, 2015 2nd time's the charm for Allergan, Richter antipsychotic drug
• Sept. 21, 2015 Obama's FDA chief nominee received more than $200K in industry fees
• Sept. 21, 2015 Lilly/BI's Jardiance found to be first diabetes med to cut CV deaths in study
• Sept. 17, 2015 Aerie Pharma's glaucoma eye drop shows promise in late-stage trial
• Sept. 17, 2015 Another big pharma exec leaves for a biotech—from Glaxo to Celyad
• Sept. 17, 2015 AstraZeneca forges partnership with BARDA to develop powerful antibiotics
• Sept. 17, 2015 Report: Glaxo withheld critical data on antidepressant Seroxat
• Sept. 17, 2015 Why several FDA reviewers recommended not approving female libido med Addyi
• Sept. 17, 2015 An update on first-ever US biosim Zarxio 2 weeks after its debut
• Sept. 17, 2015 Merck's once-weekly diabetes med as effective as daily Januvia in study
• Sept. 16, 2015 Amgen snaps up Dutch biotech Dezima for $1.55 billion
• Sept. 16, 2015 Intra-Cellular shares fly as schizophrenia drug shown effective at higher doses
• Sept. 16, 2015 Veteran NIMH director leaving agency to join Google Life Sciences
• Sept. 16, 2015 Meet Travis McCready, the next head of the MA Life Sciences Center
• Sept. 16, 2015 AbbVie, Janssen chase first-line approval of Imbruvica for CLL
• Sept. 16, 2015 Xenoport shares dive as psoriasis drug shows serious GI side effects
• Sept. 16, 2015 The gender gap is especially severe in biotech lab funding
• Sept. 16, 2015 The next hope for GW Pharma's cannabis med: Schizophrenia treatment
• Sept. 16, 2015 Steve Brill unleashing 15-part exposé on J&J, Risperdal: 'America's Most Admired Lawbreaker'
• Sept. 15, 2015 Reputation matters: Why the rift between pharma and patients is ballooning
• Sept. 15, 2015 Shire may be upping the ante in pursuit of Baxalta—with faster cash
• Sept. 15, 2015 Acacia planning $232 million IPO in London market
• Sept. 15, 2015 Takeda floats conditional $100M boost to $2.3 billion Actos settlement
• Sept. 15, 2015 10th Indian pharma plant this year makes FDA's do-not-import list
• Sept. 15, 2015 UPDATE: Mylan officially takes $27B hostile bid to Perrigo shareholders
• Sept. 15, 2015 Federal task force narrows aspirin use guidelines, suggests cancer benefit
• Sept. 14, 2015 Lilly boosting size of Kendall Square innovation center
• Sept. 14, 2015 A tale of two painkillers: Collegium gets FDA panel rec that eludes Purdue
• Sept. 14, 2015 2 new studies show Gilead's Truvada extremely effective for HIV prevention
• Sept. 14, 2015 Amgen goes after once-monthly dosing option for Repatha
• Sept. 11, 2015 Express Scripts CEO Paz to retire next May, leaving legacy of price pushbacks
• Sept. 11, 2015 Another biotech M&A? Actelion, ZS Pharma in 'strategic transaction' talks
• Sept. 11, 2015 Pfizer loses major Lyrica patent case in UK, leaving door for generics wide open
• Sept. 11, 2015 Gilead raises $10 billion, stoking fresh rumors of a monster acquisition
• Sept. 11, 2015 Georgia opens $14M bioscience training center next to Baxalta plant
• Sept. 10, 2015 How to stop a biopharma compliance breach before it happens
• Sept. 10, 2015 FDA concerned about dosing risk with Collegium's opioid painkiller
• Sept. 10, 2015 Russia's Putin reiterates commitment to 90% domestic drug-making by 2020
• Sept. 10, 2015 Africa's largest generic drug maker is on the hunt for acquisitions
• Sept. 10, 2015 ICER report says $14,000 PCSK9 meds should actually cost 70% less
• Sept. 10, 2015 Biogen strikes $544M deal with Mitsubishi Tanabe for late-stage autoimmune drug
• Sept. 9, 2015 PayPal co-founder Peter Thiel pours $200M into cancer stem cell biotech
• Sept. 9, 2015 Merck/Samsung Bioepis win their 1st biosim approval in Korea—for copycat Enbrel
• Sept. 9, 2015 Roche CEO slams 'stupid,' 'arbitrary' UK decision to cut 17 cancer meds' funding
• Sept. 9, 2015 Glaxo takes a big blow as 'son of Advair' fails to extend COPD patients' lives
• Sept. 8, 2015 New study claims Pfizer's Chantix not linked to depression, heart attacks after all
• Sept. 8, 2015 A big win for AZ as FDA clears Brilinta for long-term use
• Sept. 8, 2015 Former Hospira chief's platinum parachute: $91 million in cash
• Sept. 8, 2015 Bristol-Myers is testing out a dual-threat Opdivo/Yervoy lung cancer combo
• Sept. 4, 2015 Experimental treatment offers hope for CAR-T leukemia patients
• Sept. 4, 2015 World's largest public stem cell bank now open in CA
• Sept. 4, 2015 Valeant partners with AZ on psoriasis drug
• Sept. 4, 2015 More than half of doctors have 'no access' policies for reps
• Sept. 4, 2015 Moody's upgrades financial outlook for biopharma industry
• Sept. 3, 2015 Regeneron scientists score rare disease breakthrough with excess bone growth discovery
• Sept. 3, 2015 The key facts to know about the FDA's new 340B drug discount guidance
• Sept. 2, 2015 Amgen launching PCSK9 med Repatha in Europe at steep discount to US price
• Sept. 2, 2015 How 2014 became a banner year for biotech job growth in MA
• Sept. 2, 2015 US biosimilar era officially dawns as Novartis' Zarxio launches Thursday
• Sept. 2, 2015 Biosimilars Council chief answers 6 key questions about biosims in the US
• Sept. 2, 2015 Pharma takes major offense to French law promoting off-label Avastin use
• Sept. 2, 2015 Alexion wins EU nod for newly acquired enzyme-replacement drug
• Sept. 2, 2015 Pharma lobbies Congress for big—and expensive—changes to patent rules
• Sept. 2, 2015 Novartis and Amgen team up to take on Alzheimer's, migraines
• Sept. 2, 2015 2 major insurers draw lines in the sand for pricey PCSK9 coverage
• Sept. 1, 2015 Baxalta may have a new M&A-based strategy for spurning Shire
• Sept. 1, 2015 Bristol-Myers sets sights on a Jakafi competitor with $1.25B fibrosis firm deal
• Aug. 31, 2015 How do you solve a problem like drug shortages?
• Aug. 31, 2015 Bayer lines up a phase III trial for its dual-threat heart failure hopeful
• Aug. 31, 2015 Asterias stem cell therapy shows promise in spinal cord injury patients
• Aug. 31, 2015 Novo Nordisk acquiring 2 US biotechs, Calibrium and MB2
• Aug. 31, 2015 Oncologists question Lilly lung cancer hopeful's pricing in growing trend
• Aug. 31, 2015 Stem cell researcher at major Swedish research hub cleared of misconduct
• Aug. 31, 2015 FDA warns: DPP-4 inhibiting diabetes meds may cause severe joint pain
• Aug. 31, 2015 An experimental anti-cholesterol drug could outperform approved PCSK9 meds
• Aug. 28, 2015 Macro-level innovation: A Q&A with Bain & Company's healthcare guru
• Aug. 28, 2015 FDA's new draft guidance on naming biosimilars already drawing pushback
• Aug. 28, 2015 Lilly/BI snag another FDA approval for a diabetes drug—Synjardy
• Aug. 27, 2015 FDA demands another study for uniQure's ultra-pricey gene therapy
• Aug. 27, 2015 J&J/Genmab unveil promising data for a potential multiple myeloma superstar
• Aug. 27, 2015 Massachusetts leads states' war on high drug prices
• Aug. 27, 2015 FTC to FDA: Ramp up oversight on homeopathic drug makers
• Aug. 27, 2015 Pfenex at the forefront: How a different biosim approach is becoming a disruptive force
• Aug. 27, 2015 Novo jumping into phase III trials for major oral diabetes candidate
• Aug. 26, 2015 In big win for pharma, advocates urge WH to push broader Medicaid hep C coverage
• Aug. 26, 2015 Novo Nordisk planning $1.2 billion US expansion, bringing 700 jobs to NC
• Aug. 26, 2015 Sarepta wins priority review for hotly anticipated Duchenne drug
• Aug. 26, 2015 How Japan is trying to beef up its pharmaceutical industry
• Aug. 26, 2015 Bristol-Myers, Sanofi prevail in Plavix false claims case
• Aug. 26, 2015 UK's NHS commissions new TB drugs for first time in 50 years
• Aug. 26, 2015 Controversial fund manager Kyle Bass loses first major pharma patent battle
• Aug. 26, 2015 Could an aspirin a day keep colon cancer away?
• Aug. 25, 2015 Why Gilead's hep C scripts are slowing down in Q3
• Aug. 25, 2015 In huge victory for generics, court invalidates Takeda's Velcade patent
• Aug. 25, 2015 Study: Common beta blockers can extend ovarian cancer patients' lives
• Aug. 25, 2015 AZ poaches Genentech cancer vet Bohen, appoints him as new CMO
• Aug. 25, 2015 Why BioMarin hawked a phase III cancer drug to Medivation for $570M
• Aug. 24, 2015 US Army testing drug to protect soldiers' hearing
• Aug. 24, 2015 Excitement over Jardiance may come at Merck's expense
• Aug. 24, 2015 New tool aims to simplify cancer treatment cost/benefit analysis
• Aug. 24, 2015 Sarepta, Biomarin vie for DMD approval, priority review voucher
• Aug. 24, 2015 Novartis snaps up MS indication for Glaxo's Arzerra
• Aug. 21, 2015 Rare disease companies' existential challenge: Patient enrollment
• Aug. 21, 2015 Baxalta CEO touts new R&D model with a focus on development
• Aug. 21, 2015 Biosim behemoth? Partners Samsung and Biogen will float a $1 billion IPO
• Aug. 21, 2015 Jimmy Carter has cancer, and his treatment regimen includes Merck's Keytruda
• Aug. 21, 2015 Lilly/BI's Jardiance could be the first diabetes med to cut heart attack, stroke risk
• Aug. 21, 2015 How Addyi will change the way we talk about sex—and what it means for marketers
• Aug. 19, 2015 Lundbeck shredding 1,000 jobs, 17% of workforce—and its stock is up big
• Aug. 19, 2015 AbbVie snaps up priority review voucher from United Therapeutics for $350M
• Aug. 19, 2015 Intarcia's diabetes pump bests Merck's Januvia in head-to-head trial
• Aug. 19, 2015 Merck chief Frazier touts extra day off for workers, union not impressed
• Aug. 19, 2015 Moving beyong licensing, gene therapy firm ReGenX plans $100 million IPO
• Aug. 19, 2015 Tables turned: Mylan cited by FDA for quality violations at Indian plants
• Aug. 19, 2015 Biogen & Columbia team up to unlock ALS genetics, with some 'Ice Bucket' cash
• Aug. 19, 2015 Concordia and Par settle FTC's anti-competition charges
• Aug. 18, 2015 Merck star Keytruda nabs priority review for first-line treatment of metastatic melanoma
• Aug. 18, 2015 UPDATE: Sprout plots hiring binge after controversial female libido drug approval
• Aug. 18, 2015 Retrophin sues outspoken founder Shkreli for $65M over alleged misuse of funds
• Aug. 18, 2015 Kite Pharma does damage control, quashes drug-induced patient death rumors
• Aug. 18, 2015 Roche's immunotherapy hopeful keeps rolling, this time in phase II lung cancer trial
• Aug. 18, 2015 The next viruses in Gilead's crosshairs: HIV and hep B
• Aug. 17, 2015 Genmab receives $2 million from Novo Nordisk for DuoBody platform
• Aug. 17, 2015 Big win for Endo: Court rules against Actavis in generic painkiller patent spat
• Aug. 17, 2015 Lawmakers set their sights on Valeant and its steep heart drug price hikes
• Aug. 17, 2015 FDA approves OxyContin use in some children
• Aug. 17, 2015 In Mylan-Perrigo hostile takeover drama, it's proxy firm vs. proxy firm
• Aug. 10, 2015 Mylan reports a solid Q2, outpaces analysts' expectations
• Aug. 10, 2015 The challenges of China for Western drug makers
• Aug. 7, 2015 Where biotech is booming: From Boston, to Raleigh, and beyond
• Aug. 7, 2015 AZ, Heptares heading into immuno-oncology partnership
• Aug. 7, 2015 Novo reports stronger-than-expected Q2, raises full-year forecast
• Aug. 7, 2015 Novo's chief medical officer dishes on innovation in diabetes drug development
• Aug. 6, 2015 Armed with stronger label, can Sanofi's Toujeo perform better in the UK?
• Aug. 6, 2015 Express Scripts' 2016 formulary: Who's in, who's out, & how did they decide?
• Aug. 6, 2015 CNS-focused US cannabis patch company raises $42M in IPO
• Aug. 6, 2015 Shire's pursuit of Baxalta stymied by strong takeover defenses
• Aug. 6, 2015 India cancels EU trade talk meeting over widespread drug ban
• Aug. 5, 2015 FDA to update Novartis' Gilenya label with brain-infection risk warning
• Aug. 5, 2015 Bayer, Berkeley-based biotech labor union settle 4-year contract
• Aug. 5, 2015 Bevy of factors to lift pharma sales to $1.3 trillion by 2018: Thomson Reuters
• Aug. 5, 2015 Akorn accused of infringing Allergan's Lumigan patents
• Aug. 5, 2015 Pfizer gains EU antitrust approval for Hospira acqusition
• Aug. 4, 2015 A rare case: Young woman with Duchenne's waiting for a cure
• Aug. 4, 2015 Shire buying Foresight Biotherapeutics and its pink eye drug for $300M
• Aug. 4, 2015 AZ & Isis Pharma expanding collaborative gene therapy R&D
• Aug. 4, 2015 Merck's hep C positioning strategy: Target toughest-to-treat patients
• Aug. 4, 2015 Aprecia's Spritam becomes first FDA-approved 3D printed medication
• Aug. 3, 2015 Sanofi, riding high from a strong Q2, may put its crosshairs on acquisitions
• Aug. 3, 2015 All-in? AstraZeneca soldiers forward with psoriasis hopeful despite suicide link
• Aug. 3, 2015 Big federal funding for vets' hep C treatments sneaked into highway bill
• Aug. 2, 2015 FDA: Hospira infusion system vulnerable to hackers
• Aug. 2, 2015 Biologic patent life emerges as sticking point in failed TPP talks
• July 31, 2015 Amgen raises full-year outlook on strong Q2 earnings
• July 31, 2015 Is there a link between Teva's bribery probe and a former employee's firing?
• July 31, 2015 Afrezza sales still underperforming, but MannKind remains optimistic
• July 31, 2015 Kaiser CEO pens powerful op-ed on drug costs, calls for new pricing model
• July 30, 2015 From Glaxo to Parexel—and now, unemployed
• July 30, 2015 The Teva-Allergan deal and the power of the 'focus factor'
• July 30, 2015 Uh-oh: Glaxo facing new corruption charges—this time, in Romania
• July 30, 2015 Sanofi's LixiLan aces a late-stage trial, setting up diabetes showdown with Novo
• July 30, 2015 Largest US benefits manager warns PCSK9 meds will 'wreak havoc' on payers
• July 30, 2015 Novartis gets on risk-sharing bandwagon, spins off 3 pipeline drugs into new biotech
• July 30, 2015 Why Pfizer is abandoning its OTC Lipitor program
• July 29, 2015 Hospira's painkiller recall is ballooning—Is Pfizer getting nervous?
• July 29, 2015 Want a better placebo effect? Stick to needles over pills
• July 29, 2015 Welcome to the club: Regeneron, Sanofi to team up, join cancer immunotherapy fray
• July 29, 2015 Soon-Shiong's NantKwest has a record-setting IPO and zero approved drugs
• July 29, 2015 Stellar hep C sales help Gilead smash Q2 earnings estimates
• July 28, 2015 Aegerion CEO resigns amid tensions with institutional investors
• July 28, 2015 Could Sanofi's dengue vaccine become a game-changer?
• July 28, 2015 UCSD wins legal spat against USC over control of landmark Alzheimer's project
• July 28, 2015 Report finds pharma doesn't always report serious side effects to FDA in time
• July 28, 2015 EU upholds massive drug ban over alleged CRO data manipulation
• July 27, 2015 World Hepatitis Day: The transformation and enduring struggles of HCV treatment
• July 27, 2015 Sandoz closing three German and Indian factories
• July 27, 2015 AbbVie reports disappointing Q2 sales, better-than-expected profits
• July 27, 2015 Biogen's comeback strategy after $18B market value loss: More acquisitions
• July 27, 2015 Allergan buys Naurex for $560 million, nabs 2 antidepressants
• July 27, 2015 Teva to snap up Allergan's generics unit for $40.5B, become Big Pharma behemoth
• July 24, 2015 What's the most 'efficient' biopharma company of 2014?
• July 24, 2015 2nd gen radiotracers and Alzheimer's diagnosis in the age of early-intervention trials
• July 24, 2015 European regulators just announced a massive overhaul of pediatric waivers
• July 24, 2015 Eli Lilly stacking scientists in San Diego as part of R&D growth spurt
• July 24, 2015 US appeals court: Pharmacy responsibilities trump religious beliefs
• July 23, 2015 BMS and Exelixis make headway against Novartis in kidney cancer
• July 23, 2015 The FDA wants to figure out DTC ad claims' effect on consumers
• July 23, 2015 A tough setback for AZ as major eye cancer hopeful flunks phase III
• July 23, 2015 Roche renews commitment to R&D of two AD drugs
• July 23, 2015 Why Abbott's profits outperformed Q2 expectations
• July 22, 2015 Promising stem-cell clinical trial results for rare lung disease
• July 22, 2015 Amgen's Repatha becomes world's first approved PCSK9 inhibitor
• July 22, 2015 Q2 earnings update: Novartis sales slump on strong dollar, weak Alcon
• July 21, 2015 FDA chastises Vista Pharma for not paying generic drug user fees
• July 21, 2015 Tekmira to become Arbutus, shift focus to hep B
• July 21, 2015 An Alzheimer's update: New drugs, new insights, new hope
• July 21, 2015 NEJM: Early HIV therapy delays AIDS-related events & death
• July 20, 2015 Researchers are about to launch the largest AIDS treatment trial ever
• July 20, 2015 Bristol-Myers' rock star Opdivo continues to roll, this time in kidney cancer
• July 20, 2015 Novogen gets FDA approval for Anisina orphan drug status
• July 20, 2015 FDA grants AbbVie's anti-tau drug orphan status
• July 20, 2015 Amgen's leukemia drug excels in phase II for new indication
• July 20, 2015 NICE recommends Daiichi Sankyo's oral blood thinner
• July 20, 2015 WHO prequalifies Novartis' Coartem for malaria
• July 17, 2015 Innovation vs. access: The big drug battle in Trans-Pacific Partnership negotiations
• July 17, 2015 FDA huddles with Google to improve adverse-event reporting
• July 16, 2015 Teva gets FDA OK to market generic Axert
• July 16, 2015 Stem cell breakthrough for Salk Institute researchers
• July 16, 2015 BMS nabs EU approval for once-daily HIV combo pill
• July 16, 2015 Sun Pharma slashing Ranbaxy's contract manufacturing unit
• July 16, 2015 Sandoz closing plant in India
• July 16, 2015 Sanofi restructuring business to drive growth
• July 16, 2015 Why some new drugs are truly earning the 'innovative' label
• July 16, 2015 ASCO scorecard upgrades rating for Lilly's Alimta
• July 16, 2015 Allergan faces lost sales as Namenda generics hit market
• July 16, 2015 J&J/Bavarian Nordic launching phase II Ebola vaccine trial
• July 15, 2015 J&J could reopen closed factory, revive OTC business
• July 15, 2015 New depression treatment approach could provide relief within hours
• July 15, 2015 NHS Scotland approves funding for five new drugs
• July 15, 2015 Celgene buying Receptos for $7.2 billion
• July 15, 2015 EU agency to investigate HPV vaccine safety
• July 14, 2015 FDA approves AZ's Iressa for lung cancer
• July 13, 2015 Roche's PD-L1 drug slows bladder cancer growth in trials
• July 13, 2015 Study: Type 2 diabetes linked with cognitive decline
• July 13, 2015 Amgen awaiting FDA decision on cancer drug Kyprolis
• July 13, 2015 Janssen-Cilag's Imbruvica approved in EU to treat rare blood cancer
• July 12, 2015 Analysts back Biomarin's stock as it reaches new high
• July 12, 2015 R&D head leaving Biogen for startup
• July 12, 2015 In reversal, NHS making Takeda's Entyvio available to Crohn's patients
• July 12, 2015 FDA approves Otsuka/Lundbeck drug for both depression and schizophrenia
• July 12, 2015 Study: Off-label use of antipsychotics growing in teens/young adults
• July 10, 2015 A 21st century diabetes option: Will Oramed be first to market with oral insulin?
• July 10, 2015 What Glaxo's strategy guru thinks the future holds for HIV markets
• July 10, 2015 Walgreens taps Pessina as permanent CEO after besting Q3 expectations
• July 10, 2015 Will public pressure drive the FDA to approve a so-so female libido drug?
• July 10, 2015 FDA support for Lilly cancer drug comes down to unmet needs vs side effects
• July 10, 2015 AstraZeneca divests gastro drug for $215 million
• July 9, 2015 Insurers are getting bigger—What does that mean for pharma's pricing power?
• July 9, 2015 Senior congressman joins chorus calling for heroin antidote price cut
• July 9, 2015 One big change bolstering gene therapy enthusiasm? Better viral delivery systems
• July 9, 2015 Novartis files leukemia drug Arzerra in the EU
• July 9, 2015 UCSD calls out USC for alleged unethical recruiting of its Alzheimer's researchers
• July 8, 2015 CF Foundation gains massive windfall from Vertex's Kalydeco
• July 8, 2015 CVS Health quit tobacco—and now it's quitting the Chamber of Commerce
• July 8, 2015 Another Indian CRO in hot water, this time with the WHO
• July 8, 2015 Lilly's lung cancer drug seen as risky by FDA—but will that matter?
• July 8, 2015 Horizon Pharma in hostile pursuit of Depomed for $3 billion
• July 7, 2015 Sanofi, Gilead get boosts in Japan with new Lantus & Harvoni approvals
• July 7, 2015 Biogen pursuing AGTC's ophthalmology gene therapy—for up to $1 billion
• July 7, 2015 Pharma's newest adversaries on CME funding are... Hotel workers?
• July 7, 2015 Pharma flings accusations, dire predictions in wake of Greek financial crisis
• July 6, 2015 Will Vertex finally become profitable after FDA approval for CF drug Orkambi?
• July 6, 2015 J&J moves HIV vax to human trials after 50% protection rate in monkeys
• July 6, 2015 Another Roche Alzheimer's drug disappoints
• July 6, 2015 Promise, and caution, as gene therapy shows potential for cystic fibrosis
• July 6, 2015 Big deal for biosims? Major French hospital group opts for Hospira's Remicade copy
• July 2, 2015 In rare move, Purdue pulls out of abuse-deterrent OxyContin meeting with FDA
• July 2, 2015 Drug makers warn EU over troubled Greece: Medicine supply 'may be in jeopardy'
• July 2, 2015 FDA gives pharmacies grace period to implement 'track and trace'
• July 2, 2015 New study: Glaxo flu vax linked to increased narcolepsy risk
• July 2, 2015 Novo to halt Tresiba sales in Germany over pricing conflict
• July 2, 2015 'Innovation' is everywhere in biopharma—but what does that actually mean?
• July 1, 2015 Roche impresses with strong phase III data for MS drug candidate
• July 1, 2015 DOJ wants to fine Novartis a staggering $3.35 billion for kickbacks
• July 1, 2015 California governor signs mandatory vaccination bill into law
• July 1, 2015 Open Payments: Docs got $6.5 billion from drug/device industries in 2014
• July 1, 2015 Sanofi/MannKind might be facing a major flop with Afrezza inhaled insulin
• June 30, 2015 Generics update: FDA releases new bioequivalence guidance
• June 30, 2015 Novartis back in the pain game with $700M deal for Australia's Spinifex
• June 30, 2015 Health advocacy groups sue FDA for Gilead's hep C data
• June 30, 2015 Samsung Bioepis eyes NASDAQ IPO to fuel big name biosim R&D
• June 30, 2015 Celgene & Juno just struck a blockbuster $1B collab deal—but does it make sense?
• June 29, 2015 Parexel axing 850 jobs in big reorg
• June 29, 2015 Pfizer goes to court in UK to fight for Lyrica patent integrity
• June 29, 2015 Lilly's data mining may pay off with nearly-abandoned Alzheimer's drug
• June 29, 2015 Bristol-Myers going all-in on biotech hub Cambridge for R&D
• June 29, 2015 Is this the end of the line for Celladon after its gene therapy flop?
• June 26, 2015 EMA validates BioMarin's Duchenne Muscular Dystrophy treatment
• June 26, 2015 How Novartis' CEO wants to tackle an ever-aging world
• June 26, 2015 The cost of 'Cures': FDA bill's rare disease provisions to cost $869 million
• June 26, 2015 Bristol-Myers calls it quits on any new virology R&D programs
• June 26, 2015 Take your medicine: CA lawmakers approve mandatory vax bill for children
• June 26, 2015 REMS reform, round 2: Will the FAST Generics Act speed past the finish line this year?
• June 25, 2015 Study: Combo Rx regimen can treat bipolar depression
• June 25, 2015 Report: It pays big to focus on diabetes drugs
• June 25, 2015 Federal panel decides meningitis B vaccination not mandatory
• June 25, 2015 Alcobra flops as placebo beats its drug in phase II
• June 25, 2015 Second top AstraZeneca exec heads for the exits
• June 24, 2015 Takeda's CFO to swap industries, become Nestle's CFO
• June 24, 2015 Will the TIPP trade agreement force the FDA & EMA to harmonize?
• June 24, 2015 New generics-positive bill aims to end REMS abuse
• June 24, 2015 The early winners and losers in ASCO's highly anticipated cancer drug scorecard
• June 24, 2015 Google X unveils health-tracking wristband for clinical trials, research
• June 23, 2015 Study: Australian gov't wasting $320 million per year on drug subsidies
• June 23, 2015 Dutch or American? In takeover drama, Mylan seems to want it both ways
• June 23, 2015 Pay attention: Adults now main ADHD treatment target
• June 23, 2015 Immuno-oncology upstart Conkwest going public in $172.5M IPO
• June 23, 2015 FDA approves Medicines Co's antiplatelet drug
• June 22, 2015 Strike 2 for Teva's Copaxone in US appeals court
• June 22, 2015 China rejects Gilead's hep C drug patent
• June 22, 2015 Lilly, Teva to present late-stage migraine drug data
• June 22, 2015 Bayer beefs up R&D investment to $4.5 billion this year
• June 22, 2015 Tekmira's Ebola trials halted over efficacy concerns
• June 19, 2015 Merging pains: Sun Pharma says goodbye to 18 major Ranbaxy execs
• June 19, 2015 More than 1,000 online drug sites under FDA scrutiny
• June 19, 2015 Amgen's colorectal cancer drug shines in phase III
• June 19, 2015 Teva completes Mylan share purchases, official takeover bid could come any day
• June 19, 2015 BioMarin's childhood dwarfism drug nails it in phase II
• June 19, 2015 BIO2015 & 21st Century Cures: Why value matters more than ever
• June 18, 2015 Report: Global Rx drug sales to reach nearly $1 trillion by 2020
• June 18, 2015 Ebola vaccines require greater speed in trials
• June 18, 2015 New drug compound may beat malaria with single $1 dose
• June 18, 2015 Synergy Pharma shares soar from constipation drug study
• June 18, 2015 Despite insider sale, Receptos stock surges on takeover rumors
• June 17, 2015 GSK's decision to cast off now-valuable drugs raises questions
• June 17, 2015 Bayer, Johns Hopkins team up for eye disease R&D
• June 17, 2015 FDA to review Teva asthma biologic
• June 17, 2015 Abbott gets involved in M&A drama, backs Perrigo buy
• June 17, 2015 Study: Biopharma's pipeline-by-merger strategy isn't working
• June 16, 2015 Largest US drug testing lab negotiating settlement with feds for over-testing
• June 16, 2015 Biotech is booming—but is big pharma waning?
• June 16, 2015 CVS further widens reach with $1.9B deal for Target's pharmacies
• June 16, 2015 Avalanche gene therapy safe, modestly effective in AMD patients
• June 16, 2015 Goodbye, Actavis—hello, Allergan
• June 15, 2015 Study: Drug makers stay coy about FDA rejections & criticisms in their press releases
• June 15, 2015 The curious case of Lilly's share price and its Alzheimer's hopeful data
• June 15, 2015 1st sickle cell patient treated with Bluebird's pioneering gene therapy doing well
• June 15, 2015 FDA approves Brio's brain implant for Parkinson's
• June 15, 2015 How did Axovant raise $315M with one asset and no clinical data?
• June 12, 2015 FDA committee endorses Glaxo's severe asthma drug
• June 12, 2015 Pfizer wins another Zoloft-birth defects lawsuit
• June 12, 2015 LA county to finally distribute preventive Truvada
• June 12, 2015 Glaxo, Sanofi slammed with regulatory fines in India over vaccines
• June 12, 2015 FDA blunders labeling for Vanda sleep drug
• June 11, 2015 How 21st Century Cures could change communications between biopharma, providers, & patients
• June 11, 2015 Pennsylvania's Melior wins a Parkinson's patent
• June 11, 2015 GlobeImmune decimating its workforce after hep B drug flop
• June 11, 2015 Massive study: Merck's diabetes mega-blockbuster doesn't increase heart failure risk
• June 11, 2015 Panasonic Healthcare to snap up Bayer diabetes unit for $1.1 billion
• June 11, 2015 AZ chief med officer abruptly quits, CEO Soriot to oversee late-stage R&D
• June 10, 2015 FDA and Amarin wrangle over free speech lawsuit
• June 10, 2015 PCSK9 anti-cholesterol drug prices: How much is too much?
• June 10, 2015 Sanofi diabetes drug ready to take on FDA with safety study in the rearview
• June 10, 2015 Lilly stock soars on animal health spinoff inquiry
• June 10, 2015 FDA finally responds to demand for Duchenne Muscular Dystrophy guidance
• June 9, 2015 UPDATED: Sanofi/Regeneron's PCSK9 blockbuster-in-waiting gets prelim FDA nod
• June 9, 2015 Lilly's Trulicity and Novo's IDegLira best Lantus in trials
• June 9, 2015 Lilly's Lantus biosimilar will finally launch in Europe in Q3
• June 9, 2015 Massive new study: The statin-memory lapse connection may be unfounded
• June 9, 2015 Merck, New England Patriots boss part of investment team for ABX start up
• June 9, 2015 Report: Pfizer scientist warned management about Zoloft-birth defects link last year
• June 8, 2015 NIH halts drug production for pharma trials after FDA finds fungus
• June 8, 2015 Amgen subpoenas journalist in fight against shareholder suit
• June 8, 2015 Orexigen, Takeda take Actavis to court over obesity med Contrave generic
• June 8, 2015 Amazon, Google battle to become 'e-warehouse' of choice for genomics data
• June 5, 2015 Genzyme nabs breakthrough designation for rare enzyme disorder
• June 5, 2015 Australia to big pharma: Pay more taxes
• June 5, 2015 EU votes not to abolish animal testing despite rising advocate pressure
• June 5, 2015 Report: Metformin decreases glaucoma risk in older adults
• June 5, 2015 Vertex shareholders say 'no' to sky-high exec bonuses
• June 4, 2015 UPDATE: FDA panel recommends women's libido drug despite safety concerns
• June 4, 2015 How social media analytics can help get drugs to the right places during epidemics
• June 4, 2015 AstraZeneca chief slams UK over NICE's Lynparza decision
• June 4, 2015 Report: Many heart attack patients neglect to take their meds afterwards
• June 4, 2015 PillPack just got a $50 million infusion—could it become the Amazon of pharmacies?
• June 4, 2015 Amgen, Novartis duke it out in court over landmark Neupogen biosimilar
• June 4, 2015 Why pay-to-delay arrangements can actually be good for consumers, too
• June 3, 2015 FDA panel to review Lilly's lung cancer combo drug
• June 3, 2015 Why did Regulus Therapeutics CEO Xanthopoulos suddenly quit?
• June 3, 2015 White House meeting focuses on reducing use of antibiotics
• June 3, 2015 UPDATE: Defiant Teva to buy even more Mylan shares, setting up potential legal showdown
• June 3, 2015 NCI launching largest-ever personalized medicine study for cancer drugs
• June 2, 2015 NICE says no to AZ's Lynparza
• June 2, 2015 Ex-Obama administration official joins Sanofi
• June 2, 2015 AstraZeneca may continue R&D of drug linked to suicidal thoughts
• June 2, 2015 Could new FDA compounding guidelines stop Avastin use in AMD?
• June 1, 2015 WHO calls for report on vaccine pricing and access
• June 1, 2015 Bristol-Myers sues former immunotherapy exec for allegedly violating non-compete
• June 1, 2015 US orders major review as suspect anthrax samples found in multiple labs
• May 29, 2015 Report: Public health threat lurking at biolabs nationwide
• May 29, 2015 Biopharma execs have big presence among top-paid CEOs
• May 29, 2015 Gilead on R&D hiring spree
• May 29, 2015 New evidence-based consensus: Start HIV treatment at diagnosis
• May 29, 2015 Otsuka's efforts to block generic Abilify fail
• May 29, 2015 Merck submits NDA for new 2-in-1 hepatitis C treatment
• May 28, 2015 Supreme Court: Pharma companies must finance drug take-back programs
• May 28, 2015 Juno to use Editas gene-editing platform for CAR-T cancer R&D
• May 28, 2015 Express Scripts pushes 'pay-for-performance' drug policy in latest challenge to pharma
• May 28, 2015 Retrophin sells Sanofi priority review voucher for $245m
• May 28, 2015 Report: Greece owes pharma companies more than $1.2 billion in debts
• May 27, 2015 CEO of cancer vax rising star Bavarian Nordic: We are not for sale
• May 27, 2015 Boehringer Ingelheim nabs US approval for COPD combo
• May 27, 2015 Vertex CEO gets called out over huge $45.8 million pay package
• May 27, 2015 Disadvantage, Amgen? Dosing could be deciding factor in PCSK9 marketing battle
• May 27, 2015 White House: Human germline editing 'a line that should not be crossed'
• May 26, 2015 Trouble for AZ as Amgen quits psoriasis blockbuster hopeful collab over suicide risk
• May 26, 2015 Bayer CEO: G7 will see creation of multinational antibiotic R&D fund
• May 26, 2015 Sanofi prostate drug chief's exit latest in firm's oncology exodus
• May 26, 2015 'Hard switch' gets a hard no: Actavis must keep older Namenda on the market
• May 26, 2015 Hypertension drug from India no longer banned in EU—but 100s of others still are
• May 22, 2015 Word on the street: A massive Pfizer deal is coming
• May 22, 2015 Otonomy's inner-ear drug flops in trials
• May 22, 2015 Valeant chief latest pharma CEO to question M&A mania, calls it a 'bit of a bubble'
• May 22, 2015 Sanofi/Regeneron's arthritis drug nails it in phase III
• May 22, 2015 ProPublica opens up the Advair vault, raises safety and marketing ethics questions
• May 22, 2015 UPDATE: Amgen's PCSK9 cholesterol med beats Sanofi's to an EU recommendation
• May 21, 2015 J&J, Achillion strike $225 million hep C drug development pact
• May 21, 2015 Study: Tylenol use during pregnancy may lower testosterone in male offspring
• May 21, 2015 AbbVie, other pharma companies dominate list of 'most meaningful' places to work in US
• May 21, 2015 J&J's ambitious plan: 10 new potential blockbusters filed by 2019
• May 21, 2015 Valeant reportedly in acquisition talks with big Egyptian pharma
• May 20, 2015 GW Pharma moves CEO to US to lay groundwork for cannabis-epilepsy med approval
• May 20, 2015 Sanofi/Regeneron reports glowing phase 2b results for versatile asthma hopeful
• May 20, 2015 Compounding pharmacy linked to meningitis outbreak to pay $200M to victims
• May 20, 2015 Why biosimilars may not be the huge cost-saver people hope
• May 19, 2015 Endo to scoop up rival Par Pharma for $8B in bid to expand generics portfolio
• May 19, 2015 Unregulated stem cell clinics doing big business in the US
• May 19, 2015 WHO plays hardball with Novartis & Roche, favors cheaper Avastin over Lucentis
• May 19, 2015 AstraZeneca bets big on biotech with large new Swedish plant
• May 19, 2015 Perrigo CEO changes tune, would consider Mylan merger—at right price
• May 18, 2015 A rare win for US pharma: Indian court stops Glenmark sales of Merck diabetes copycats
• May 18, 2015 Niger meningitis cases triple in 2 weeks amid dearth of vaccines
• May 18, 2015 Amgen boasts promising phase II results for migraine drug
• May 18, 2015 FDA sued by ADHD generics maker for revoking drug's Concerta bioequivalence
• May 18, 2015 FDA warns popular Lilly, AZ, J&J, Boehringer diabetes meds could cause ketoacidosis
• May 15, 2015 Why are analysts still optimistic about Orexigen's stock after the Contrave imbroglio?
• May 15, 2015 One more potential Teva-related challenge for Mylan's shareholders: A huge tax bill
• May 15, 2015 US class action against India's Ranbaxy cites dishonesty, manipulation of FDA rules
• May 15, 2015 Hotly anticipated AZ lung cancer combo effective, but side effects remain a problem
• May 15, 2015 A preview of the new lung cancer data Roche will debut at ASCO
• May 14, 2015 VT senator to Veterans Affairs: Break Gilead's Sovaldi patents
• May 14, 2015 Belgian biotech harnessing antibodies from... llamas?
• May 14, 2015 Sanofi moving forward on Celiac disease immunotherapy development
• May 14, 2015 How pharma is amping up R&D with gene sequencing
• May 14, 2015 Rapid diagnostics emerging for Chagas disease
• May 13, 2015 MannKind: Marketing glitches, delays explain slow Afrezza uptake
• May 13, 2015 Glaxo CEO skeptical about pharma's M&A frenzy
• May 13, 2015 Analysts answer: How long will it take the first Copaxone generics to gain market share?
• May 13, 2015 How do you test an Ebola vaccine when almost no one has Ebola?
• May 13, 2015 Challenges ahead for Vertex's controversial Kalydeco combo despite FDA panel nod
• May 12, 2015 Drug-resistant typhoid 'superbug' becoming global problem
• May 12, 2015 Alexion planning major expansion in Ireland
• May 12, 2015 4 drugmakers dismissed from Chicago opioid lawsuit
• May 12, 2015 7 drugs get SMC backing
• May 12, 2015 HIV cure, not just treatment, is goal of Glaxo-UNC partnership
• May 11, 2015 CA justices rule against pharma in first appellate court 'pay-for-delay' suit
• May 11, 2015 What the Tories' election victory means for the NHS and UK pharma
• May 11, 2015 FDA staff raises red flags over new Vertex cystic fibrosis med's cost
• May 11, 2015 In challenge to pricey Gilead meds, WHO adds hep C drugs to 'essentials' list
• May 11, 2015 Liberia declared Ebola-free
• May 8, 2015 M&A mayhem: Q1 biopharma deal values surpass 2014's total
• May 8, 2015 AbbVie, Roche nab FDA breakthrough designation for top leukemia prospect
• May 8, 2015 Study: Measles vax may protect against other infections
• May 8, 2015 Sheer power of CAR-T therapies leads drug makers to develop an 'off' switch
• May 8, 2015 Mark your calendars: FDA will hold public meeting on off-label use this summer
• May 7, 2015 Former Novo exec Schultz will become a CEO after all—just at another pharma
• May 7, 2015 Glaxo reverses course, won't spinoff lucrative ViiV Healthcare HIV unit
• May 7, 2015 An update on Tekmira: From Ebola promise to a strong hep B focus
• May 7, 2015 Glaxo hoping for the best, prepping for the worst on Advair generics
• May 7, 2015 Congress calls for gender equity in clinical trials
• May 6, 2015 7 questions you might have about biosimilarity, answered
• May 6, 2015 New report: Digoxin risky for certain patients
• May 6, 2015 Sanofi shareholders slam big pay packages for chiefs Viehbacher, Brandicourt
• May 6, 2015 DaVita settles $450 million Medicare fraud lawsuit
• May 6, 2015 IMS: Global cancer drug spending soared past $100 billion in 2014
• May 6, 2015 UN: New Ebola cases fall to lowest level since mid-2014
• May 5, 2015 Study: FDA bends over backwards to accommodate orphan drug developers
• May 5, 2015 Bayer buys rights to Isis anti-clotting drug in $155M deal
• May 5, 2015 The new Medicare Part D drug spending report only tells part of the story
• May 5, 2015 Vyvanse binge eating push, NPS acquisition drives steady Q1 sales for Shire
• May 5, 2015 Glaxo becomes first big pharma to file for a gene therapy approval
• May 4, 2015 Why did Novo's supposed CEO-in-waiting suddenly leave the firm?
• May 4, 2015 Viagra bucks global slowdown trend in China, sales soar 47%
• May 4, 2015 Amgen successfully defends melanoma hopeful T-Vec, gets positive FDA feedback
• May 4, 2015 21st Century Cures changes would loosen Sunshine Act's CME disclosure rules
• May 4, 2015 Novartis kickback case settlement will cost Express Scripts $60 million
• May 1, 2015 Gilead dazzles, profits double in Q1 on strong hep C sales
• May 1, 2015 Oklahoma gov OKs marijuana derivative for epilepsy clinical trial
• May 1, 2015 FDA approves Glaxo's asthma drug Breo Ellipta for adults
• May 1, 2015 Experts: Polio on the verge of global eradication thanks to vax campaigns
• May 1, 2015 Pfizer emerges as mystery bidder for rare disease firm Swedish Orphan
• April 30, 2015 Merck antibiotic combo Zerbaxa shows efficacy in complicated infections
• April 30, 2015 Perrigo rejects Mylan's third takeover offer
• April 30, 2015 FDA approves Kythera's double-chin injection
• April 30, 2015 Amgen hiring staff for Cambridge and SF sites
• April 30, 2015 Valeant CFO to resign; company beats expectations for quarter
• April 30, 2015 Can the new FDA guidance on biosimilarity expedite development and approval?
• April 29, 2015 Q1 reports: Dollar dogs Pfizer, cancer immunotherapies buoy Bristol-Myers, Merck
• April 29, 2015 Game on: FDA approves first generics of blockbuster antipsychotic Abilify
• April 29, 2015 FDA officially reject's Merck's Bridion—again
• April 29, 2015 Merck gains advantage over AZ, Takeda as top diabetes med determined heart safe
• April 29, 2015 Controversy ahead: HHS inspector general encourages more Part D drug rebates
• April 28, 2015 Bristol-Myers, Gilead hep C combo shines in late-stage trial
• April 28, 2015 Snap up a rival, then hike its drugs' prices—is this pharma's new normal?
• April 28, 2015 Why tech transfer could be key to growing pharma in Africa
• April 28, 2015 Good news for Lilly: Cyramza nabs yet another FDA approval
• April 27, 2015 Report: Multiple sclerosis drug prices skyrocketing—even for older meds
• April 27, 2015 Workers wanted: Seattle Genetics experiencing a growth spurt
• April 27, 2015 Biogen ups the phase III ante on Alzheimer's breakthrough hopeful
• April 27, 2015 Rare disease firm Swedish Orphan flies on mystery takeover offer
• April 27, 2015 A tale of 2 takeover bids: Teva-Mylan-Perrigo M&A drama goes hostile
• April 24, 2015 New study: Alcoholic hepatitis drugs not effective
• April 24, 2015 Novartis chief: We're actively looking for $2-$5 billion acquisitions
• April 24, 2015 Mapp Biopharma nabs federal liability protection for Ebola drug
• April 24, 2015 Merck, Gilead duke it out with next-gen hep-C combos
• April 24, 2015 More Q1 earnings: Novartis flies, Humira keeps AbbVie afloat, AZ feels patent sting
• April 24, 2015 What biopharma needs to know about CAR-T cancer therapies
• April 23, 2015 Milestone: Chinese researchers genetically modify human embryos
• April 23, 2015 Are steady generic drug price hikes coming to an end?
• April 23, 2015 Abbott's Mylan deal paying off big as M&A speculation sends shares soaring
• April 23, 2015 Earnings roundup: Lilly bests estimates on new drugs, Abbott racks up $2.29B earnings
• April 23, 2015 Inside Gilead's ambitious new hep C elimination project in Georgia
• April 22, 2015 Research links poor quality medicines and potential global pandemic
• April 22, 2015 Scientists to provide real-time genomic sequencing data on Ebola, MERS
• April 22, 2015 Bernstein analyst to Gilead: 'Pull the trigger' and buy Vertex
• April 22, 2015 How Amgen achieved its stellar Q1 earnings
• April 22, 2015 US, Cuban research firms forge historic pact on lung cancer vax development
• April 21, 2015 UPDATE: Teva scores a takeover talking point as Perrigo board rejects Mylan bid
• April 21, 2015 Wave of the future: The Ebola crisis as a tipping point for pharmaceutical R&D
• April 21, 2015 Glaxo uncovers quadrivalent flu vax potency problems, pulls it from market
• April 21, 2015 Allergan laying off 577 more workers in Orange County
• April 21, 2015 Teva to pay whopping $512 million fine in Provigil pay-to-delay suit
• April 21, 2015 Small, early Novartis CAR-T trial shows promise in solid tumors
• April 21, 2015 Sun Pharma tanks as Daiichi starts divesting $3.6B in stakes
• April 20, 2015 EU's first-ever gene therapy bumps up against renewed regulatory scrutiny
• April 20, 2015 Pfizer notches key victory in first of many Zoloft birth-defect cases
• April 20, 2015 Merck files Keytruda for lung cancer, drug bests Bristol-Myers' Yervoy in melanoma
• April 20, 2015 WHO promises reforms after 'slow and insufficient' Ebola response
• April 17, 2015 Benefits manager warns Vertex's cystic fibrosis Kalydeco combo too pricey
• April 17, 2015 Otsuka pulling out all the stops to deter copycats of blockbuster Abilify
• April 17, 2015 Sandoz wins first FDA nod for generic of Teva MS flagship Copaxone
• April 17, 2015 Bayer pumping $100M into new hemophilia-focused Berkeley testing facility
• April 17, 2015 Study: Common heartburn meds linked with kidney failure risk in elderly
• April 17, 2015 Star Scientific 2.0 falters in drug dev efforts after Va. gov corruption scandal
• April 16, 2015 Ibrance late-stage trial stopped early amid impressive results
• April 16, 2015 FDA approves first major new heart failure drug in a decade
• April 15, 2015 The blood cancer boom: Nearly 250 meds in development, but plenty left to do
• April 15, 2015 GW Pharma's cannabis-based epilepsy drug cuts seizure rates by 50%
• April 15, 2015 Why did Rx drug spending in the US reach an all-time high in 2014?
• April 15, 2015 FDA panel endorses new heart failure warnings for key AZ diabetes med
• April 15, 2015 WHO calls for universal clinical trial transparency
• April 15, 2015 J&J Q1 earnings highlight rising dollar's tumultuous effect on global pharmas
• April 14, 2015 How NewLink Genetics defied its location and put Iowa on biotech's map
• April 14, 2015 What a Celgene stake in Mesoblast means for the stem cell firm's prospects
• April 14, 2015 Ichor, J&J to collaborate in $85M hep B immunotherapy deal
• April 14, 2015 Roche's aggressive 2015 goal: 11 cancer immunotherapy drugs in late-stage trials
• April 14, 2015 Glaxo to tweak unique US sales rep compensation plan amid complaints
• April 13, 2015 Angelina Jolie-driven surge in pricey genetic test requests has payers on edge
• April 13, 2015 Ebola phase III studies underpopulated as epidemic wanes
• April 13, 2015 Water under the bridge: Allergan, Ackman drop hostile takeover lawsuits
• April 13, 2015 Eisai plans big US layoffs in reorg
• April 13, 2015 Mylan's $29B Perrigo bid seen as defensive play against M&A threat
• April 10, 2015 Lawusit claims Pfizer knew about Zoloft birth defect risks
• April 10, 2015 Billionaire Fidelity CEO betting big on cancer companies with personal money
• April 10, 2015 Alzheon CEO calls out Biogen, says his firm will be 1st to Alzheimer's finish line
• April 10, 2015 Politicians still going after Actavis for its Namenda hard-switch
• April 10, 2015 Shire nabs priority review for potential blockbuster dry eye drug
• April 9, 2015 Mid-cap biotechs best larger companies to emerge as 2014's growth kings
• April 9, 2015 Merck's HCV drug candiate gets another breakthrough therapy designation
• April 9, 2015 Silence Therapeutics raises $58 million to advance R&D
• April 9, 2015 Report questions acetaminophen's efficacy in lower back, joint pain
• April 8, 2015 Inside the FDA labeling fight that could upend the generics market
• April 8, 2015 Report: Viagra most effective ED treatment, but has more side effects
• April 8, 2015 VBI Vaccines, Sanofi Pasteur to collaborate on vaccine R&D
• April 7, 2015 Hospira gets yet another FDA warning letter before Pfizer buyout
• April 7, 2015 Shire bullish on 2017 approval of new, longer-lasting ADHD pill
• April 7, 2015 Valeant commences its post-Salix deal job cuts
• April 7, 2015 Targacept merger in jeopardy as Pfizer ends deal with buyer Catalyst
• April 7, 2015 Hedge fund activist Bass takes aim at pricey Shire, Jazz drug patents
• April 7, 2015 MorphoSys CEO stays bullish on cancer drug despite Celgene split
• April 7, 2015 Juno, Novartis settle cancer patent spat for $12 million
• April 7, 2015 Amgen CEO scores big pay package on record profits
• April 6, 2015 Glaxo's post-Novartis vax deal reorg could uproot hundreds of jobs
• April 6, 2015 Did Novartis try to sabotage Avastin ophthalmic trials?
• April 6, 2015 Scientists milk snakes to make more stable broad spectrum anti-venom
• April 6, 2015 UK scientists push back against animal testing critics
• April 2, 2015 Big bonus bonanza coming up at Actavis
• April 2, 2015 Partners wanted: Roche seeking collaborators in cancer immunotherapy
• April 2, 2015 FDA issues final guidance on abuse-deterrent opioids
• April 1, 2015 Amgen loses Neupogen biosimilar battle—again
• April 1, 2015 Provocative: Analyst says hot new PD-1 cancer drugs are massively overrated
• April 1, 2015 Report claims FDA is behind the times on employees' free speech
• March 31, 2015 PETA hawks animal testing alternatives to CROs in San Diego
• March 31, 2015 Merck Serono and Intrexon initiate $941 million CAR-T deal
• March 31, 2015 UK opposition leader gives pharma a pass on his profit margin cap proposal
• March 31, 2015 What UnitedHealth's $12.8B Catamaran deal means for pharma's pricing war
• March 31, 2015 Glaxo settles J&J suit over allergy med advertisement claims
• March 30, 2015 Alibaba, other e-retailers may foray into Rx drugs in China
• March 30, 2015 In final speech, outgoing FDA chief defends US drug approvals record
• March 30, 2015 Glaxo finally strikes UK deal for Bexsero that eluded Novartis
• March 30, 2015 Confirmed: Sanofi's Toujeo launches in US Monday, setting up diabetes race
• March 27, 2015 Novo to try for US Tresiba approval once again
• March 27, 2015 J&J moving forward in China despite regulatory crackdowns
• March 27, 2015 MorphoSys and Celgene call it quits
• March 25, 2015 How PCSK9 cholesterol drugs will shift pharma's pricing trends
• March 25, 2015 Guinea becomes focus of Merck Ebola vaccination study
• March 25, 2015 Treatment for inhalational anthrax wins US approval
• March 25, 2015 Regeneron's Eylea nabs yet another FDA approval for expanded label
• March 25, 2015 FDA's rare disease pediatric voucher program could become permanent
• March 25, 2015 RA drug that caused 'elephant man' side effect gets another chance
• March 25, 2015 Merck's Keytruda bests Yervoy, shows promise as first-line melanoma med
• March 25, 2015 CAR-T biotech Cellectis boosts IPO 50% to $197 million
• March 25, 2015 FDA to reconsider homeopathy regulatory framework after 25 years
• March 24, 2015 U of Minnesota called out for clinical trial practices—again
• March 24, 2015 Regeneron CEO riding high with $42M salary, but with fewer perks
• March 24, 2015 The Biogen ripple effect: Analyst recommends Genworth as proxy buy
• March 24, 2015 FDA won't relabel Lilly's schizophrenia injectable after patient deaths
• March 24, 2015 Paper: SSRIs impact teens' sexual function, too
• March 23, 2015 3D printing debuts in pharma
• March 23, 2015 Gilead warns against Sovaldi, heart drug combo after patient death
• March 23, 2015 J&J's Janssen gets a mixed bag in 2nd Risperdal case
• March 23, 2015 Here comes the blockbuster: Novartis' Cosentyx bests Stelara in psoriasis trials
• March 23, 2015 Congress wants to make it easier to get EU-approved drugs to the US
• March 20, 2015 Namenda antitrust suit heats up in NY court
• March 20, 2015 9 important things to know about PCSK9 cholesterol drugs
• March 20, 2015 Judge refuses to block Novartis biosimilar of Amgen drug
• March 19, 2015 MannKind has a $100 million debt problem, and the clock is ticking
• March 19, 2015 FDA approves first-ever med for rare bile disorder
• March 18, 2015 MSF: Sovaldi profit protection measures squeeze out patients in poor nations
• March 18, 2015 FDA advisory committee to talk Tekmira, Mapp Ebola vaccines in May
• March 18, 2015 Celgene emerges as biotech partnering king of 2014
• March 18, 2015 Glaxo's combo respiratory drug deemed safe by FDA staff
• March 18, 2015 New obesity drugs jockey for market uptake
• March 18, 2015 How Novo Nordisk plans to keep its eyes on the diabetes prize
• March 18, 2015 US Novartis arm smacked with $110 million gender discrimination class action
• March 18, 2015 Allergan CEO Pyott heading for the exits as Actavis finalizes buyout
• March 17, 2015 Meet the Biogen vet who's about to become Chiasma's new CEO
• March 17, 2015 Scientists may have uncovered next powerhouse antibiotic in horse dung
• March 17, 2015 FDA panel: Pharmacyclics' Imbruvica cancer data strong enough to unblind
• March 17, 2015 Novartis slapped with $12.6M fine for fuzzy Medicare pricing math
• March 17, 2015 Could Biogen's Alzheimer's therapy become a breakthrough?
• March 17, 2015 Why China's drug approval backlog spiked last year
• March 16, 2015 US District Judge says FDA can revoke Ranbaxy drug approvals
• March 16, 2015 Study: AZ's Brilinta shows promise, but comes with risks
• March 16, 2015 Merck's anesthesia reversal drug faces 3rd likely FDA rejection
• March 13, 2015 Neuralstem shares tank on discouraging ALS stem cell therapy data
• March 13, 2015 The unlikely vaccine that's boosting immunooncology efforts
• March 13, 2015 Bill & Melinda Gates Foundation bets big on CureVac's mRNA platform
• March 13, 2015 Gilead, Vertex balk as SEC upholds shareholders' voting rights
• March 13, 2015 23andMe's next big ambition: Drug development
• March 12, 2015 Zogenix selling painkiller Zohydro to Pernix in huge deal
• March 12, 2015 J&J's CEO nabbed a hefty raise in 2014
• March 12, 2015 Public Citizen to FDA: Don't let sales reps distribute data downplaying drug risks
• March 12, 2015 Will Pradaxa reversibility be the final death knell for warfarin?
• March 12, 2015 J&J to pay $25 million to settle children's Tylenol, Motrin contamination case
• March 12, 2015 India denies patent protection to Bayer, BI blockbusters
• March 11, 2015 Concordia acquiring Covis assets for $1.2 billion
• March 11, 2015 Apple's new ResearchKit raises hopes, questions for medical studies
• March 11, 2015 Why CNS drug maker Acadia's shares soared on Tuesday
• March 11, 2015 More black box grief for Pfizer's Chantix as FDA adds alcohol, seizure warnings
• March 11, 2015 United Therapeutics nabs priority review voucher, approval for rare pediatric cancer drug
• March 10, 2015 Novartis CEO: Watch out for more cost-cutting on the horizon
• March 10, 2015 Is that clinical trial doc getting pharma money? Patients want to know
• March 10, 2015 What's next for Kythera after unanimous FDA rec for its double-chin injection?
• March 9, 2015 Ackman becomes Valeant's 5th largest shareholder with $3.3B gamble
• March 9, 2015 Amgen: The biotech that's getting on the biosimilar R&D bandwagon
• March 9, 2015 Bangladeshi pharma launches $10 version of Sovaldi
• March 9, 2015 Bribery scandal still dogging Glaxo as pharma giant axes 110 jobs in China
• March 9, 2015 Astellas nabs FDA approval for new antifungal
• March 9, 2015 Merck to start hacking away at Cubist's workforce with 128 R&D layoffs
• March 9, 2015 In latest blow to Lilly, German court clears Actavis generics of lung cancer blockbuster
• March 6, 2015 Dawn of a new era: FDA approves first-ever biosimilar, Novartis/Sandoz's Zarxio
• March 6, 2015 Flu vax committee picks next year's virus strains after 2014 debacle
• March 6, 2015 FDA to pharma: Watch out for unapproved Facebook claims
• March 6, 2015 Vanda's atopic dermatitis drug fall flat in mid-stage trial
• March 6, 2015 UPDATE: Shire's Boston move involves 'mass layoff' of up to 600 employees
• March 5, 2015 FDA launches first drug-shortages mobile app
• March 5, 2015 AstraZeneca to spin off antibiotics R&D for $40 million
• March 5, 2015 Genentech denies knowledge of distribution-related problems
• March 5, 2015 Akorn latest to reject use of its drugs for lethal injection
• March 5, 2015 21st Century Cures: Making Breakthrough Therapy designations more effective
• March 4, 2015 BMS' Opdivo wins lung cancer indication more than 3 months before PDUFA date
• March 4, 2015 The post-acquisition cuts begin: Valeant lays off 77 Dendreon employees
• March 4, 2015 BI files its Pradaxa 'antidote' in North America, EU
• March 4, 2015 Could Sangamo's gene therapy 'cure' HIV?
• March 4, 2015 FDA clamps down on testosterone labeling rules
• March 4, 2015 Orexigen shoots itself in foot with early disclosure of positive Contrave heart data
• March 3, 2015 Celgene's Abraxane approved in EU for first-line treatement of NSCLC
• March 3, 2015 AZ board to CEO Soriot: Want that big bonus? Show us the money
• March 3, 2015 US lawmakers push Amphastar for answers on naloxone prices
• March 3, 2015 Survey: New Genentech distribution policy delaying cancer patients' care
• March 3, 2015 Gilead seals generic Sovaldi deal with Natco, NICE rec for Harvoni in UK
• March 2, 2015 Sanofi's Toujeo nabs EU rec and efficacy shoutout on heels of FDA blessing
• March 2, 2015 Indian advisory board proposes waiving phase III for certain drugs
• March 2, 2015 A biotech is bringing a new IUD to market—but the company's a nonprofit
• March 2, 2015 Ousted Sanofi chief Chris Viebacher lands at PureTech
• Feb. 27, 2015 Positive phase II Provenge data a good early sign for ambitious Valeant
• Feb. 27, 2015 EU approves first new chemical entity for Parkinson's in a decade
• Feb. 27, 2015 A booming Bayer projects 10% pharma-driven growth in 2015
• Feb. 27, 2015 Gilead raking in billions off of foreign tax laws
• Feb. 27, 2015 GSK's CEO faces another pay cut—and it's a big one
• Feb. 26, 2015 How 23andMe used rigorous clinical trials to win a landmark FDA authorization
• Feb. 26, 2015 Pharmacyclics surges on news of potential sale to J&J, Novartis
• Feb. 26, 2015 Shire puts binge-eating disorder on the medical map
• Feb. 26, 2015 Federal judge strikes down Maine's controversial prescription drug import law
• Feb. 26, 2015 It's been a good year: Juno's top management nabs big bonuses
• Feb. 26, 2015 CA lawmaker to pharma: Show us, with numbers, why drugs cost so much
• Feb. 25, 2015 Merck, MPP team up to provide low-cost HIV pediatric meds in poor countries
• Feb. 25, 2015 French government slams Sanofi over new CEO's pay
• Feb. 25, 2015 Public Citizen requests FDA ban on certain antifungal meds
• Feb. 25, 2015 Shire keeps acquisition train rolling with $70M Meritage Pharma deal
• Feb. 25, 2015 Platinum parachute? Allergan CEO Pyott could get $100M exit fee
• Feb. 24, 2015 Toronto Star retracts piece suggesting injuries linked to Merck's Gardasil
• Feb. 24, 2015 BMS strengthens oncology pipeline with two big deals worth $1.6B
• Feb. 24, 2015 Novartis' Farydak wins FDA approval for multiple myeloma
• Feb. 24, 2015 Duchenne, orphan drug maker PTC Therapeutics fielding takeover bids
• Feb. 24, 2015 Lilly's long-acting insulin not ready for prime time
• Feb. 23, 2015 Is there still a place for the mighty pharmaceutical sales force?
• Feb. 23, 2015 Compounding pharmacies chafe at FDA's disciplinary actions
• Feb. 23, 2015 Corgenix's 15-minute Ebola test approved by WHO
• Feb. 23, 2015 FDA to review Pfizer's rare lung disease drug for women
• Feb. 23, 2015 Holoclar makes history: Europe approves West's first stem-cell therapy
• Feb. 22, 2015 Cellectis files $115M IPO to fund unique CAR-T program
• Feb. 20, 2015 Ohio seeks its own deal with Amphastar for heroin antidote
• Feb. 20, 2015 New Jersey residents' parting gift to Roche: A lawsuit
• Feb. 20, 2015 NewLink wins $20 million Ebola vaccine milestone from Merck
• Feb. 20, 2015 New company, new name: Actavis to rebrand as Allergan post-buyout
• Feb. 20, 2015 Biogen, academic collaborators discover new ALS gene
• Feb. 19, 2015 UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO
• Feb. 19, 2015 Why so little uptake of preventive Truvada in the at-risk gay community?
• Feb. 19, 2015 Team of rivals? Scientist nominated for AZ board has history of dinging pharma
• Feb. 19, 2015 Gilead's Harvoni supplants Sovaldi as top-selling launch drug
• Feb. 19, 2015 Why FDA's label expansion for Celgene's Revlimid could foretell a global sales surge
• Feb. 19, 2015 Biotech battle: Regeneron's Eylea bests Genenetch's Lucentis in head-to-head
• Feb. 18, 2015 Shanghai official to serve 19 years over GSK bribery case
• Feb. 18, 2015 The more, the merrier? Endo also pursuing Salix Pharma bid
• Feb. 18, 2015 CVS fires controversial warning shot in opening salvo of PCSK9 price wars
• Feb. 18, 2015 Sprout Pharma submits 'women's Viagra' for approval once again
• Feb. 17, 2015 FDA reopens conversation about controversial generic labeling rules
• Feb. 17, 2015 Profits fall for India's largest drug maker
• Feb. 17, 2015 Can AZ finally solidify a deal for its anti-infectives unit?
• Feb. 17, 2015 GSK replaces US pharma ops head Connelly amid struggles
• Feb. 17, 2015 NAFTA patent spat rages on between Canada and Lilly
• Feb. 13, 2015 How ViiV Healthcare became a pharma favorite for patient groups
• Feb. 13, 2015 Valeant arranges financing for potential Salix Pharma bid
• Feb. 13, 2015 Indian pharma giants scuffle to snap up injectables maker Claris
• Feb. 13, 2015 AZ to settle Nexium kickback case for $7.9M
• Feb. 12, 2015 Teva's internal probe turns up 'likely' corruption
• Feb. 12, 2015 Shire raises 2015 forecast on NPS acquisition
• Feb. 12, 2015 EMA defends data black-out policy for AbbVie's Humira
• Feb. 12, 2015 Riken stem cell saga continues as Obokata and other scientists face reprimands
• Feb. 12, 2015 GSK broadens vax portfolio with $190M GlycoVaxyn deal
• Feb. 11, 2015 Former Merck financial analyst to plead guilty to insider trading
• Feb. 11, 2015 Nanotrending: FDA adopts another nanotech standard
• Feb. 11, 2015 Another one bites the dust: FDA to revoke breakthrough status for BMS hep C med, too
• Feb. 11, 2015 Former MN gov demands more trial transparency at UMN in wake of '04 suicide
• Feb. 11, 2015 Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again
• Feb. 10, 2015 Juno forges ahead with novel cancer therapy, opens manufacturing facility
• Feb. 10, 2015 Merck fights back after BC Health Ministry drops diabetes drug
• Feb. 10, 2015 ICYMI: Sanofi undertakes major sales reorg of US diabetes business
• Feb. 10, 2015 New research: Could Novartis CVD game-changer increase dementia risk?
• Feb. 10, 2015 BIO survey finds more series A VC funding for fewer recipients
• Feb. 9, 2015 Roche's blockbuster Lucentis nabs fourth FDA approval
• Feb. 9, 2015 FDA warning for blockbuster hopeful edoxaban hits Daiichi where it hurts
• Feb. 9, 2015 Pfizer may still be hungry after Hospira deal
• Feb. 9, 2015 FDA proposes new consumer-friendly print drug ad guidance
• Feb. 9, 2015 Arkansas settles Vertex Medicaid suit over pricey Kalydeco
• Feb. 6, 2015 Isis earns $10 million milestone from Biogen Idec
• Feb. 6, 2015 Why the FDA wants to double inspectors at Indian manufacturing facilities
• Feb. 6, 2015 FDA simplifies compassionate use process in a big way
• Feb. 6, 2015 NY Attorney General nabs price reduction for heroin-fighting naloxone
• Feb. 6, 2015 Q4: Allergan soars past estimates, again
• Feb. 5, 2015 Passing the torch: Ralph Neas' tenure at the Generic Pharmaceutical Association
• Feb. 5, 2015 Promising Roche Parkinson's med causes lung toxicity in monkey trials
• Feb. 5, 2015 Study: Drug makers fail to meet adverse-event reporting requirements
• Feb. 5, 2015 Trans-Pacific Partnership trade talks fail to resolve patent & IP issues
• Feb. 5, 2015 Pfizer on fire with early FDA nod for blockbuster Ibrance, $15B Hospira buyout
• Feb. 5, 2015 Merck's hep C treatment loses FDA breakthrough status
• Feb. 4, 2015 Another FDA warning letter for India-based Apotex
• Feb. 4, 2015 Moody's: Patent-cliff challenges will continue to dog big pharma
• Feb. 4, 2015 Merck's Belsomra for insomnia now available in US
• Feb. 4, 2015 US to launch large-scale universal flu shot testing in 2016
• Feb. 4, 2015 Valeant reportedly considering Salix acquisition
• Feb. 3, 2015 FTC: Ranbaxy must sell acne drug to Torrent Pharma before Sun takeover
• Feb. 3, 2015 FDA approves new Zohydro ER pankiller formulation
• Feb. 3, 2015 Chimerix shifts from Ebola focus to adenoviruses, CMV as outbreak wanes
• Feb. 3, 2015 Ireland threatens to cap drug prices
• Feb. 2, 2015 Pro-life groups blame Merck, in part, for surging measles cases
• Feb. 2, 2015 Valeant to make $296M 'stalking horse' bid on Seattle-based Dendreon
• Feb. 2, 2015 Shire's Vyvanse nabs FDA approval for binge-eating disorder
• Feb. 2, 2015 Roche's Tamiflu vindicated in new analysis of data
• Feb. 1, 2015 What will the new federal budget mean for pharmaceutical R&D tax credits?
• Jan. 30, 2015 Alexion COO Hallal named company's next CEO
• Jan. 30, 2015 J&J's Imbruvica gets expanded label for rare blood cancer treatment
• Jan. 30, 2015 Some UK cystic fibrosis patients being denied breakthough treatment
• Jan. 30, 2015 J&J under continued scrutiny for off-label pediatric use of Risperdal
• Jan. 30, 2015 Biogen Idec re-enters gene therapy R&D with hemophilia focus
• Jan. 29, 2015 Study: Parkinson's patients' response doubles with 'expensive' placebo
• Jan. 29, 2015 Pfizer dodges class-action trial with $400 million settlement
• Jan. 29, 2015 Express Scripts claims it's saved US healthcare $4B through hep C deals
• Jan. 29, 2015 Earnings update: Roche plateaus, Amgen stock slides despite solid performance
• Jan. 29, 2015 Largest US health insurer latest to give Harvoni preferred hep C drug status
• Jan. 28, 2015 Gilead to launch generic Sovaldi in India this summer
• Jan. 28, 2015 E. coli-sniffing One Codex search platform scores CDC cash prize
• Jan. 28, 2015 Actavis to buy Auden McKenzie for $465M
• Jan. 28, 2015 Google, Biogen Idec partnering to study causes of multiple sclerosis
• Jan. 28, 2015 NIH to launch Down syndrome research portal
• Jan. 27, 2015 Counterfeit Roche cancer drug smuggler gets 30 months in jail
• Jan. 27, 2015 Novo deploys 500 rep army to take Saxenda message to MDs
• Jan. 27, 2015 Average Rx drug prices spiked 10.9% last year
• Jan. 27, 2015 Rumor mill churns as Duke's Dr. Robert Califf appointed FDA deputy commish
• Jan. 27, 2015 UPDATE: Pfizer gives poor nations modest discount after vax price blowback
• Jan. 27, 2015 Teva wins big as FDA approves its generic Nexium
• Jan. 26, 2015 GSK denies reports of imminent job cuts in China
• Jan. 26, 2015 Shire pleased as NPS Pharma wins Natpara approval
• Jan. 26, 2015 Sanofi tops new index that measures pharma's commitment to infectious diseases
• Jan. 26, 2015 EMA suspending almost 50 drugs over flawed CRO clinical studies
• Jan. 26, 2015 Novartis nabs FDA nod for group B meningitis vaccine Bexsero
• Jan. 23, 2015 Hindsight: Valeant CEO admits mistakes in approach to Allergan bid
• Jan. 23, 2015 Digital dawn: Online interactions with MDs leading to more prescripts
• Jan. 23, 2015 EU approves Genzyme's Cerdelga for type 1 Gaucher patients
• Jan. 23, 2015 Express Scripts determined to influence prices for cancer drugs
• Jan. 23, 2015 Regulators get creative on Ebola vaccine testing as infections decline
• Jan. 22, 2015 The M.D. perspective: Who stands to benefit from clinical trial transparency?
• Jan. 22, 2015 J&J: Regulatory delays in China are stymying drug approvals
• Jan. 22, 2015 UN Ebola chief requests one last $1 billion in funding to fight outbreak
• Jan. 22, 2015 Chasing transparency in the pharmaceutical industry: How much is enough?
• Jan. 22, 2015 Out with the old: Merck discontinues US sales of hep C med Victrelis
• Jan. 22, 2015 Plaintiffs wanted: Law firms seek shareholders to launch a Sanofi kickback suit
• Jan. 22, 2015 Salix Pharma reportedly exploring options, considering sale
• Jan. 21, 2015 Teva wins Copaxone patent protection suit in US Supreme Court
• Jan. 21, 2015 Ambitious RNA biotech Alnylam raising $450M, looking for acquisitions
• Jan. 21, 2015 Colorado-based ViroCyt raises $3.5M to market its Virus Counter
• Jan. 21, 2015 J&J's Q4 earnings: A solid 2014
• Jan. 20, 2015 One more push: Senators reintroduce bill to expedite antibiotic approval
• Jan. 20, 2015 China FDA to reverse course, allow online Rx drug sales
• Jan. 20, 2015 Hospira closes North Carolina plant over cost concerns
• Jan. 20, 2015 AbbVie strikes hep C discount deal with US state-based AIDS programs
• Jan. 16, 2015 UPDATED: Yet another major insurance company strikes hep C deal with Gilead
• Jan. 16, 2015 Pfizer warns UK MDs: Lyrica is still on patent for pain
• Jan. 16, 2015 J&J: Women were inappropriately pressured to file pelvic mesh suits
• Jan. 16, 2015 Pharma stocks plunge as Switzerland discontinues fixed-price peg to euro
• Jan. 15, 2015 Blast from the past: Roche's dalcetrapib, HDL-raising meds could work for some patients
• Jan. 15, 2015 Flu vaccine only 23% effective this season
• Jan. 15, 2015 Intrexon, Ziopharma invest $100M in MD Anderson cancer immunotherapy tech
• Jan. 15, 2015 UPDATED: Gilead to appeal India's rejection of Sovaldi patent protection
• Jan. 15, 2015 FDA approves novel weight-loss device
• Jan. 15, 2015 Johnson & Johnson to release trial data
• Jan. 15, 2015 New Brilinta data supports extending use beyond one year
• Jan. 14, 2015 BMJ physicians urge reexamination of widespread hep C screening
• Jan. 14, 2015 Digital marketing slowly gaining traction with US doctors
• Jan. 14, 2015 Actavis betting on conversion to new Namenda
• Jan. 14, 2015 J&J licensing IBD drug from microbiome specialist Vedanta
• Jan. 14, 2015 Merck invests $50 million in Moderna
• Jan. 13, 2015 Mersana Therapeutics expands $300M R&D pact with Takeda
• Jan. 13, 2015 UK's Cancer Drugs Fund gets cash infusion, but loses 16 drugs
• Jan. 13, 2015 Merck goes after non-small cell lung cancer indication for Keytruda
• Jan. 13, 2015 Mylan's REMS lawsuit against Celgene gaining traction
• Jan. 13, 2015 Roche buys majority stake in Foundation Medicine for $1.03B
• Jan. 12, 2015 Cempra announces $100M stock sale after antibiotic impresses in pneumonia trials
• Jan. 12, 2015 Biogen Idec, Columbia University forge $30 million genetics research pact
• Jan. 12, 2015 Done deal: Shire acquires NPS Pharma for $5.2 billion
• Jan. 12, 2015 Daiichi Sankyo, DOJ reach $39 million settlement in kickback suit
• Jan. 9, 2015 Novartis seeks FDA approval for two smoker's cough drugs
• Jan. 9, 2015 How one hedge fund manager plans to take on big pharma patents
• Jan. 9, 2015 Tensions with pharma run high as UK's Cancer Drugs Fund cuts expenses
• Jan. 9, 2015 Finally approved: FDA says 'yes' to Impax's Parkinson's drug
• Jan. 9, 2015 Biogen Idec's novel optical nerve repair therapy shows promise, but only some
• Jan. 8, 2015 Siga ordered to pay $113M to PharmaAthene in smallpox case
• Jan. 8, 2015 Novartis OTC advertising under fire after Pfizer complaint
• Jan. 8, 2015 Namenda controversy continues as Actavis awaits court decision
• Jan. 8, 2015 Study reveals no Gardasil-MS link
• Jan. 8, 2015 The first groundbreaking antibiotic in 25 years may literally come out of the ground
• Jan. 8, 2015 UPDATE: Novartis Neupogen biosimilar takes yet another step toward FDA approval
• Jan. 7, 2015 AZ taps new immuno-oncology leader as two valued veterans depart
• Jan. 7, 2015 Gilead acquires Phenex's FXR liver drugs in $470 million deal
• Jan. 7, 2015 FDA grants drug makers 'track and trace' reprieve until May
• Jan. 7, 2015 Billionaire Mark Cuban to host first Pediatric Health Pitch Day at SXSW arts fest
• Jan. 7, 2015 Pharma companies unite to fight CA drug take-back program
• Jan. 6, 2015 Minnesota Investment Board will not support Medtronic-Covidien inversion deal
• Jan. 6, 2015 Moderna raises record $450M from investors with groundbreaking RNA tech
• Jan. 6, 2015 NIH awards $28 million in grants to unlock mysteries of gene regulation
• Jan. 6, 2015 J&J and Isis strike $835 million co-development deal
• Jan. 5, 2015 Massachusetts mulls legal action over marketing practices for pain drugs
• Jan. 5, 2015 Out with the old: Novartis completes Lilly animal health sale as part of overhaul
• Jan. 5, 2015 ICYMI: 9 big biopharma predictions for 2015, according to industry experts
• Jan. 5, 2015 Chiasma raising $56M to develop acromegaly drug—without Roche
• Jan. 5, 2015 An 18-year record: FDA approved 41 drugs in 2014
• Jan. 5, 2015 Japan first nation to approve potential Novartis blockbuster Cosentyx
• Jan. 1, 2015 Neuroderm stock surges, then plunges, after positive Parkinson's data
• Dec. 31, 2014 It's over: Teva and OncoGenex dissolve custirsen cancer partnership
• Dec. 23, 2014 J&J investing $125M up front for MacroGenics' blood cancer drug
• Dec. 23, 2014 Disgraced Japanese scientist fails to replicate stem-cell breakthrough results
• Dec. 23, 2014 Vanda, Novartis reach settlement in schizophrenia drug licensing spat
• Dec. 23, 2014 Tekmira, Oxford University team up to test new investigational Ebola therapy
• Dec. 23, 2014 HHS's BARDA grants $30M Ebola vax development contract to NewLink
• Dec. 22, 2014 Actavis considering Almirall acquisition to expand European foothold
• Dec. 22, 2014 FDA approves Cubist's novel antibiotic Zerbaxa for complicated infections
• Dec. 22, 2014 FDA unexpectedly approves AZ's Lynparza for advanced ovarian cancer
• Dec. 19, 2014 2014's 9 biggest biopharma game-changers, according to industry experts
• Dec. 19, 2014 AbbVie pins hopes for first major approval in 10 years on hep C drug
• Dec. 19, 2014 GSK shingles vax shows major promise, could challenge Merck's Zostavax
• Dec. 19, 2014 Glaxo assures shareholders: Dividend payout secure despite sluggish sales
• Dec. 19, 2014 Amgen leukemia drug Blincyto's massive price tag: $178,000
• Dec. 19, 2014 Controversial pay-to-delay deals on the decline in the EU
• Dec. 18, 2014 14 pharmacy execs arrested, 2 charged with murder over 2012 meningitis deaths
• Dec. 18, 2014 Actavis reveals post-merger management plans: Saunders to stay as CEO
• Dec. 18, 2014 Will this Pfizer orphan drug emerge as the Duchenne victor?
• Dec. 18, 2014 Report: Shire still hunting for a deal, maybe with NPS Pharma
• Dec. 18, 2014 FDA approves Novartis/Alcon's Xtoro for swimmer's ear
• Dec. 17, 2014 Google Ventures ventures more aggressively into healthcare, life sciences
• Dec. 17, 2014 The US Patent Office just gave a big gift to biopharma companies
• Dec. 17, 2014 Sanofi/Regeneron's opening move on PCSK9 marketing: 'Cholesterol Counts' campaign
• Dec. 17, 2014 FDA forces Pfizer to put another warning on antipsychotic Geodon
• Dec. 17, 2014 Former Onyx CEO tackles hard-to-treat CNS diseases with new biotech
• Dec. 16, 2014 FDA approves two new plasma-based tests, expands use of a third
• Dec. 16, 2014 Pfizer, OPKO reach growth hormone drug pact worth up to $570M
• Dec. 16, 2014 The other victims of scuttled AbbVie-Shire deal? Big banks
• Dec. 16, 2014 Senate bill would give 15 years' data exclusivity to drugs for unmet needs
• Dec. 16, 2014 How Teva's CEO is preparing for a 2015 of patent expirations
• Dec. 15, 2014 Abbott closes Veropharm deal amidst US-Russia political tension
• Dec. 15, 2014 Indian Supreme Court rejects Bayer's bid to block cheap cancer generic
• Dec. 15, 2014 Federal judge: Actavis must keep selling older version of Alzheimer's drug
• Dec. 15, 2014 Jazz pushing potential $1B rare disease drug through rolling NDA
• Dec. 15, 2014 Novartis psoriasis drug bests J&J's Stelara in head-to-head trial
• Dec. 12, 2014 Lawmakers propose new antibiotics pathway to combat superbugs
• Dec. 12, 2014 Gavi pledges $300M to get Ebola vaccines to hard-hit countries
• Dec. 12, 2014 Compromise: Branded biologics, biosimilar firms reach hard-won agreement
• Dec. 12, 2014 Philly transit authority launches class action against Gilead over Sovaldi price
• Dec. 12, 2014 Teva 2015 revenue forecast $1 billion lower than expected
• Dec. 11, 2014 Brave new world of digital pharma marketing has privacy advocates balking
• Dec. 11, 2014 'Audition' for a job? Pfizer gets creative in its hiring approach in Sweden
• Dec. 11, 2014 Mylan to foot $20M tax penalty for top execs after inversion merger
• Dec. 11, 2014 Teva launches generic of Pfizer's arthritis med Celebrex in the US
• Dec. 11, 2014 FDA approves new HPV super-vaccine, Merck's Gardasil 9
• Dec. 10, 2014 After failed Allergan offensive, Valeant finally taking break from M&A focus
• Dec. 10, 2014 HHS extends legal immunity to Ebola vaccine makers
• Dec. 10, 2014 A $3B case of bad timing? Merck defends Cubist deal after judge invalidates patents
• Dec. 10, 2014 Bluebird shares skyrocket on promising gene therapy-blood disorder data
• Dec. 10, 2014 Feds refuse to hear Sandoz case related to biosimilar development efforts
• Dec. 10, 2014 ICYMI: AARP and GPhA on what to do about generic drug price hikes
• Dec. 9, 2014 Feds drop wire fraud charges against former Lilly scientists
• Dec. 9, 2014 France, Germany, other EU countries suspend Indian generics approvals
• Dec. 9, 2014 Pfizer creating gene therapy platform to expand rare disease efforts
• Dec. 9, 2014 Microsoft co-founder Allen donates $100M to unlock mysteries of the human cell
• Dec. 8, 2014 FDA: A defined biosimlar pathway is coming—soon
• Dec. 8, 2014 Some more firsts for Incyte: Jakafi approved for chronic bone marrow disease
• Dec. 8, 2014 Merck, BMS PD-1 drugs continue to roll, show promise for Hodgkin's lymphoma
• Dec. 8, 2014 Why CRO employee turnover is still so high
• Dec. 8, 2014 Merck to buy antibiotics powerhouse Cubist for $9.5 billion
• Dec. 5, 2014 Big pharma meets medical marijuana? Dutch firm to build cannabinoid gum factory
• Dec. 5, 2014 Google's secretive Calico looking to hire bioinformatics pro
• Dec. 5, 2014 The FDA's new effort to make it easier to create generics of risky drugs
• Dec. 5, 2014 GSK reverses course, retracts plan to sell older drugs
• Dec. 4, 2014 Whistleblower: Sanofi, ex-CEO Viehbacher paid out $34M in kickback scheme
• Dec. 4, 2014 FDA OKs Amgen's Blincyto to treat rare form of acute lymphoblastic leukemia
• Dec. 4, 2014 Mice infused with human brain cells shed light on cognitive function
• Dec. 4, 2014 Beyond ABC: FDA finalizes labeling rules for pregnant, lactating women
• Dec. 4, 2014 Actavis to lay off 200 workers in California
• Dec. 3, 2014 ICYMI: Are low-cost generic drugs a thing of the past?
• Dec. 3, 2014 Security firm: Hackers trying to manipulate global markets by stealing pharma emails
• Dec. 3, 2014 Patent cliff ahead: Otsuka to buy Avanir for $3.5B and a slate of new products
• Dec. 3, 2014 A $945 million breakup: J&J, Astellas call off major rheumatoid arthritis deal
• Dec. 3, 2014 Promising Biogen Alzheimer's drug leapfrogs from phase I to phase III
• Dec. 3, 2014 Puma Biotech plummets in after hours trading after delaying breast cancer NDA
• Dec. 2, 2014 Meet the healthcare and pharma industry vet who will be Teva's next chairman
• Dec. 2, 2014 Mylan strikes deal to make Gilead's HIV drugs more accessible to poor nations
• Dec. 2, 2014 Done deal: Pfizer completes acquistion of Baxter's vaccines
• Dec. 2, 2014 Why BMS is getting ready to slash up to 1,000 jobs in China
• Dec. 2, 2014 Despite deaths, Italian regulators declare Novartis flu vaccine safe—for now
• Dec. 1, 2014 Report: China considering large-scale eradication of drug price caps
• Dec. 1, 2014 The key to successful clinical trial recruitment? Patient empowerment
• Dec. 1, 2014 EU green lights BI's Vargatef for advanced lung cancer
• Dec. 1, 2014 Job cuts ahead: GSK plans US workforce restructuring
• Dec. 1, 2014 Glaxo/NIH Ebola vaccine elicits immune response in human trials
• Nov. 26, 2014 Generic drug price hikes move Congress to consider consumer relief measures
• Nov. 26, 2014 Trouble for J&J? Amgen/AZ plaque psoriasis drug bests Stelara in phase III
• Nov. 26, 2014 Lilly's once-weekly diabetes drug approved in EU
• Nov. 26, 2014 FDA: No decision on Novartis' troubled panobinostat for 3 months
• Nov. 26, 2014 Takeda US CEO leaving after 22 years
• Nov. 25, 2014 A lead investigator reveals how Baxter's Hyqvia got its hard-won approval
• Nov. 25, 2014 Top UK fund manager to launch major new biotech fund in 2015
• Nov. 25, 2014 3 compounding pharmacies sue Express Scripts over blocked coverage
• Nov. 25, 2014 Lundbeck CEO resigns after serious conduct breaches
• Nov. 25, 2014 Novartis scientist who fabricated data fired and banned from receiving funding
• Nov. 25, 2014 In search of new opportunities, Bayer considers selling $2.5B diabetes unit
• Nov. 24, 2014 UK life sciences minister: Hospitals must aid in clinical trial process
• Nov. 24, 2014 Hep C wars heat up as AbbVie scores likely EU approval for Harvoni challenger
• Nov. 24, 2014 EU regulators weigh in on hotly debated testosterone, heart attack link
• Nov. 24, 2014 AZ to ramp up biologics production with new plant, jobs in MD
• Nov. 24, 2014 Merck, NewLink strike exclusive deal to scale up Ebola vaccine production
• Nov. 21, 2014 Sacré bleu! Sovaldi to cost 38.8% less in France than in US
• Nov. 21, 2014 EMA's updated conflict of interest policy reflects pragmatism, flexibility
• Nov. 21, 2014 Judge refuses to block Ranbaxy's generic competitors
• Nov. 21, 2014 Sanofi can't shake its diabetes business blues—and investors aren't happy
• Nov. 21, 2014 Purdue joins burgeoning abuse-deterrent pain pill field with Hysingla approval
• Nov. 20, 2014 Another first: Gilead spends $125M on priority review voucher for mystery drug
• Nov. 20, 2014 These execs are on Sanofi's CEO short list
• Nov. 20, 2014 In massive transparency effort, feds push for failed clinical trial data reporting
• Nov. 20, 2014 Goodbye Philly, hello Boston: Shire moves US HQ, 500 jobs
• Nov. 20, 2014 Novartis aims to put more 'tech' in biotech
• Nov. 19, 2014 ICYMI: Inside Indian pharma's push to reform and modernize
• Nov. 19, 2014 GSK, Clovis team up to study treamtents for mutant form of lung cancer
• Nov. 19, 2014 Regeneron/Sanofi PCSK9 inhibitor could become cholesterol top dog
• Nov. 19, 2014 India's Ranbaxy sues FDA for yanking Nexium, Valcyte generics approval
• Nov. 19, 2014 Rainmaker: Gilead's Harvoni approved in the EU
• Nov. 19, 2014 Has the price of developing drugs really doubled in the last 11 years?
• Nov. 18, 2014 Plot twist: Controversial Merck cholesterol drugs Zetia, Vytorin work
• Nov. 18, 2014 Docs breathe sigh of relief as Actavis buyout ends Valeant-Allergan drama
• Nov. 18, 2014 Merck dances: Keytruda more than doubles PFS in some melanoma patients
• Nov. 18, 2014 How pharma has improved patients' access to drugs since 2012
• Nov. 18, 2014 FDA commish to talk drug safety at China regulatory chief confab
• Nov. 17, 2014 2 DRG analysts dish on the 'unprecedented' Valeant-Allergan struggle
• Nov. 17, 2014 Another big win for Roche as Avastin nabs FDA ovarian cancer indication
• Nov. 17, 2014 Finally: FDA reverses course, OKs Sanofi's Lemtrada for MS
• Nov. 16, 2014 EU's top drug regulator forced out by EMA panel
• Nov. 14, 2014 Japanese transparency data raises eyebrows about pharma spending
• Nov. 14, 2014 AstraZeneca in preclinical development for Brilinta reversal agent
• Nov. 14, 2014 Apollo Global Manangement joins bidding wars for GSK's mature drugs
• Nov. 14, 2014 FDA approves new Invega indication for schizoaffective disorder
• Nov. 14, 2014 FDA has concerns over bioequivalence of two Concerta generics
• Nov. 14, 2014 Pfizer, Gates Foundation team up to get injectable contraceptives to poor countries
• Nov. 14, 2014 ICYMI: India's fixed-dose combo problem: Too much of a good thing?
• Nov. 13, 2014 Let's make a deal: Allergan, Actavis talk $60 billion merger
• Nov. 13, 2014 Indian pharma really feeling the pain of lagging US generic approvals
• Nov. 13, 2014 Advaxis wants to investigate a compound for head & neck HPV-related cancers
• Nov. 13, 2014 GSK applying for expanded Revolade indication in the EU
• Nov. 13, 2014 No more half measures: Senate to add Ebola to priority review program
• Nov. 12, 2014 Gilead, AbbVie hep C drugs score 97% cure rates, Regulus gets cold shoulder
• Nov. 12, 2014 10 major hospitals ask Congress to scrutinize Genentech distribution changes
• Nov. 12, 2014 Shire CEO: The future looks bright—who needs AbbVie?
• Nov. 12, 2014 GE Healthcare and Takeda to take on liver disease R&D together
• Nov. 12, 2014 Does a common 'algae virus' found in humans really make them dumb?
• Nov. 11, 2014 Swing and a miss: Merck's ambitious 4-week hep C regimen fails
• Nov. 11, 2014 Cigna responds to discrimination claims with cheaper HIV meds in Florida
• Nov. 11, 2014 Pfizer: Nothing shady about our relationship with Missouri Attorney General
• Nov. 11, 2014 Amgen gets PDUFA date for hotly anticipated PCSK9 anti-cholesterol drug
• Nov. 10, 2014 Decisions, decisions: UCB to sell its generic unit to private equity firms
• Nov. 10, 2014 Isis Pharma wins $10M neurodegeneration treatment milestone from Biogen
• Nov. 10, 2014 Political unrest in Russia nixes deal with German pharma company
• Nov. 10, 2014 Salix Pharmaceuticals' inventory woes ruined potential Allergan buyout
• Nov. 10, 2014 The cost of a cure: $188B to treat all US hep C patients with pricey new drugs
• Nov. 7, 2014 FDA sends Sciecure Pharma rare, scathing letter over insomnia drug sales aid
• Nov. 7, 2014 This billionaire hedge fund manager may sue over busted AbbVie-Shire deal
• Nov. 7, 2014 Allergan, Actavis talk merger while Valeant gets the cold shoulder
• Nov. 7, 2014 Ranbaxy loses $250M while US consumers lose a Nexium generic
• Nov. 7, 2014 FDA approves JNJ's Olysio in combo with Sovadi for hep C treatment
• Nov. 6, 2014 Largest US pharma benefits manager may seek alcohol/tobacco-free network
• Nov. 6, 2014 AZ's $2B ovarian cancer drug-in-development could be a 2-for-1 deal
• Nov. 6, 2014 UPDATED: Novartis cancer hopeful panobinostat not on track for FDA approval
• Nov. 6, 2014 Why GSK's promising hep C vaccine is good news for its Ebola drug
• Nov. 6, 2014 FDA presents novel plan for testing and fast-tracking Ebola drugs
• Nov. 5, 2014 Innovation in fixed-dose combos: HIV/AIDS therapeutics edition
• Nov. 5, 2014 Some payments exempt from Sunshine Act pharma database reporting
• Nov. 4, 2014 Bayer injects $25 million cash into biotech venture capital fund
• Nov. 4, 2014 Allergan-Valeant standoff rages on as Allergan loses in court
• Nov. 4, 2014 Regeneron posts solid Q3 on Eylea strength
• Nov. 4, 2014 Lundbeck's schizophrenia drug wallops competition in novel head-to-head trial
• Nov. 4, 2014 One-fifth of all drug sales in 2020 could be for pricey, specialty orphan meds
• Nov. 4, 2014 India-based Wockhardt's profits plummet as it faces continued FDA export ban
• Nov. 4, 2014 Diagnostics giant LabCorp buys CRO Covance for $6.1 billion
• Nov. 4, 2014 BMS gets heat from advocates over pricing plan for its hep C drug
• Nov. 4, 2014 Will Boehringer win an asthma indication for Spiriva Respimat?
• Nov. 3, 2014 Feds probe whether US officials engaged in insider trading over Dendreon drug
• Nov. 3, 2014 Scientists identify treasure trove of plasma-based cancer markers
• Nov. 3, 2014 Express Scripts gearing up to snub Gilead in favor of AbbVie hep C drug
• Nov. 3, 2014 Most UK diabetes patients fall short of evidence-based treatment goals
• Nov. 3, 2014 FDA panel endorses approval of Daaichi's blood clot, stroke drug
• Oct. 31, 2014 Scientists seek to make remote-controlled drug delivery device that works in space
• Oct. 31, 2014 Abbott acquires heart-mapping company Topera for $250 million
• Oct. 31, 2014 Sacked Sanofi chief's golden parachute more like a bronze parachute
• Oct. 31, 2014 Pfizer's meningitis drug becomes first FDA-approved breakthrough therapy
• Oct. 31, 2014 BMS's novel Opdivo exceeds expectations in late-stage lung cancer trials
• Oct. 30, 2014 With Viehbacher gone, who will be the next Sanofi chief?
• Oct. 30, 2014 US senators propose FDA vouchers to expedite Ebola drug development
• Oct. 30, 2014 J&J to open major new Shanghai-based 'Asia Pacific Innovation Center'
• Oct. 30, 2014 Diving into the future of fixed-dose combos
• Oct. 30, 2014 India to ban use of plastic bottles for liquid drugs
• Oct. 30, 2014 Cara Therapeutics' opioid alternative could be a true game changer
• Oct. 29, 2014 Gilead shares fall on lower-than-expected Sovaldi sales
• Oct. 29, 2014 Secretive Google[x] developing nano pill to detect cancer, monitor health
• Oct. 29, 2014 UPDATED: Judge slashes Actos class action award from $9 billion to $36.8 million
• Oct. 29, 2014 Cost-effectiveness: Treat prisoners with Sovaldi now, save money later
• Oct. 29, 2014 Pfizer posts weaker-than-expected Q3 while Sanofi CEO gets the boot
• Oct. 28, 2014 Pfizer pulls the plug on pain deal with Pain Therapeutics
• Oct. 28, 2014 Novartis smashes in Q3 as earnings soar 45%
• Oct. 28, 2014 Novartis sells off flu vaccines business to CSL for $275 million
• Oct. 28, 2014 Sarepta's mega-orphan Duchenne's drug faces more roadblocks
• Oct. 28, 2014 Roche to spend $3.2B on massive R&D cluster in Basel
• Oct. 27, 2014 EU panel recommends approval of Clinuvel's sunburn-prevention drug
• Oct. 27, 2014 Determined Shire ratchets up 2014 forecast, again
• Oct. 27, 2014 FDA approves Baxter's hemophilia orphan drug
• Oct. 27, 2014 EMA recommends approval of AZ's ovarian cancer drug
• Oct. 24, 2014 EU reverses course, won't cede drug-related decisions to pharma
• Oct. 24, 2014 EMA establishes expedited review framework for Ebola vaccines
• Oct. 24, 2014 Actavis to cut more jobs, this time in New York
• Oct. 24, 2014 Soliris sales drive Alexion's Q3 earnings beyond the loftiest expectations
• Oct. 23, 2014 Biogen shares down as Tecfidera-treated patient dies from viral brain infection
• Oct. 23, 2014 Anti-inflammatories may boost the effects of antidepressants
• Oct. 23, 2014 UK patients rally online to demand lower price for Roche's Kadcyla
• Oct. 23, 2014 WHO decries funding gap for tuberculosis R&D
• Oct. 23, 2014 Is Regulus' injectable the next HCV blockbuster in the making?
• Oct. 22, 2014 Best of BD: Biosimilars in China: The coming revolution
• Oct. 22, 2014 Lilly, Boehringer fixed-dose diabetes combo could win FDA blessing soon
• Oct. 22, 2014 Study: Parkinson's disease drugs make some patients want to party
• Oct. 22, 2014 Glaxo, Abbott Q3 earnings best analyst expectations
• Oct. 22, 2014 How the FDA plans to stop facilities from undermining inspections
• Oct. 22, 2014 Mylan investor pulls $70 million as lethal injection controvery heats up
• Oct. 21, 2014 Useful insights: Europe slow to embrace biosimilars of antibody-based drugs
• Oct. 21, 2014 Study: Viagra could be used to protect against heart disease
• Oct. 21, 2014 PhRMA fights back, blames insurance companies for drug access woes
• Oct. 20, 2014 Genentech strikes rare $1.15B cancer pact with NewLink Genetics
• Oct. 20, 2014 These anti-inflammatories may enhance the effects of schizophrenia treatment
• Oct. 20, 2014 EMA approves J&J's Imbruvica for two rare blood cancers
• Oct. 20, 2014 EU contemplates adaptive licensing in the face of Ebola threat
• Oct. 20, 2014 US orders 3 state-of-the-art labs to ramp up Ebola drug ZMapp production
• Oct. 20, 2014 Fearing creation of deadlier viruses, US tells scientists to halt bird flu research
• Oct. 20, 2014 FDA approves Pfizer's addiction-fighting pain pill as US heroin deaths soar
• Oct. 17, 2014 How new FDA flexibility in breast cancer trials can help high-risk patients
• Oct. 16, 2014 HHS puts third Ebola vaccine on the fast-track
• Oct. 16, 2014 New, top-shelf breast cancer drug sales lift Roche above Q3 expectations
• Oct. 16, 2014 Potential Novartis psoriasis blockbuster inches closer to approval
• Oct. 16, 2014 EMA considers relaxing clinical trial rules for rare-cancer patients
• Oct. 16, 2014 FDA to generic drug makers: Looks matter
• Oct. 16, 2014 FDA approves two competing 'breakthrough' IPF drugs in one day
• Oct. 16, 2014 Astellas to collaborate with Harvard team on ophthalmological gene therapy
• Oct. 16, 2014 Indian pharma: We're stymied by 'overzealous' drug regulators
• Oct. 16, 2014 The Critical Path Initiative: 10 years later
• Oct. 15, 2014 FDA approves telescope implant for younger end-stage AMD patients
• Oct. 15, 2014 NICE to Celgene: We won't authorize NHS funding for Imnovid
• Oct. 15, 2014 Pharma balks at new FDA final guidance on fixed-dose combinations
• Oct. 15, 2014 FDA not likely to drop black box suicide warning for Pfizer's Chantix
• Oct. 15, 2014 Patent battle brewing over Biogen's MS blockbuster Tecfidera
• Oct. 14, 2014 Chinese pharma firm says it has an Ebola cure
• Oct. 14, 2014 J&J forecast up big in Q3 on strong pharma sales
• Oct. 14, 2014 Novartis may be fined $49M by Indian pricing authority
• Oct. 14, 2014 Eisai/Helsinn's Akynzeo scores FDA approval for chemo-induced nausea
• Oct. 14, 2014 Research, royalties, and recreation: What pharma paid docs in 2013
• Oct. 13, 2014 Australian docs fight to ban meetings between physicians, pharma sales reps
• Oct. 13, 2014 Study: Pricey specialty med costs worth it in the long run
• Oct. 10, 2014 Severe asthma drug breathes new life into AstraZeneca pipeline
• Oct. 10, 2014 Study: Lung cancer can hide out for 20 years
• Oct. 10, 2014 Class-action gender discrimination suit against Merck to move forward
• Oct. 10, 2014 Endo to buy Auxilium at a premium for $2.6 billion
• Oct. 10, 2014 Here come the layoffs: Targacept-AstraZeneca R&D partnership nixed
• Oct. 10, 2014 How 2 companies are revolutionizing flu vaccine manufacturing
• Oct. 9, 2014 University of Utah scientists may have just discovered the key to an Ebola cure
• Oct. 9, 2014 Cash for compliance: West Pharma, HealthPrize team up to boost drug adherence
• Oct. 9, 2014 Groups urge stronger psych warnings for controversial Pfizer anti-smoking drug
• Oct. 9, 2014 Flu vaccine development as a hotbed of innovation: Who knew?
• Oct. 9, 2014 Look out, AbbVie: Here comes Amgen's Humira biosimilar
• Oct. 8, 2014 Catalyst Pharma to ramp up hiring after impressive orphan drug trial
• Oct. 8, 2014 Novare Pharmaceuticals launches in Boston
• Oct. 8, 2014 Watching the 'Watchman:' Boston Scientific to face FDA over heart device today
• Oct. 8, 2014 Tylenol for tots: FDA provides guidance on liquid acetaminophen for kids
• Oct. 8, 2014 Sanofi faces bribery allegations in East African, Middle Eastern markets
• Oct. 7, 2014 Acacia Pharma braces for approval of potential blockbuster post-op nausea drug
• Oct. 7, 2014 British Medical Association to UK officials: Cancer, dementia treatment at risk
• Oct. 7, 2014 Teva's downsizing efforts squeeze out women's health and cancer R&D
• Oct. 7, 2014 First US Ebola patient being treated with experimental Chimerix antiviral
• Oct. 7, 2014 Actavis shores up infectious disease franchise with Durata acquisition
• Oct. 6, 2014 How pharma and patients can work together to improve drug access
• Oct. 6, 2014 Baxter invests $45M in Rockwell Medical
• Oct. 6, 2014 Nobel committee announces 2014 winners in Physiology or Medicine
• Oct. 6, 2014 Novartis and BMS co-testing lung cancer therapies
• Oct. 6, 2014 Optos to collaborate with UK government and universities
• Oct. 6, 2014 Ascension Health bans Genentech sales reps from campus
• Oct. 3, 2014 NICE rejects funding for Roche's leukemia drug
• Oct. 3, 2014 Lilly abandons lupus drug after late-stage trial failures
• Oct. 3, 2014 Study: NSAID-related GI bleeding risk increases with combo therapy
• Oct. 3, 2014 Breast cancer drug sales to increase almost two-fold by 2023
• Oct. 3, 2014 EMA expands clinical data access to researchers and public
• Oct. 2, 2014 FDA issues final guidance on cybersecurity of medical devices
• Oct. 2, 2014 Salud: NHS to endorse daily pill for heavy drinkers in England
• Oct. 2, 2014 Specialty pharma ready to dispense Xtandi after expanded indication
• Oct. 2, 2014 Pfizer, Kyowa Hakko Kirin partner on immuno-oncology study
• Oct. 2, 2014 Bayer a top OTC player after $14.2B deal with Merck
• Oct. 1, 2014 Open Payments: Pharma, device companies shelled out $3.5B in 5 months [CHART]
• Oct. 1, 2014 BI spending $1.26 million to expand Respimat inhaler production
• Oct. 1, 2014 UK shores up its stem cell banking system with non-profit support
• Oct. 1, 2014 Acquisition update: J&J buys Alios for $1.75 billion
• Sept. 30, 2014 Horizon hailed as 'world's leading gene-editing' company after acquiring Sage
• Sept. 30, 2014 Report: 700-plus biosimilars in development worldwide
• Sept. 30, 2014 Amag Pharma buys maternal health specialist Lumara in $1B deal
• Sept. 30, 2014 Indian government: Major US think tank 'smeared' our pharma industry
• Sept. 30, 2014 Access wanted: What it takes for patients to get the drugs they need
• Sept. 30, 2014 Acquisition update: Daiichi Sankyo buys Ambit Biosciences for $410 million
• Sept. 29, 2014 EU regulators to patients: Help us evaluate drugs
• Sept. 29, 2014 Shareholders bullish on Nicox after phase III glaucoma trial
• Sept. 29, 2014 AbbVie racks up another Humira approval from the FDA
• Sept. 29, 2014 Merger Monday: Pfizer snaps up Innopharma in $360M deal
• Sept. 29, 2014 15 new medications headed toward EU approval
• Sept. 26, 2014 Actavis to continue sales of cheaper Alzheimer's drug for 60 days
• Sept. 26, 2014 Almirall, AZ big winners as key committee recommends COPD combo
• Sept. 26, 2014 BI scores an FDA approval for mist-based COPD drug
• Sept. 26, 2014 Novartis to seek approval for potential psoriatic arthritis blockbuster
• Sept. 25, 2014 BI to cut up to 600 jobs in Germany
• Sept. 25, 2014 Cost concerns drive UK authority to spurn popular ulcerative colitis drugs
• Sept. 25, 2014 FDA approves Celgene's potential blockbuster Otezla for psoriasis
• Sept. 25, 2014 India's drug-pricing authority drops price caps on nonessential drugs
• Sept. 24, 2014 Innovators wanted: FDA issues $500K challenge for better food pathogen detection
• Sept. 24, 2014 UK launches beta of transparency site MyNHS
• Sept. 24, 2014 How the NIH is trying to get more women to participate in clinical trials
• Sept. 24, 2014 Nigerian health minister declares Nigeria 'Ebola-free'
• Sept. 24, 2014 CDC: Dire outlook for Ebola in West Africa
• Sept. 23, 2014 Collaborating with Chinese pharma: Inside one company's success story
• Sept. 23, 2014 Does this month mark the beginning of a new era in cancer care?
• Sept. 23, 2014 Wales NHS approves Celgene's Abraxane for pancreatic cancer
• Sept. 23, 2014 UK public health advocates: Boys need HPV vaccine, too
• Sept. 23, 2014 Merck KGaA buys lab supplies manufacturer in major $17 billion deal
• Sept. 23, 2014 Amgen seeks FDA approval for breakthrough orphan leukemia drug
• Sept. 22, 2014 India's Sun Pharma, Merck pen unique $80M development deal
• Sept. 22, 2014 Study: Just one dose of antidepressant changes brain connectivity
• Sept. 22, 2014 AZ's new formulation performs well in phase III diabetes study
• Sept. 22, 2014 Gilead's Zydelig approved in the EU for rare blood cancers
• Sept. 19, 2014 Pharma breathes a sigh of relief as Scots say 'No' to independence
• Sept. 19, 2014 President Obama issues Executive Order to combat antibiotic resistance
• Sept. 19, 2014 NICE approves comprehensive funding for GSK melanoma drug Tafinlar
• Sept. 19, 2014 NICE agrees to fund Janssen's Olysio for hep C
• Sept. 19, 2014 Bayer to spin off material science division into separate company
• Sept. 18, 2014 Pfizer nabs exclusive option for MedGenesis Parkinson's treatment
• Sept. 18, 2014 Denovo snaps up Lilly's failed cancer drug for undisclosed price
• Sept. 18, 2014 Endo bids $2.2 billion for Auxilium
• Sept. 18, 2014 Sanofi, MyoKardia team up to take on cardiomyopathy
• Sept. 18, 2014 Gilead's pancreatic cancer hopeful crashes in phase II
• Sept. 18, 2014 ICYMI: How one Shanghai pharma became a model for malaria drug production
• Sept. 17, 2014 EU approves updated and expanded Gardasil labeling
• Sept. 17, 2014 UK approves first therapy under new fast-track access program
• Sept. 17, 2014 AstraZeneca's opioid constipation drug wins US approval
• Sept. 17, 2014 AstraZeneca, Lilly plan sprint to Alzheimer's drug development
• Sept. 17, 2014 Recordati to market Plethora's premature ejaculation spray
• Sept. 16, 2014 Shire's ADHD blockbuster Vyvanse scores priority review for binge eating disorder
• Sept. 16, 2014 FDA panel recommends NPS Pharma's orphan drug Naptara
• Sept. 16, 2014 Avanir Pharma soars to 8-year high on positive Alzheimer's drug results
• Sept. 16, 2014 Roche starts phase III trials for advanced wet AMD drug
• Sept. 16, 2014 Roche's cheaper vision loss drug just as effective as Novartis' Lucentis
• Sept. 15, 2014 Asterias, Cancer Research UK to collaborate on lung cancer vaccine
• Sept. 15, 2014 FDA panel recommendation paves way for Novo Nordisk obesity drug approval
• Sept. 15, 2014 Dompé bullish on novel eye disease treatment
• Sept. 15, 2014 Baxter's once-monthly Hyqvia for immune disorders wins FDA approval
• Sept. 15, 2014 Advocates furious over EU decision to cede authority back to pharma
• Sept. 12, 2014 R&D update: PhRMA and BHA provide insight into HIV/AIDS pipeline
• Sept. 12, 2014 Genmab partners with Seattle Genetics for exclusive use of ADCs
• Sept. 12, 2014 Report: Psoriatic arthritis market to cross $3.7 billion by 2023
• Sept. 12, 2014 EMA approves first-ever insulin biosimilar, Lilly/BI's Abrasia
• Sept. 11, 2014 FDA panel cautiously supports polypill
• Sept. 11, 2014 FDA approves expanded use of Xtandi for prostate cancer
• Sept. 11, 2014 NICE demands more transparency from pharma
• Sept. 11, 2014 Severe misconduct: Hyperion and Evotec halt diabetes drug trial
• Sept. 11, 2014 New statin guidelines: Thoughts from a physician on the front lines
• Sept. 10, 2014 Pfizer and Astellas Pharma to no longer co-distribute Caduet in Japan
• Sept. 10, 2014 A good deal for Roche just got better: Intermune reports new Esbriet data
• Sept. 10, 2014 Astrazeneca not deterred when COPD drug fails to meet primary endpoints
• Sept. 9, 2014 FTC files first-ever 'pay-for-delay' lawsuit against Teva, AbbVie
• Sept. 9, 2014 NICE rejects Celgene's Abraxane for pancreatic cancer
• Sept. 9, 2014 Advanced Cell Tech scores US patent for dendritic cell manufacturing
• Sept. 9, 2014 BMS sues Merck over historic PD-1 cancer drug Keytruda
• Sept. 9, 2014 Report: Government-supported cancer services at risk in the UK
• Sept. 9, 2014 The statin stumper: Are new cholesterol guidelines prudent or overzealous?
• Sept. 8, 2014 Wellspring acquires OTC motion sickness drug
• Sept. 8, 2014 Game on: Novartis' COPD drug bests GSK blockbuster in phase III trials
• Sept. 8, 2014 Servier slammed for withholding antidepressant trial data
• Sept. 8, 2014 FDA gives a qualified 'yes' to Keryx's chronic kidney disease drug
• Sept. 8, 2014 FDA approves first-ever kidney injury diagnostic NephroCheck
• Sept. 5, 2014 AbbVie and Infinity to collaborate on blood cancer treatment
• Sept. 5, 2014 History is made: FDA approves Merck's PD-1 inhibitor Keytruda for melanoma
• Sept. 5, 2014 Teamwork: Pfizer to promote Novartis' COPD drugs in the UK
• Sept. 5, 2014 Viiv's 3-in-1 HIV combo drug Triumeq nabs European marketing authorization
• Sept. 5, 2014 Facing patent expirations, Teva launches patient-centric MS e-health site
• Sept. 4, 2014 BMS opts out of RA drug deal with Alder Biopharmaceuticals
• Sept. 4, 2014 AZ, RedX Pharma to collaborate on genetic oncology research
• Sept. 4, 2014 NICE reverses course, says 'yes' to Alexion's pricey Soliris
• Sept. 4, 2014 Roche cuts jobs in Spain in response to price controls
• Sept. 4, 2014 EU expands use of Allergan's Ozurdex again
• Sept. 3, 2014 AstraZeneca's Brilinta falls short in phase IV study
• Sept. 3, 2014 Florida researchers: Marijuana may be key to Alzheimer's treatment
• Sept. 3, 2014 Belgium-based Ablynx pens development deal with China's Eddingpharm
• Sept. 3, 2014 BI's Ohio plant plagued by continuing woes
• Sept. 3, 2014 Novo Nordisk walks away from inflammatory disease R&D
• Sept. 2, 2014 Exelixis prostate cancer drug falls flat in trials, prompts massive layoffs
• Sept. 2, 2014 AZ's PD-1 immunotherapy drug advances in colorectal cancer studies
• Sept. 2, 2014 Novartis soars on groundbreaking heart failure drug trial results
• Sept. 2, 2014 Sanofi, Regeneron reveal positive data from alirocumab cholesterol trials
• Sept. 2, 2014 10-year data show no link between Actos and bladder cancer risk
• Aug. 29, 2014 Amgen files first-in-class cholesterol drug with FDA
• Aug. 29, 2014 Amgen scores priority review for chronic heart failure drug
• Aug. 29, 2014 Could low-dose aspirin be a cheaper alternative to anti-clotting drugs?
• Aug. 29, 2014 Final guidance: NICE recommends Biogen Idec's Tecfidera for RRMS
• Aug. 29, 2014 NICE sounds costs concerns over BI's Jardiance, requests more data
• Aug. 28, 2014 The biosimilars are coming: Tackling uncertainty and interchangeability
• Aug. 28, 2014 EU approves BMS's Daklinza for hep C combo therapy
• Aug. 28, 2014 Does Gilead have its sights set on Achillion Pharma?
• Aug. 28, 2014 Velphoro wins EU approval for treating hyperphosphalemia
• Aug. 28, 2014 GSK's Promacta scores FDA approval for rare bone marrow disorder
• Aug. 27, 2014 Alexion reprimanded for lax manufacturing practices
• Aug. 27, 2014 The biosimilars are coming: Why Basaglar and Zarzio are harbingers of a new pharma landscape
• Aug. 27, 2014 Pfizer, Merck team up to develop metastatic cancer immunotherapy
• Aug. 27, 2014 AZ, Illumina join forces to develop companion diagnostic tests for cancer drugs
• Aug. 27, 2014 FDA approves Iroko's Zorvolex for treatment of osteoarthritis pain
• Aug. 27, 2014 MultiCell Tech scores patent for cancer-fighting immunotherapy platform
• Aug. 27, 2014 Alexion vies to add another eculizumab indication with kidney graft trial
• Aug. 26, 2014 Mylan introduces generic of Upsher-Smith's Klor-Con
• Aug. 26, 2014 J&J's Janssen buys Covagen
• Aug. 26, 2014 EMA prepares to review new Cubist antibiotic
• Aug. 26, 2014 Merck, Advaxis partner up on prostate cancer research
• Aug. 26, 2014 Actavis, UCB Pharma butt heads over generic Neupro
• Aug. 25, 2014 Pfizer, GSK's Viiv Healthcare nabs FDA approval for 3-in-1 HIV drug
• Aug. 25, 2014 Experts call for an end to alternative medicine clinical trials
• Aug. 25, 2014 Auxilium's CCH reduces cellulite in phase IIa trial
• Aug. 25, 2014 J&J pursues stem cell diabetes deal with ViaCyte
• Aug. 25, 2014 Lilly's psoriasis drug scores big in phase III trials
• Aug. 22, 2014 Migalastat generates positive phase III results in Fabry patients
• Aug. 22, 2014 Novartis-funded study shows 75% of asthmatics are at risk
• Aug. 22, 2014 Jordan-based Hikma Pharma posts strong results amidst regional turmoil
• Aug. 22, 2014 Illumina to provide personalized oncology diagnostics for big-pharma studies
• Aug. 22, 2014 Pfizer, BMS score FDA hat-trick with another Eliquis approval
• Aug. 21, 2014 FDA approves GSK asthma inhaler Arnuity Ellipta
• Aug. 21, 2014 Novartis buys stake in Israeli stem-cell company
• Aug. 21, 2014 NICE reverses course, recommends Celgene's Revlimid for rare MDS form
• Aug. 20, 2014 Apricus Biosciences launches topical ED treatment in Germany
• Aug. 20, 2014 Amgen kidney drug for dialysis patients hits phase III targets again
• Aug. 20, 2014 Lilly, Boehringer win tentative FDA approval for Sanofi diabetes biosimilar
• Aug. 20, 2014 Novo hit with fine for stalling Tresiba rejection disclosure
• Aug. 20, 2014 Analysts: Transition to generic antidepressants will be offset by new options
• Aug. 19, 2014 Pfizer files NDA for breast cancer breakthrough therapy
• Aug. 19, 2014 Sanofi gears up for mass production of malaria drug
• Aug. 19, 2014 US Justice Department stops investigation of AstraZeneca's Brilinta trial
• Aug. 19, 2014 Eisai files thyroid cancer drug in US, EU
• Aug. 19, 2014 Advocates slam NICE, Janssen over prostate cancer drug 'fiasco'
• Aug. 17, 2014 Jilting generics: Part 2 of an exclusive interview with GPhA CEO Ralph Neas
• Aug. 17, 2014 FDA committee recommends approval of Boehringer COPD drug
• Aug. 17, 2014 Turkish citizens arrested for selling fake cancer drugs
• Aug. 15, 2014 Amgen's multiple myeloma drug fails in phase III single-drug study
• Aug. 15, 2014 Word on the street: IPF drug maker InterMune is taking bids
• Aug. 15, 2014 UK's NICE gives Gilead's Sovaldi a qualified 'yes'
• Aug. 15, 2014 FDA approves Avastin for treatment of metastatic cervical cancer
• Aug. 14, 2014 Debt-ridden Dendreon struggles to stay afloat
• Aug. 14, 2014 AstraZeneca's severe asthma drug breezes into phase III trials
• Aug. 14, 2014 Roche backs out of $600 million development deal with Chiasma
• Aug. 14, 2014 Jilting generics: Part 1 of an exclusive interview with GPhA CEO Ralph Neas
• Aug. 14, 2014 Pfizer, 23andMe team up to study the genetics of bowel disease
• Aug. 14, 2014 Celltrion submits FDA filing for biosimilar Remicade
• Aug. 13, 2014 AstraZeneca drug routs gout in phase III trials
• Aug. 13, 2014 Indiana University research team discovers new heart molecule
• Aug. 13, 2014 Falling sales, Sovaldi force Vertex to ditch hep C drug
• Aug. 13, 2014 Boehringer to slash global workforce as earnings fall
• Aug. 12, 2014 Intercept Pharma's shares fly high on positive liver drug results
• Aug. 12, 2014 Boehringer sales fall, but long-term prospects look good
• Aug. 12, 2014 Does faster regulatory approval translate into safety problems?
• Aug. 12, 2014 FDA green lights J&J's 2-in-1 diabetes drug
• Aug. 11, 2014 EU launches landmark decentralized generic drug approval pilot program
• Aug. 11, 2014 UK regulators say Roche's Kadcyla is too expensive
• Aug. 11, 2014 Astellas, Cancer Research Technology team up for pancreatic cancer research
• Aug. 11, 2014 Sex, drugs, and bribes: More on GSK's Chinese misadventures
• Aug. 8, 2014 Another perspective on Sovaldi: Spend more now, save much more later
• Aug. 8, 2014 EMA green lights Pfizer bid to broaden pneumonia vaccine use
• Aug. 8, 2014 Sarepta Therapeutics urges government to approve its Ebola drug
• Aug. 8, 2014 AbbVie-Shire, other inversions on the chopping block as government mulls action
• Aug. 8, 2014 FDA approves another antibacterial drug for skin infections
• Aug. 7, 2014 Actelion focusing on patient experience through PatientsLikeMe initiative
• Aug. 7, 2014 Cytori's stock plummets as stem-cell clinical trials are halted
• Aug. 7, 2014 Pfizer to pay $35 million in Rapamune settlement
• Aug. 7, 2014 Pfizer's Enbrel approved in the EU for rare inflammatory disease
• Aug. 7, 2014 EU approves Avastin for recurrent ovarian cancer
• Aug. 6, 2014 Can an aspirin a day keep the cancers away?
• Aug. 6, 2014 Australia's drug regulator says Pradaxa safety advice will not change
• Aug. 6, 2014 Roche to buy Santaris, add gene-silencing research to its portfolio
• Aug. 6, 2014 UK to fund Roche's cash-saving cancer injection
• Aug. 6, 2014 AbbVie's glioblastoma drug granted orphan status in US, EU
• Aug. 5, 2014 Prevention efforts critical as HIV stigma falls
• Aug. 5, 2014 Pfizer locks out workers at Indian manufacturing plant
• Aug. 5, 2014 Amgen's multiple myeloma drug meets phase III targets
• Aug. 5, 2014 Analysts: Pfizer may have its sights set on GSK
• Aug. 5, 2014 EU broadens target population for life-saving cystic fibrosis drug
• Aug. 5, 2014 BMS and Allied Minds team up to turn academic research into a clinical reality
• Aug. 4, 2014 Postdoctoral fellow admits to faking Novartis brain tumor study results
• Aug. 4, 2014 High-dose estrogen birth control may increase breast cancer risk, study finds
• Aug. 4, 2014 FDA expands use of Genzyme's Pompe disease treatment for young children
• Aug. 4, 2014 FDA approves Boehringer/Eli Lilly Alliance type 2 diabetes drug
• July 31, 2014 NICE gives Celgene's myeloma treatment the cold shoulder
• July 31, 2014 PCI to acquire Penn Pharma
• July 31, 2014 Gilead scores exclusive licensing rights for Theraclone's HIV antibodies
• July 31, 2014 Adamis tries to make its mark with low-cost epinephrine injector
• July 31, 2014 Sunshine Biopharma seeks global market through new Canadian subsidiary
• July 31, 2014 AZ buys rights to Almirall's respiratory portfolio in $2.1 billion deal
• July 31, 2014 GSK's once-weekly diabetes injection launches in U.S. pharmacies
• July 31, 2014 FDA approves Eylea for treatment of DME
• July 30, 2014 Merck outperforms second-quarter expectations as earnings surge
• July 30, 2014 Pfizer's Q2 earnings-per-share rise despite plummeting revenues
• July 30, 2014 Novartis' Simbrinza approved for glaucoma treatment in the EU
• July 30, 2014 Generic drug use is saving UK's NHS $21 billion per year
• July 30, 2014 US-based Alimera Sciences gets approval to market Iluvien in Norway
• July 29, 2014 Can GSK overcome its Q2 blues by focusing on the future?
• July 29, 2014 AcelRx stock tumbles on FDA rejection of pain pill dispenser
• July 29, 2014 Roche developing diagnostic test to support AZ's lung cancer candidate
• July 29, 2014 Boehringer and Zealand Pharma team up again to tackle obesity, diabetes
• July 29, 2014 Analysts on AbbVie's Shire deal: billions in tax savings
• July 28, 2014 Two diabetes treatments recommended for EMA approval
• July 28, 2014 Onco360 to distribute Gilead's Zydelig
• July 28, 2014 Bad news for Bayer/Amgen's blockbuster Nexavar in late-stage breast cancer trials
• July 28, 2014 Reckitt Benckiser to spin off pharmaceutical business
• July 28, 2014 Gilead, Janssen-Cilag blood cancer drugs headed for European approval
• July 27, 2014 Anatomy of a drug price valuation
• July 25, 2014 Investigation raises new questions about Boehringer's blood thinner
• July 25, 2014 Celgene's 25% profit spike driven by multiple myeloma, cancer drugs
• July 25, 2014 Biogen Idec zips past analysts' earnings forecasts
• July 25, 2014 GSK vies for approval of first-ever malaria vaccine
• July 25, 2014 Gilead earnings soar on Sovaldi's success
• July 24, 2014 With new facility, Merck bets on China as a market for growth
• July 24, 2014 Gilead enters the cancer drug arena as FDA approves Zydelig
• July 24, 2014 FDA approves extended-release pain pill with built-in abuse deterrent
• July 24, 2014 FDA releases 37 new bioequivalence studies
• July 23, 2014 Puma stock soars nearly 300% on positive breast cancer drug trial results
• July 23, 2014 Durata's landmark Qualified Infectious Disease Product launches in U.S.
• July 23, 2014 Could evolocumab become the gold-standard in cholesterol reduction?
• July 23, 2014 FDA inspects and approves two French Novosep manufacturing sites
• July 22, 2014 EMD Serono's Egrifta effective against drug-induced fatty liver disease in trial
• July 22, 2014 Regeneron and Bayer's DME drug shows promise in phase III trials
• July 22, 2014 Lannett inks exclusive deal to distribute ACEON generic in the U.S.
• July 22, 2014 FDA boosts Office of Generic Drugs in reorganization
• July 22, 2014 Allergan hopes to stave off Valeant with Q2 growth, cost-cutting
• July 22, 2014 Major Allergan shareholder dumps stock in vote of no confidence
• July 21, 2014 Niacin: the poster child for post-marketing drug surveillance
• July 21, 2014 AstraZeneca's Cambridge site aimed at optimizing R&D operations
• July 21, 2014 Could Gilead's Sovaldi also treat Hep C in HIV patients?
• July 21, 2014 Abbott Labs CEO defends tax inversions in Wall Street Journal
• July 21, 2014 Study: GSK's combo melanoma drug bests Roche's Zelboraf
• July 18, 2014 Will India's latest round of price caps force pharma out of the market?
• July 18, 2014 FDA gives Dutch angioedema drug the green light
• July 18, 2014 NICE urges doctors to cut threshold for statin use in half
• July 18, 2014 Reports: Ukraine plane crash may have claimed more than 100 AIDS conference attendees' lives
• July 18, 2014 AbbVie, Shire agree to $54.6 billion merger to slash corporate tax rate
• July 18, 2014 Novartis profits rise on emerging markets, MS drug
• July 17, 2014 Lilly, Immunocore partner to develop immunotherapy-based cancer treatments
• July 17, 2014 Dicerna Pharmaceuticals moving to Cambridge, MA
• July 17, 2014 FDA hits Italian drug manufacturer for destroying data
• July 17, 2014 Pfizer brings InnoPharma into the fold
• July 17, 2014 FDA fast-tracks review of Avastin as supplemental cancer drug
• July 16, 2014 GSK, Theravance's new COPD drug moves to Phase III testing
• July 16, 2014 Oncology CROs merging to offer broader range of services
• July 16, 2014 FDA tackles informed consent concerns with new guidance
• July 16, 2014 How electronic records can cut clinical trial costs, yield more reliable results
• July 16, 2014 Otsuka and Lundbeck file application for schizophrenia and depression drug
• July 15, 2014 Novartis to use Google 'smart lens' technology
• July 15, 2014 Valeant moves forward with premerger notification to FTC, Allergan holds its own
• July 15, 2014 AbbVie increases offer price for Shire
• July 15, 2014 Abbott selling part of generics portfolio to Mylan
• July 15, 2014 In reversal, NICE recommends Biogen's Tecfidera for some MS cases
• July 15, 2014 How pharma learned to stop worrying and love the tweet
• July 14, 2014 HD Biosciences, Marshall U. launch Chinese drug venture
• July 14, 2014 Bayer, Oxford partner on gynecology research
• July 14, 2014 Sanofi's dengue vaccine shows progress in trials
• July 14, 2014 EMA approves 39 drugs in first half of year
• July 14, 2014 Another product recall for Sun Pharma
• July 11, 2014 International CMOs prepare for Russian market as Pharma 2020 policy unfolds
• July 11, 2014 Phase III trial of Regado's antithrombotic system placed on hold
• July 11, 2014 Pfizer, CliniWorks creating health management platform
• July 11, 2014 NIH pulls Iowa State grant over falsified AIDS study
• July 11, 2014 EC comes down hard, fines Servier $582M for collusion
• July 10, 2014 Novartis spending $35 million to build data center in Texas
• July 10, 2014 FDA reprimands Gilead for paid-search link
• July 10, 2014 Allergan making moves to be leaner
• July 10, 2014 Newly acquired Forest Labs lays off 190 employees in Missouri
• July 10, 2014 What does it mean to be innovative in the pharma industry?